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SUMMARY 
 
Half a century ago thalidomide caused one of the biggest pharmaceutical tragedies known 
by now. It was widely prescribed to pregnant women as a sedative, but displayed teratogenic 
properties, causing limb malformations and other developmental defects in more than 10,000 
babies worldwide. Nevertheless, thalidomide and its derivatives are used nowadays in treatment 
of leprosy and multiple myeloma. The protein cereblon was identified as a primary target of 
thalidomide in the cell. As a substrate receptor, cereblon (CRBN) is linked via the damaged DNA 
binding protein 1 (DDB1) and cullin 4A to the E3 ubiquitin ligase machinery. The drug binds to 
the C-terminal region of cereblon, also referred to as CULT domain (cereblon domain of 
unknown activity, binding cellular ligands and thalidomide). This domain represents the most 
conserved part of cereblon and is also found solely in single-domain proteins in bacteria and, as a 
secreted form, in eukaryotes. Based on its ligand binding properties, its high degree of 
conservation and its intracellular as well as extracellular localization, a common interest arose in 
understanding the functional role of the CULT domain in vivo. 
The CULT domain carries a number of highly conserved cysteine and tryptophan residues 
within its amino acid sequence. In the solved crystal structure of the bacterial CULT domain, four 
conserved cysteines stabilize the protein fold by coordinating a zinc ion. Three invariant 
tryptophan residues build an aromatic cage, to which the ligand binds. Considering the structural 
similarity of uridine and thalidomide, we tested uridine binding to the hydrophobic pocket and 
could show an identical mode of binding. So far, uridine represents the only natural ligand, for 
which an interaction with the CULT domain has been shown. Further studies demonstrated that 
parts of the CULT domain fold upon ligand binding, thus stabilizing the protein. The pocket is 
highly similar to the aromatic cages found in histone readers that recognize methylated lysine or 
arginine residues in chromatin. This structural similarity suggests analogous ligands for cereblon, 
which include a distinct type of post-translational modifications. 
We developed a FRET-based in vitro assay for testing and characterizing ligand binding to 
cereblon. The determination and comparison of the substrate affinities for three CULT domains, 
from Homo sapiens, Magnetospirillum gryphiswaldense, and the secreted Caenorhabditis 
elegans, revealed similar values for the same ligands on a relative scale. This study convincingly 
confirmed the bacterial protein as a robust model system for both: (i) testing the specificity of the 
CULT domain to its ligands; and (ii) deciphering the function of cereblon proteins. Using the 
FRET-assay, we showed that various therapeutically relevant pharmaceuticals display 
affinities to the CULT domain with binding constants in the micromolar range. These off-
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target effects were further validated by applying an in vivo assay in zebrafish embryos to test 
the teratogenic potential of these compounds mediated via their interaction with cereblon. 
Searching for proteins interacting with cereblon in vivo, we identified transcription 
termination factor Rho to bind to the bacterial CULT domain. The assumption of a possible role 
of cereblon in transcriptional regulation is further supported by the fact that hCRBN interacts with 
LSD1, a demethylase which is essential for transcriptional regulation in multicellular organisms. 
Taken together, our data imply a potential function of cereblon in transcriptional repression and/or 
activation, particularly during limb formation. 
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ZUSAMMENFASSUNG 
 
Der Contergan-Skandal in der Mitte des letzten Jahrhunderts war eine der größten 
Tragödien in der Geschichte der Arzneimittelentwicklung und -zulassung. Die Behandlung 
von Schwangerschaftsübelkeit mit dem Beruhigungsmittel Contergan basierend auf dem 
Wirkstoff Thalidomid, führte zu fatalen Fehlbildungen bei über 10000 Neugeborenen 
weltweit. Aufgrund ihrer sowohl entzündungshemmenden als auch immunsuppressiven 
Eigenschaften, finden Thalidomid und seine Derivate trotz ihrer teratogenen Eigenschaften 
auch heute noch eine breite Anwendung in der Behandlung von Lepra und Multiplem 
Myelom.  
Fast 60 Jahre dauerte es, bis das Protein Cereblon, als ein zelluläres Target von 
Thalidomid identifiziert wurde. Als Substratrezeptor ist Cereblon durch Wechselwirkung mit 
DDB1 (damaged DNA binding protein 1) mit dem Cul4A E3 Ubiquitin-Ligase-Komplex 
verbunden. Durch die Bindung von Thalidomid an die C-terminale Domäne von Cereblon, 
auch als CULT-Domäne (cereblon domain of unknown activity, binding cellular ligands and 
thalidomide) bezeichnet, wird die Substraterkennung von Cereblon moduliert. Die CULT-
Domäne ist hochkonserviert. Man findet ausschließlich aus dieser Domäne bestehende 
Homologe sowohl in Bakterien als auch in einer Gruppe von eukaryotischen sekretierten 
Proteinen. Aufgrund ihrer Eigenschaft Thalidomid zu binden, ihres hohen 
Konservierungsgrades und ihres sowohl extrazellulären als auch intrazellulären Vorkommens, 
besteht großes Interesse, die funktionellen Aspekte der CULT-Domäne in vivo zu verstehen. 
Mit Lösung der Kristallstruktur einer bakteriellen CULT-Domäne konnten wir zeigen, 
dass streng konservierte Cysteinreste durch Bindung eines Zinkions zur Stabilisierung des 
Proteins beitragen. Ebenfalls hoch konservierte Tryptophanreste bilden eine 
Substratbindetasche, in der Thalidomid gebunden wird. Weitere Untersuchungen ergaben, 
dass Uridin, welches in seiner Struktur Thalidomid ähnelt, auf die gleiche Art und Weise 
gebunden wird. Es repräsentiert damit den bisher einzigen bekannten Cereblonliganden 
natürlicher Herkunft. Strukturelle Studien zeigten, dass Ligandenbindung das Protein 
stabilisiert, da einige Teile des Proteins erst dadurch falten. Die Bindetasche der CULT-
Domäne zeigt eine starke Ähnlichkeit zu ebenfalls aromatischen, käfigartigen Bindestellen in 
anderen Proteinen mit verschiedenen Arten von Liganden. Dazu gehören z.B. die sogenannten 
Histone reader, welche methylierte Lysin- bzw. Argininreste binden. 
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Wir haben einen fluoreszenzbasierten in vitro Assay (FRET-Assay) entwickelt, welcher 
die Identifizierung und nachfolgende Charakterisierung von Cereblonliganden ermöglicht. 
Mit Hilfe dieses Assays zeigten wir in einer vergleichenden Analyse der CULT-Domänen aus 
Magnetospirillum gryphiswaldense, Caenorhabditis elegans und dem Menschen ähnliche 
Ligandenspezifitäten als auch -affinitäten. Dies ermöglicht die Anwendung des, im Vergleich 
zu seinen Homologen, sehr robusten bakteriellen Proteins als: (i) Modellsystem zur 
Identifizierung potentieller, pharmakologisch interessanter Cereblonliganden und (ii) zur 
Entschlüsselung der zellulären Funktion der CULT-Domäne. Unter Nutzung des bakteriellen 
Modellsystems konnten wir mit Hilfe des FRET-Assays die Bindung von therapeutisch 
relevanten Pharmaka an die CULT-Domäne mit Affinitäten im mikromolaren Bereich zeigen. 
Mögliche teratogene Auswirkungen dieser unerwünschten Wechselwirkung zwischen 
Cereblon und Arzneimittelwirkstoff als auch zwischen Cereblon und weiteren identifizierten 
Verbindungen wurden anschließend in einem In vivo-Assay in Zebrafischembryonen 
analysiert. 
In Bakterien durchgeführte Experimente zur Identifizierung zellulärer Bindeproteine der 
CULT-Domäne zeigten eine Interaktion mit dem Transcription termination factor Rho. Eine 
mögliche regulatorische Funktion von Cereblon in der Kontrolle der Transkription wird durch 
den Befund unterstützt, dass für das humane Homologe eine Interaktion mit LSD1, einer für 
multizelluläre Organismen essentiellen Demethylase, gezeigt werden konnte. 
Zusammengefasst lassen alle vorliegenden Ergebnisse und Beobachtungen eine 
potentielle Beteiligung von Cereblon an Vorgängen der transkriptionellen Regulation, 
insbesondere während der Embryonalentwicklung, vermuten.  
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1 INTRODUCTION 
 
Thalidomide was elaborated in 1954 as a sedative by the pharmaceutical company 
Grünenthal. From 1957 to 1962 it was prescribed to pregnant women for the treatment of 
nausea. During these years the drug was distributed to over 40 countries in Europe, 
Australia, Japan, but banned in the USA because of concerns about peripheral neuropathy 
initiation. After its teratogenic effects were reported, thalidomide was immediately 
withdrawn from the market. By then, over 10,000 children worldwide were born with 
multiple defects, which turned to be the most tragic pharmaceutical catastrophe registered 
so far (Lenz, 1988). The use of thalidomide during the first trimester of pregnancy caused 
numerous birth anomalies of limbs (amelia and phocomelia), heart disorders, 
malformations of the inner and outer ear, ocular abnormalities in babies. In contrast, these 
effects were not detected on rodents, demonstrating that difference between species 
requires additional examination. This tragedy illustrated a sharp importance of a more 
rigorous and systematic testing of pharmaceuticals for developmental toxicity before their 
distribution into the market. Interest in thalidomide was reestablished due to its 
immunomodulatory, anti-inflammatory, anti-angiogenic properties, which are efficient in 
treatment of erythema nodosum leprosum, cancer, autoimmune diseases, and AIDS 
(Franks et al., 2004). On the account of its teratogenicity the prescription of thalidomide is 
strictly controlled by the System for Thalidomide Education and Prescribing Safety 
(S.T.E.P.S.) program in the USA (Zeldis et al. 1999). Nevertheless, the usage of 
thalidomide during pregnancy still causes many malformations in the newborn in 
developing countries due to a poor medical surveillance (WHO 2014; BBC News, 2013). 
 
 
1.1 The teratogenic phenotype induced by thalidomide 
 
As for any drug, the dose and exposure period are very important to balance its 
positive and negative properties. In 1960s it was demonstrated that the timing of exposure and 
the dosage of thalidomide played a critical role in evoking teratogenic effects (Lenz, 1988). 
The susceptible period of fetal development to drug treatment is between 20 and 34 days 
postfertilization. The window of exposure in humans for malformations of arms is 21-32 days 
after fertilization, for legs 27-32 days, for thumb hypoplasia 21-28 days, for outer ear 
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disorders 20-24 days, and for inner ear 24-34 days (Miller and Strömland, 1999). Amelia 
(birth defect of absence one or more limbs) and phocomelia (birth defect of truncated limb(s)) 
were the most common thalidomide-induced abnormalities. Ear disorders were also often 
observed and varied from microtia to anotia. Along with main limb anomalies, other defects 
were reported, namely kidney malformations, dental disorders, central nervous system, and 
ocular anomalies. Furthermore, mental retardation, Duane syndrome, and autism were also 
recorded in affected kids, even though the rate was low. The risk of birth defects was 
estimated to be 10 % – 50 %. Even a single 50 mg dose was sufficient to cause severe harm, 
when the drug was consumed by pregnant woman during the first trimester of pregnancy 
(Newman, 1986). The mortality rate for the newborn “thalidomide babies” was 40 % mostly 
due to serious internal organs disorders.  
 
 
1.2 Chemistry and pharmacokinetics of thalidomide 
 
Thalidomide consists of two imide rings: phthalimide and glutarimide. It has two 
conformations, S- and R-enantiomers, which rapidly racemize under physiological conditions 
and are impossible to be separated from each other. The S-enantiomer is thought to be 
teratogenic, whereas R-enantiomer has sedative effect. Because of thalidomide’s low 
solubility in water, dimethyl sulfoxide (DMSO) is used as a solvent for its application in 
experiments. In vivo, it undergoes non-enzymatic hydrolytic breakdown, generating multiple 
chemically inactive metabolites. Additionally, thalidomide is hydroxylated by cytochrome 
P450 in the liver like most of the drugs during their metabolism in the body. The highest 
concentration of thalidomide in the blood is reached 3-6 hours after being administered. It is 
eliminated in the urine with the average half-life of 7.3 hours (Chung et al., 2004). Due to 
thalidomide’s poor solubility, its absorption rate in the gastrointestinal tract is much slower 
than its elimination.  
The conventional dose of thalidomide applied for treatment of multiple myeloma and 
leprosy is 50-800 mg per day, which leads to the average concentration in the body between 3 
and 48 µM according to single-compartment model (Chung et al., 2004). This amount of the 
drug is enough to cause both sedative and teratogenic effects. In rabbits the anti-angiogenic 
and the teratogenic activity was observed at 100-400 mg/kg dose, leading to approximate 
body concentration between 385 and 1,540 µM. Fin malformation in zebrafish was induced 
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by thalidomide at concentrations of 200-400 µM in E3 medium (Ito et al., 2010). The general 
concentration of the drug in the body is hard to estimate due to its unknown penetration 
properties through the epidermis. Seemingly, the working concentration of thalidomide varies 
even among thalidomide-sensitive species. 
 
 
1.3 Development of thalidomide derivatives 
 
The discovery of immunomodulatory and anti-cancer activity of thalidomide has 
awakened growing interest in an elaboration of structural analogues, which are less harmful 
and preserve the healing properties. In the last decade, multiple preclinical and clinical studies 
showed their high potential in the treatment of multiple myeloma and other malignancies. 
This demonstrated a vital importance for the development of immunomodulatory drugs 
(IMiDs) as well as thorough investigation of the mechanism of their anti-proliferative activity. 
Today, the second generation of IMiDs is effectively used in the treatment of 
thalidomide-resistant myeloma pointing out the divergent characteristics of these compounds. 
Lenalidomide and pomalidomide, the most effective substitutes of thalidomide known by now 
(Fig. 1.1), possess less negative clinical consequences, although the teratogenicity issue still 
remains unresolved. While sharing important immunomodulatory properties, they differ in 
their efficiency and toxicity profiles in the treatment of different diseases. For instance, in 
zebrafish embryo, the effective immunomodulatory concentration of pomalidomide does not 
confer fins malformation compared to the other IMiDs (Mahony et al., 2013).  
 
 
 
Figure 1.1. Structures of thalidomide, lenalidomide, and pomalidomide. 
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1.4 Hypotheses of thalidomide teratogenicity 
 
More than half a century scientists worldwide tried to reveal the mystery of 
thalidomide teratogenicity. To elucidate molecular mechanisms of limb malformations, more 
than 30 hypotheses have been proposed, including:  
 1) oxidative damage  
 2) intercalation and inhibition of DNA synthesis 
 3) inhibition of angiogenesis 
 4) cereblon binding 
  2) DNA oxidation 
  3) modification of cytokine metabolism 
  4) downregulation of adhesion molecules 
  5) ascorbic acid synthesis 
  6) acylation of macromolecules 
  7) folic acid antagonism 
 8) glutamate metabolism misbalance. 
Oxidative damage. Thalidomide has been shown to promote generation of reactive 
oxygen species (Hansen and Harris, 2004). Nuclear factor kB (NF-kB) is a redox-sensitive 
transcriptional factor, which activity is abnormally regulated upon thalidomide treatment. Fgf 
8 and Fgf 10, the downstream targets of NF-kB and essential factors for limb growth 
signaling, display a reduced expression in the mesoderm beneath the apical ectodermal ridge 
(AER) in rabbits after exposure to the drug (Hansen et al., 2002). Bone morphogenetic 
proteins (Bmp) and Dickkopf-1 (Dkk-1) are the other cytokines, which play an essential role 
in embryogenesis, and are upregulated by thalidomide (Knobloch et al., 2007). Furthermore, 
Bmps downregulate Fgf signaling in limb development (Pajni-Underwood et al., 2007). 
Importantly, they are expressed in the distal epidermal cells in the region of the AER and 
particularly necessary for limb patterning. Under physiological conditions NF-kB negatively 
regulates abundance of Bmps, which are upregulated upon thalidomide exposure (Hansen and 
Harris, 2004). By mediating Bmps expression, thalidomide blocks Wnt and Akt signaling 
pathways, which control cell proliferation and survival (Knobloch et al., 2008; Grotewold and 
Ruther, 2002). The disturbance of these signaling pathways has been hypothesized to cause 
apoptosis of progenitor cells in limb buds. 
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DNA oxidation represents another harmful consequence of oxidative stress since the 
genetic code is under the threat of unpredicted irrevocable changes. Although this hypothesis 
seems to be plausible and additionally clarifies anti-proliferative activity of the drug, it does 
not explain the tissue-specificity of thalidomide-induced effects. 
Anti-angiogenesis. The inhibition of blood vessel formation by thalidomide entailed 
limb deformities in different species from zebrafish to mammals (D’Amato et al., 1994, 
Therapontos et al., 2009, Ito et al., 2010). This statement advocates not only the teratogenic 
properties of thalidomide, but also the anti-cancer medication since many anti-neoplastic 
drugs are targeted to block vessel formation in tumors. Handa and colleagues showed that a 
violation of angiogenesis was rather a secondary consequence of the inhibition of 
vasculogenesis since transcriptional changes of Fgf8/Fgf10 and morphological abnormalities 
preceded marginal blood vessel formation (Ito et al., 2010).  
DNA intercalation. Thalidomide was reported to interact with GC-rich promoters by 
intercalation, which leads to a disturbed transcriptional activity of the associated genes. For 
example, insulin-like growth factor 1 (IGF-1) and Fgf2 transcription was decreased as a result 
of thalidomide treatment in chicks. (for a review see e.g. Stephens et al., 2000). These 
proteins promote angiogenesis, therefore DNA intercalation theory is also consentient with 
anti-angiogenic activity of the drug.  
Cereblon binding. As described above, none of the existing hypotheses clarifies all 
the aspects of thalidomide teratogenicity, although they substantially contribute to the 
knowledge about the mechanism of thalidomide action. They are unable to give an 
explanation to species specificity and, what is more important, provide no insight into direct 
target(s) of thalidomide in the cell. Identification of a primary target of thalidomide was a 
crucial step towards revealing the molecular mechanisms of caused teratogenicity. To 
accomplish this, Handa and co-workers developed ferrite-glycidyl methacrylate (FG) beads, 
which had a carboxyl-type derivative of thalidomide attached to amino-group of FG (Ito et al., 
2010). These beads allowed the isolation of target molecules from the cell extract, using their 
magnetic properties. The extracts of human cell lines were used for affinity purification of the 
thalidomide-binding molecules. Two proteins of the apparent molecular mass of  ̴ 55 kDa and 
127 kDa were eluted with free thalidomide after binding procedures, which signified that this 
interaction is thalidomide specific. Mass spectrometric analysis revealed that these were 
cereblon ( ̴ 55kDa) and DNA damage-binding protein1 (DDB1, ̴ 127 kDa). Further studies 
showed that CRBN is the direct target of thalidomide, whereas DDB1 indirectly interacts with 
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thalidomide via CRBN (Fig. 1.2). Via its interaction with DDB1, CRBN is connected to E3 
ubiquitin ligase machinery, but the functional relevance of this interaction was unclear (Ito et 
al., 2010). In contrast to the intensively studied DDB1, the precise cellular role of cereblon 
was poorly understood. It is an adaptor protein associated with DDB2, which links two 
cellular processes: DNA excision repair and ubiquitination (Wittschieben and Wood, 2003). 
Further research demonstrated that DDB1 is a subunit of a cullin 4 (Cul4)-based E3 ubiquitin 
ligase machinery. The complex consists of Cul4 (Cul4A or Cul4B), regulators of cullins, 
DDB1, and a substrate receptor (Groisman et al., 2003), which binds to different substrates 
that are targeted for ubiquitin-dependent degradation and are subsequently processed by the 
proteasome.  
 
Figure 1.2. Cereblon functions as a component of E3 ubiquitin ligase complex 
(adapted from Ito et al., 2010). 
 
 
This mission is crucial for sustaining a well-being of the cell as an excess of certain 
protein molecules in the specific time window might lead to a physiological misbalance. E3 
ubiquitin ligase complexes control such processes as cell cycle, embryogenesis, immune 
response, and cancerogenesis (Bedford et al., 2011; Cohen and Tcherpakov, 2010). DDB1 is 
one of the adaptor proteins employed by Cul4, which binds numerous substrate receptors 
expanding the range of action of the whole machinery. They are called DDB1- and Cul4-
associated factors (DCAF). Mostly, DCAFs contain a specific WD-40 domain (WDXR), for 
instance DDB2 and Cockaine syndrome A, but not cereblon. Nevertheless, CRBN is capable 
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to compete with DDB2 for binding to DDB1, presenting a novel type of substrate receptors 
(Ito at al., 2010). Thalidomide treatment blocks CRBN auto-ubiquitination, suggesting that 
the drug inhibits E3 ubiquitin ligase. The connection between the thalidomide-induced birth 
defects and CRBN was demonstrated in vivo in Danio rerio embryos. The zebrafish cereblon 
ortholog (zCRBN) shares ̴ 70 % sequence identity to human CRBN. Both thalidomide 
exposure and zcrbn knockdown, cause pectoral fin defects, otic vesicles disorder, and 
reduction of Fgf8 expression in the fin buds in Danio rerio embryos. Tetrapod limbs and 
zebrafish fins are homologous in terms of early patterning and gene expression, albeit the 
skeletal structures are quite different in the adult forms. The thalidomide-induced phenotype 
was rescued in zebrafish and chicks by injection of the zcrbn
 YW/AA
 mRNA encoding binding-
deficient mutant of CRBN, but not by injection of wild type zcrbn mRNA. Although this 
undoubtedly confirms that CRBN is a direct in vivo target of thalidomide, the issues about its 
tissue-specific teratogenic effects and rodents’ resistance to the drug are still debated. The key 
question: What are the cellular cereblon substrate(s)?; also remains poorly explored. Albeit 
there are few CRBN substrates found, they provide insight neither into CRBN-mediated 
thalidomide teratogenicity nor into universal cereblon function (Krönke et al., 2013; Lu et al., 
2013; Gandhi et al., 2013; Krönke et al., 2015). 
 
 
1.5 Species- and tissue-specificity of thalidomide action 
 
Thalidomide administration leads to limbs deformities not only in humans, but also in 
monkeys, rabbits, and chicks (Knobloch and Ruther, 2008). Additionally, zebrafish embryos 
demonstrated fins malformations upon drug treatment (Ito et al., 2010). Rabbits and monkeys 
suffer from amelia and phocomelia, whereas in chicks only amelia occurs (Knobloch and 
Ruther, 2008). The fibroblast growth factor 8 (Fgf8) is expressed in the apical ectodermal 
ridge (AER) and plays an important role in limbs/fins development in vertebrates. 
Thalidomide application decreased expression of Fgf8 in the AER in susceptible animals, 
signifying a common teratogenic effect of the drug in different species. Rodents, however, are 
not susceptible to the thalidomide even at the exceptionally high doses (up to 4g/kg) (Brent, 
1964). Given the high level of cereblon evolutionary conservation and binding of thalidomide 
to mice cereblon, the reason for such a difference between species still remains ambiguous 
(PDB-ID 4TZC, deposited, to be published by Chamberlain et al). Mutational analysis 
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revealed a single amino acid difference between human and mouse cereblon to provoke the 
blockage of lenalidomide-dependent CK1ɑ substrate ubiquitination in a myeloid cell line 
(Krönke et al., 2015). Although the role of this substrate in thalidomide teratogenicity is 
completely unknown, these data demonstrate differences in the responsiveness to 
lenalidomide that are based on a minor variation in the amino acid sequence and have a 
striking influence on cellular function. Complementary, the mystery of the species 
susceptibility to thalidomide is being discussed with various cereblon-independent 
hypotheses.  
Firstly, the differences in pharmacokinetics have to be considered as a cause of species 
specificity. Thalidomide is quickly metabolized to many side products in vitro and in vivo, 
giving rise to non-teratogenic breakdown compounds (Melchert, List et al., 2007). Orally 
administered thalidomide has a half-life of 0.5 hours in mice, 2.2 hours in rabbits, and 7.3 
hours in human plasma, supporting the idea of species-specific pharmacokinetic variance 
(Chung F et al., 2004). However, the drug does not cause limb defects in mice even with 
increased dosage (Janer, Slob., et al 2008). 
Secondly, the requirement of prior bioactivation of thalidomide in the liver was 
suggested for its activity, which may be distinct in different species. This observation is based 
on the fact that the drug displays its anti-angiogenic activity in the presence of rabbit or 
human liver microsomes, but not the microsomes from the rat liver. In contrast, thalidomide-
induced morphological and transcriptional changes were reported to be independent from its 
anti-angiogenic properties (Ito et al., 2010). Moreover, the bioactivation model contradicts the 
study showing thalidomide`s direct interaction with cereblon, which has been proven multiple 
times by different groups (Ito, et al., 2010; Lopez-Girona et al., 2012; Zhu et al., 2011). In 
chicks and zebrafish, the teratogenic effects were caused by exposure of these animals to the 
drug at the developmental stages, when liver is not yet functional (Field et al., 2003; Ito et al., 
2010). 
Thirdly, given a short time-window of thalidomide action as a teratogenic agent, the 
minor differences in gestational development could cause distinct species response to the 
thalidomide exposure (Janer, Slob et al., 2008). Finally, generation of reactive oxygen species 
upon thalidomide treatment varies from species to species as well (Parman, Wiley et al., 
1999). 
Taken together, these hypotheses discuss various possibilities of the origin of species-
specific thalidomide susceptibility, but none of them has provided its credibility yet. The 
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details of thalidomide teratogenicity remain to be elucidated, but numerous studies have 
paved the way for clarification the aspects of the tragedy. 
The tissue specificity of thalidomide might descend from CRBN binding. In 48-hpf 
zebrafish embryos zcrbn expression is detectable at high level in the brain, pectoral fin, and 
head vasculature, but not in somites, which is consistent with detected drug-induced 
teratogenic effects (Ito et al., 2010). In comparison, in the adult human and mouse tissues 
CRBN is ubiquitously expressed (Su et al., 2004). Concurrently, CRBN is required, but might 
be not sufficient, for thalidomide teratogenicity. 
 
 
1.6 Cereblon is a primary target in myeloma treatment  
 
Thalidomide and related immunomodulatory drugs possess anti-tumor activity with 
particularly high efficiency in the treatment of multiple myeloma (MM). About 30 % of MM 
patients show therapeutic effects after treatment with thalidomide or its derivatives 
lenalidomide and pomalidomide. In combination with dexamethasone or bortezomib the 
efficacy of IMiDs was more than doubled, yielding a response rate for thalidomide ˃ 60 % 
and even higher for lenalidomide ˃ 80 % (Weber et al., 2007; Lacy et al., 2009). Despite such 
a remarkable achievement in clinical usage, the molecular mechanisms of anti-proliferative, 
anti-angiogenic, pro-apoptotic, and immunomodulatory effects of IMiDs remain elusive. 
After discovery of CRBN as a primary target of thalidomide in the cell, it was crucial to 
understand whether the anti-tumor activity of IMiDs is mediated by CRBN. Indeed, CRBN-
deficient human multiple myeloma cells displayed IMiDs resistance, demonstrating that 
CRBN presence is an absolute must for the IMiDs therapeutic effect (Zhu et al., 2011). 
Moreover, CRBN expression level in the patients with reported lenalidomide resistance was 
significantly reduced (by 20 % - 90 %) before and after IMiD treatment, which again affirms 
that the response to the drug correlates with the CRBN level in the cell. Stewart and co-
workers demonstrated that acquired lenalidomide and pomalidomide resistance is a 
consequence of CRBN expression reduction in the MM1.S cell line (Zhu et al., 2011). 
Additionally, to ascertain the role of CRBN in gained lenalidomide resistance, H929 cell line 
was exposed to increasing doses of the drug (Lopez-Girona et al., 2012). This caused a 
decrease of CRBN mRNA level accompanied with elevated anti-proliferative resistance, 
which correlates with published data. Crbn knockdown results in a significant mutilation of 
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IMiD-induced effects including IRF4 downregulation and cell cycle arrest, which mimics the 
usage of binding-deficient mutant CRBN
YW/AA
 (Zhu et al., 2011). 
Fluorescent thermal melt shift studies illustrated that lenalidomide and pomalidomide 
bind cereblon with ten times higher affinity (Lopez-Girona et al., 2012). They inhibit 
autoubiquitination of CRBN within the DDB1-containing E3 ligase machinery similarly to 
thalidomide, which is abolished in the binding-deficient mutant CRBN
YW/AA
. All three 
compounds induce expression of a key cell cycle regulator – the cycline dependent kinase 
inhibitor 1 (p21/waf1), which controls cyclin dependent kinase activity (Lopez-Girona et al., 
2012). The anti-angiogenic effect results from a reduced secretion of VEGF and bFGF from 
stromal and myeloma cells inhibiting endothelial cell adhesion and movement. Furthermore, 
IMiDs cause G0/G1 cell cycle arrest and induce apoptosis in multiple myeloma cells via an 
increased apoptosis protein-2 expression, elevated sensitivity to Fas induction, and activation 
of caspase-8. Interferon regulatory factor 4 (IRF4), a transcription factor regulating interferon 
signaling, is downregulated by IMiDs, causing death of the myeloma cell. Thalidomide and 
its derivatives also mediate production of TNFα, NF-κB, IL-2, IL-6, which are essential for 
cell growth, adhesion, survival, and proliferation of MM cells (for a review see e.g. Shortt et 
al., 2013). IMiDs further stimulate T-cell activity, escalating the NK-T- and NK-cell 
cytotoxicity against cancer cells (Lopez-Girona et al., 2012). CRBN seems to be the main 
trigger of thalidomide, lenalidomide, and pomalidomide functioning, although the broad 
spectrum of their action has initially challenged the notion of a single target. These 
compounds might also possess some secondary effects as a result of promiscuous binding to 
off-target factors, which could explain the differences in their clinical influence. 
Despite the pleiotropic effects of IMiDs, their main target in the cell remains CRBN 
within the DDB1-containing E3 ubiquitin ligase machinery. Altered ubiquitination of 
cereblon substrates seems to be a plausible explanation of IMiD-induced changes in the cell, 
although the knowledge about cereblon substrates is limited.  
The homeobox transcription factor MEIS2 was identified as a first endogenous target 
of cereblon, the degradation of which was 2-fold decreased upon IMiD treatment (Fischer et 
al., 2014). MEIS2 is implicated in many aspects of human development, which partially 
overlap with thalidomide-affected organs. However, the phenotypes caused by MEIS2 
overexpression/mutations differ from thalidomide-induced teratogenic effects. 
In the 2014 study, Ebert and co-workers used SILAC-based quantitative mas-
spectrometric analysis to characterize lenalidomide caused ubiquitination and degradation in 
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the multiple myeloma cells (Krönke et al., 2014). Two B-cell specific transcription factors, 
namely IKZF1 and IKZF3, showed decreased abundance upon compound treatment. 
Remarkably, these proteins interact with cereblon only in the presence of lenalidomide, which 
causes their cullin-dependent ubiquitination and subsequent degradation. CRBN knockdown 
or expression of the CRBN
YW/AA 
mutant abolishes IKFZ1 and IKFZ3 degradation and induces 
IMiD resistance in multiple myeloma cells. Strikingly, single amino acid change in IKFZ1 
Q146H (or IKFZ3 Q147H) abrogates lenalidomide-dependent ubiquitination, providing 
evidence why lenalidomide possesses differential sensitivity for Ikaros family members 
(IKFZ2 and IKFZ4 are lenalidomide invulnerable) (Krönke et al., 2014). These findings are 
completely consistent with the data of Kaelin, Chopra, and their co-workers, who used 
another approach in determination of cereblon substrates, but deduced similar conclusions (Lu 
et al., 2014; Gandhi et al., 2013). The degradation of IKFZ1/3 is associated with a decreased 
level of IRF4 expression and enhanced T-cell IL-2 production as they regulate promotor 
regions of these genes. This data supports previous studies of anti-proliferative activity of 
IMiDs suggesting that IKFZ1/3 targets modulate the therapeutic response. IKFZ1 and IKFZ3 
play an important role in B-cell biology, and their disposal from the cell explains the efficacy 
of lenalidomide activity in cancer treatment.  
Caseine kinase 1A1 (CK1ɑ) is another IMiD-induced cereblon substrate. Lenalidomide 
promotes its ubiquitination by E3 ubiquitin ligase, resulting in CK1ɑ degradation in myeloid 
cell line KG-1 (Krönke et al., 2015). The CK1ɑ mRNA is transcribed from CSNK1A1 gene, 
which deletion causes myelodysplastic syndrome (MDS) because of haploinsufficiency. 
Lenalidomide is highly efficient in the treatment of MDS promoting remission in more than 
50 % of the cases. The ubiquitination and subsequent reduction of CK1ɑ level in the cell leads 
to apoptosis. Interestingly, it is not targeted for degradation by mouse cereblon due to an 
amino acid sequence difference. Only 5 variant residues were found in the thalidomide-
binding domain of mouse and human cereblon. A substitutional analysis of non-conserved 
positions in human CRBN with the matching amino acids from mouse CRBN revealed that 
the exchange of human V387 for mouse isoleucine I391 disrupted the lenalidomide-induced 
substrate degradation. The same effect was also observed for lenalidomide-triggered 
ubiquitination of IKFZ1 and IKFZ3 in HEK293T cells with human CRBN V387I (Krönke et 
al., 2015). The bulkier isoleucine residue causes a spatial arrangement, disengaging hydrogen 
bond formation between cereblon and IKFZ or CK1ɑ and preventing their ubiquitination. 
Taken together, these data illustrate that lenalidomide selectively regulates IKFZ1/3 and 
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CK1ɑ levels, unraveling a new mechanism of action of IMiDs - cereblon gain of function 
effect. Consequently, cereblon was considered as a precursory biomarker for the efficiency of 
IMiD therapy (Gandhi et al., 2014).  
Recent findings suggest two possible explanations of IMiD-induced teratogenicity: (I) 
inhibition of substrate binding with cereblon and their increased abundance in the cell; (II) 
creation of a new binding surface upon IMiD harboring, which causes ubiquitination of 
unusual substrates and their subsequent degradation. Besides, these substrates may vary in 
different cellular lineages, leading to tissue-specificity effects. 
Lenalidomide and pomalidomide in cancer treatment. The clinical potency of 
lenalidomide is higher than thalidomide, but lower than pomalidomide, which has been shown 
in a number of cellular systems and in vivo (Lopez-Girona et al., 2012; Mahony et al., 2013). 
Lenalidomide belongs to the second-generation of IMiDs possessing pleiotropic 
effects in cancer treatment, including increased anti-proliferative and immune cell stimulation 
activities. It downregulates IRF4 and SPIB transcription factors in a cereblon-dependent 
manner, which leads to an elevated IFNβ production and blockage of the pro-survival NF-κB 
signaling pathway in the diffuse large B-cell lymphoma. Additionally, lenalidomide reduces 
expression of anti-apoptotic factors; displays anti-angiogenic activity by modulation of TNFα, 
VEGF, and endothelial cell migration (Dredge et al., 2005); modifies cytokine production, 
thereby enhancing cytolitic activity of CD8+ T-cells (for a review see e.g. Martiniani el al., 
2012). 
Pomalidomide is the third-generation IMiD displaying a higher potency in anti-
myeloma activity in comparison to thalidomide and lenalidomide due to: (I) lower toxicity 
and reduced side effects at its working dose, (II) fast metabolism prior to excretion, and (III) 
efficiency in patients refractory to thalidomide and lenalidomide (Lacy et al., 2011). In 
comparison to its structural analogs, pomalidomide exhibits its anti-inflammatory activity at 
notably lower concentration that is non-teratogenic in zebrafish and chicken (Mahony et al., 
2013). Although pomalidomide was recently licensed for the clinical usage, US Food and 
Drug Administration indicates that it may be teratogenic in some mammalian species.  
Thalidomide does not induce limb deformities in rodents, but does it in rabbits. Some 
other developmental defects, namely rib, eye disorders were reported after thalidomide 
administration to pregnant rats (Parkhie and Webb, 1983). Concurrently, lenalidomide did not 
cause teratogenic effects in rats and rabbits, but affected monkeys’ limb development 
(Celgene, unpublished data). Pomalidomide provoked developmental defects in rats and 
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rabbits, but was reported to be safe for zebrafish and chicken, when used at the anti-
inflammatory working dose.  
The molecular mechanism of IMiDs action is very complex including the divergence 
and complementarity in the treatment of different diseases. Unfortunately, the valuable 
properties of IMiDs appear to be inseparable from their harmful clinical side effects, such as 
nerve-damage, teratogenicity, myelosuppression, since they are caused by the same molecular 
targets. Considering their exceptional efficiency in multiple myeloma treatment, a new search 
of harmless IMiDs is highly beneficial. Alternatively, identification of cereblon downstream 
targets that can be therapeutically manipulated by novel drugs could significantly improve the 
clinical picture of multiple myeloma patients. 
 
 
1.7 Cereblon is a protein with various functions 
 
Human crbn contains 11 exons and encodes a 442–amino acid protein. CRBN is 
highly conserved from plants to humans and was originally identified as a candidate gene for 
autosomal recessive mild mental retardation (Higgins et. al., 2004). An R419X non-sense 
mutation in CRBN causes the truncation of the C-terminal 24 amino acids, which is linked to 
autosomal recessive non-syndromic mental retardation (ARNSMR), memory and learning 
defects. The mutant protein preserves its ability to form a fully functional E3 ubiquitin ligase 
complex with Cul4A and DDB1 since it ubiquitinates AMPKα1 and calcium activated 
potassium channel (Xu et al., 2013). At the same time, R419X mutation enhances CRBN 
autoubiquitination and its subsequent proteasomal degradation, causing its decreased 
abundance in the cell. Interestingly, thalidomide reduces ubiquitination of wild type CRBN, 
but not CRBN R419X, indicating that it can’t be considered as a drug against mental 
retardation. However, proteasome inhibitors are able to restore physiological level of CRBN 
R419X in the cells, thus appearing to be potential drugs for intellectual disability treatment 
(Xu et al., 2013).  
Immunoprecipitation from rat brain lysate showed rat CRBN (rCRBN) interacts 
directly with the cytosolic C-terminus of the calcium activated potassium channel α subunit 
(Jo et al., 2005). In situ hybridization experiments represented the ubiquitous expression 
pattern of rcrbn mRNA with a prominent signal in brain, liver, kidney, and testis. Notably, the 
highest level of CRBN expression was detected in the hippocampus, cerebellum, and cortex, 
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what overlaps with mRNA distribution of calcium activated potassium channel (Jo et al., 
2005; Aizawa et al., 2011). The cell surface expression and assembly of the channel tetramers 
are suppressed by rCRBN overexpression, suggesting an explanation of the involvement of 
cereblon in cognitive processes (Jo et al., 2005; Rajadhyaksha et al., 2011; Liu et al., 2014). 
Moreover, the voltage-gated chloride channel (CIC-2) was identified as CRBN binding 
partner, and shown to be functionally modulated in the retina (Hohberger, Enz, 2009; Chen et 
al., 2015).  
CRBN is widely expressed in all tissues in the organism (Jo et al., 2005; Hohberger 
and Enz, 2009; Aizawa et al., 2011). Although it plays an important role in the functioning of 
the nervous system, the regulation of its expression in neuronal cells is only poorly 
understood. Herold and co-workers illustrated that mental disorders can be inflicted by 
hypoxia (Tenyi el al., 2008). To follow up this idea, Park and colleagues monitored the 
regulation of CRBN expression under conditions of hypoxia and reoxygenation (Lee et al., 
2010). They registered an increase of CRBN mRNA and protein expression levels in mouse 
neuroblastoma cells, which was stimulated by transcription factor Nrf2. Nrf2 (NF-E2-related 
factor 2) is a transcription factor that not only binds cereblon promoter, but also activates 
antioxidant response elements, which protect the cell from the oxidative damage. Thus, 
CRBN is speculated to be one of the components of the antioxidant defense in the cell, but the 
experimental evidence supporting this hypothesis is missing (Lee et al., 2010).  
Opportune protein degradation is crucial for the function of the central nervous system 
since it defines a synaptic plasticity and signal transmission. In addition to its involvement in 
ubiquitination process, CRBN was demonstrated to inhibit the 26S proteasome activity. By 
interacting with the β7 subunit of the 20S core particle, CRBN disrupts its assembly in a 
neuroblastoma cell line (Lee et al., 2012). Many neuron disorders result from proteasome 
dysfunction and cereblon-mediated mental retardation might also be one of them in the light 
of cereblon R419X non-sense mutation. CRBN also binds to the α1 subunit of AMP-activated 
protein kinase (AMPK) and inhibits its activity, leading to dramatic changes in the 
consumption and production of ATP in the cell (Lee et al., 2011). Similarly, crbn knockout in 
mice causes a significant energy misbalance, especially when mice are on the fat-rich diet 
(Lee et al., 2013).  
To elucidate the physiological role of cereblon, conditional and germ-line crbn 
knockout mice were generated (Rajadhyaksha et al., 2011). They are affected in 
hippocampus-dependent associative memory and learning, thus representing a good in vivo 
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model for studying functionality of these disorders. Park and colleagues studied influence of 
the whole body crbn deficiency in mice under a normal and a high-fat diet (Lee et al., 2013). 
Crbn-deficient mice showed a hyperphosphorylation of AMPK leading to a significant 
elevation of its activity, which demonstrated a negative regulatory effect of cereblon on 
AMPK. 
 
 
1.8 The domain structure of cereblon 
 
Cereblon received its name due to the presence of a LON domain, its high expression 
in the cerebellum and its important role in brain development. CRBN appears in all 
eukaryotes except fungi. Its size varies from 400 to 600 amino acids and it occurs only once 
in each genome (Lupas et al., 2015). Cereblon has a conserved LON domain located 50-100 
amino acids from the N-terminus (Fig. 1.3). The LON domain comprises the N-terminal part 
of the ATP-dependent Lon protease, which does not possess the protease or ATPase activity, 
but is crucial for protein-protein interaction. The LON domain consists of two regions: an N-
terminal six β-stranded pseudo-barrel, covered on one side by a helix (LON-N); and a helical 
bundle of four to five helices (LON-C). These two parts are separated by a stretch of amino 
acid residues, which was identified by Handa and co-workers as DDB1-binding region (Ito et 
al., 2010). A deletion analysis demonstrated that the cereblon mutant, which lacks the middle 
region between 187 to 260 amino acids, lost its capacity to interact with DDB1.  
At the very N-terminus cereblon homologs have an extension of up to 100 amino acid 
residues, which is the least conserved part of the protein. The region flanking the LON 
domain at the N-terminus gains conservation from early eukaryotes to plants and humans. It 
has a notable FDxxLPxxHxYLG motif with yet unpredicted function (Lupas et al., 2015).  
The C-terminal part of CRBN, which is most conserved among all species, is 
responsible for thalidomide binding (Ito et al., 2010). This region contains numerous strictly 
conserved residues preserved from early eukaryotes to humans. Sequence analysis 
additionally identified other proteins comprising only the thalidomide-binding domain, which 
was named CULT for cereblon domain of unknown activity, binding cellular ligands and 
thalidomide. 
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Figure 1.3. Schematic view of the domains of cereblon (modified from Lupas et al., PLoS 
Computational Biology, 2015). 
 
 
1.9 The CULT domain 
 
Regardless the high level of conservation and the wide distribution of the CULT 
domain, pointing on a basic function in nature, its role in the organism remains so far 
uncovered. Detailed bioinformatic analysis with a focus on the thalidomide-binding domain 
showed that, beside LON-containing cereblon proteins, other groups comprising a CULT 
domain do exist (Fig. 1.4). The two biggest clusters are: (I) prokaryotic proteins from δ-
proteobacteria, a few representatives from α- and γ-proteobacteria, and one spirochete; and 
(II) animal proteins from simplest multicellular organisms up to fish (Lupas et al., 2015).  
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Figure 1.4. Cluster map of CULT domain proteins (adapted from Lupas et al., PLoS 
Computational Biology, 2015) 
 
 
The bacterial cereblon proteins consist exclusively of the CULT domain, whereas their 
animal homologs additionally contain an N-terminal secretion signal sequence (Hostomska et 
al., 2009). The other two groups are evolutionary more distant and provide different context 
for the CULT domain. In oomycetes it is positioned between the N-terminal signal sequence 
and a carbohydrate-binding domain and in kinetoplastids the CULT precedes a C-terminal 
region with an unknown architecture and function. The multiple sequence alignment of 
representatives from the main groups of cereblon proteins illustrates a high level of 
conservation among different clusters (Fig. 1.5). Two CxxC cysteine motifs are a distinctive 
feature of a zinc binding site, which compose such a site in domains structurally homologous 
to the CULT domain. Further, the multiple sequence alignment shows three invariant 
tryptophan residues with their conserved neighborhood. 
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Figure 1.5. Multiple alignment of CULT domains from representatives of the groups shown in 
Fig. 1.4 (based on the results of a PSI-Blast search with the CULT domain of human 
cereblon). The sequences are: (cereblon) HS - Homo sapiens, DR - Danio rerio, DM - 
Drosophila melanogaster, CE - Caenorhabditis elegans, AT - Arabidopsis thaliana, EH - 
Entamoeba histolytica; (secreted eukaryotic) DR - Danio rerio, CE - Caenorhabditis elegans, 
TA – Trichoplax adhaerens, NV - Nematostella vectensis; (bacterial) MG - Magnetospirillum 
gryphiswaldense, GP – gamma proteobacterium BDW918, HO - Haliangium ochraceum, DT - 
Desulfonatronospira thiodismutans; (oomycete) PP - Phytophthora parasitica INRA-310, SP - 
Saprolegnia parasitica CBS 223.65; (kinetoplastid) LM - Leishmania major strain Friedlin, 
TC - Trypanosoma cruzi Dm28c (modified from Lupas et al., PLoS Computational Biology, 
2015). 
 
The CULT domain belongs to the group of β-tent fold proteins (Lupas et al., 2015). 
Members of this group share a common arrangement of two four-stranded, antiparallel β-
sheets oriented at a right angle with a zinc ion at their tip providing the name for the whole 
group. Lupas and co-workers performed the search for remote homologs using profile Hidden 
Markov Model (HMM) comparison in HHpred and yielded a protein family of eukaryotes, 
yippee, as the best match for the CULT domain (Lupas et al., 2015). Mammalian yippee 
proteins are involved in signal transduction and anti-proliferative activity, but the mechanism 
of their action is still obscure (Kelley et al., 2010). Along with yippee, another eukaryotic 
protein Mis18 (absent in plants), which is implicated in centrosome assembly, was found 
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(Hayashi et al 2004; Fujita et al., 2007). Methionine sulfoxide reductase (MsrB) and the 
regulatory domain of retinoic acid-induced gene-1 (RIG-I) are two distant CULT homologs 
with known structure and completely distinct functions. MsrB is a universal protein found in 
all domains of life, that guards the cellular environment from oxidative damage by reducing 
methionine sulfoxide to methionine, whereas RIG-I is found only in animals and senses viral 
RNA (Lee B. et al., 2009; Leung and Amarasinghe, 2012). This data suggests that CULT 
domain, yippee, MsrB, RIG-I and other homologs not mentioned here can be grouped 
together based on their structural, but not functional similarities.  
 
 
1.10 Aims of the thesis 
 
Cereblon is a protein widely spread from plants to humans. Its C-terminal highly 
conserved CULT domain binds the drug thalidomide and mediates its teratogenic effects. 
However, the natural ligands of this domain as well as its function are still unknown. 
The presence of homologs entirely composed of the CULT domain up to fish, together with 
the high grade of conservation points at the importance of this domain in nature and is 
indicative for a conserved function. At the beginning of the work within the framework of this 
thesis, the structure of a bacterial CULT domain from M. gryphiswaldense was just solved by 
our lab. Choosing the thalidomide-binding domains from human CRBN and the secreted C. 
elegans homolog, the first goal of this work was to solve the structure of a eukaryotic CULT 
domain to provide a basis for comparative structural and functional analyses.  
Another important aim was the identification of so far unknown natural ligand(s) of 
the CULT domain. Based on its high stability, availability and easiness in handling, MsCI4 
was used in our lab as a robust model system not only for structural studies, but also for the 
development of a FRET-based in vitro assay for determination of binding affinities of ligands 
to the CULT domain. Within the framework of this thesis, we aimed to use this assay to 
comparatively study the affinities of the CULT domains from human, worm, and bacteria for 
thalidomide and structurally related low-molecular weight substances, including various 
pharmacological compounds. Based on these in vitro studies, we intended to apply an in vivo 
assay using zebrafish embryos to validate the teratogenic potential of the identified ligands.  
Aiming at the elucidation of the function of the CULT domain and its involvement in 
cellular processes, we further planned the use of MsCI4 in pull down analyses in the presence 
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or absence of thalidomide in order to identify binding candidates of the CULT domain in the 
cell. 
Expecting that the additional domains of human CRBN, the N-terminal unstructured 
region and the LON domain containing the DDB1 binding region, play an important role in 
protein functionality and could provide a clue towards the understanding of the cellular role of 
the CULT domain in the eukaryotic cell, we further extended our studies beyond the bacterial 
model system. In order to gain first insight into the cereblon basic function in the eukaryotic 
cell, we outlined comparative proteome analysis of the proteins bound to human cereblon 
with and without drug treatment.  
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2 MATERIALS AND METHODS  
 
In this chapter I am describing the materials and methods used during my PhD, but not 
presented in our publications. The according unpublished results are summarized in 
chapter 3.4 
 
 
2.1 Cloning, expression, and protein purification  
 
The coding DNA of target genes or gene regions was amplified by polymerase chain 
reaction (PCR) with sequence specific oligonucleotides carrying restriction enzyme sites, 
using the plasmid or cDNA as a matrix (Saiki et al., 1988). After running a 1 % agarose gel 
(Sambrook et al., 1989), the according PCR product was extracted from the gel (Qiagen kit), 
cleaved with appropriate restriction enzymes and subsequently ligated into an expression 
vector treated with the same enzymes unless otherwise specified. Cloning details for genes 
expressed for structural studies are summarized in the Appendix I.  
FLAG-MsCI4 and MsCI4
YW/AA
 was constructed by inserting an annealed primer pair 
encoding the FLAG-tag and flanked by NcoI sites in the NcoI site of the available expression 
clone containing MsCI4 in pETHis1a (Hartmann et al., 2014). The resulting construct 
contains a 6xHis tag followed by a TEV cleavage site, a FLAG tag, and MsCI4 (Fig. 2.1.1). 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.1. Insertion of the FLAG-tag DNA coding sequence into clone containing MsCI4 in 
pETHis1a (schematic overview). Only the coding DNA strand is depicted on the picture. 
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The genes of candidate binders of MsCI4 were amplified, using the M. gryphiswaldence 
genomic DNA, and cloned in the petHis1a vector. Further details of cloning and expression 
concerning these constructs are summarized in the Appendix II. 
Plasmids were delivered into E. coli competent cells by heatshock. A positive clone 
selection was performed based on the antibiotic resistance and correctness was confirmed by 
DNA sequencing. Overexpression of the genes in E. coli was optimized with respect to 
temperature and isopropyl-β-D-1-thiogalactopyranoside (IPTG) concentration. 
The standard purification protocol included loading soluble fractions of cellular extracts 
in 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM 2-mercaptoethanol on a nickel affinity 
column followed by cleavage of the tag and a second step of affinity purification unless 
otherwise specified. SDS-PAGE analysis was performed at each stage to monitor purity of the 
sample (Laemmli, 1970).  
Eukaryotic proteins were produced in the baculovirus-insect cell expression system as 
described here (Boichenko et al., 2016). For DDB1 isolation, additional ion exchange and size 
exclusion chromatography steps were required to obtain pure protein.  
Folding of the proteins and formation of secondary structures was further validated by 
NMR or CD spectroscopy (Jasco CD-Spectropolarimeter J-810) (Kelly et al., 2005) 
 
 
2.2 Electrophoretic mobility shift assay (EMSA) 
 
Protein was mixed with RNA or either single-stranded or double-stranded DNA 
(optionally containing single uracil nucleotides) in a molar ratio of 1:10 (Appendix III). The 
mixture was incubated for 30 minutes in 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 % 
glycerol, 0.5 mM 2-mercaptoethanol at room temperature. Afterwards samples were run on 
the NativePAGE (Invitrogen) or a 2 % agarose gel. Gels were stained, using Stain G (Serva) 
or 0.5 μg/ml ethidium bromide solution (Hellman and Fried, 2007). 
 
 
2.3 DNA pull down assay 
 
The His-tagged protein was mixed with either single- or double-stranded biotinylated 
DNA (optionally containing single uracil nucleotides) in a ratio of 1:10 in the presence or 
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absence of thalidomide (Appendix III). The mixture was incubated for 1 hour in the binding 
buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 % glycerol, 0.5 mM 2-mercaptoethanol) 
at room temperature. Samples were further applied on streptavidin sepharose (Sigma) 
equilibrated with the binding buffer. The beads were washed 3 times with 1 ml wash buffer 
(20 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 % glycerol, 0.5 mM 2-mercaptoethanol, 0.5 % 
Nonidet P-40). Afterwards LDS sample buffer was added to the beads and a Bis-Tris gel 
(Invitrogen) was run followed by Western blot analysis using anti-His antibodies (Wu, 2006). 
For some experiments, the procedure was adapted in a way that cell lysate instead of 
binding buffer was added to the samples. Bacterial lysate was prepared as described by 
method 2.7. For studying the human protein, HEK293T cells overexpressing HA-tagged 
CRBN were used. The mammalian cell lysate was prepared as described by method 2.10.4. 
All steps were carried out at 4 °C. 
 
 
2.4 Histone code peptide microarray 
 
The peptide microarray slide (JPT Peptide Technologies) was incubated with 0.1 mg/ml 
His-tagged protein solution in 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5 mM 
2-mercaptoethanol for 4 hours at 4 °C. Subsequently, the slides were washed 5 times with 
1 ml TBST buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % Tween) and incubated 
with mouse anti-His antibodies (1/1,000; Dianova) in 2 % BSA in TBST. Following 5 steps 
of a washing procedure, anti-mouse-Cy5 antibodies were applied in 2 % BSA in TBST 
(1/5,000; Abcam). After an additional washing step, the signal was recorded on the GenePix 
microarray scanner (Molecular Devices) using fluorescent signal. Data were analyzed with a 
PepSlide_Analyzer_Win-1.5.8 (SICASYS Software GmbH). 
 
 
2.5 Analytical size-exclusion chromatography 
 
Appropriate amounts of either RNA or DNA was incubated with protein in a molar ratio 
of 1:1 in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM 2-mercaptoethanol for 10 minutes. 
200 µl of sample were further loaded on a Superdex 200 10/300 G column. RNA, DNA or 
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protein solutions were run separately as controls. Elution was recorded by UV absorption at 
260 and 280 nm. 
 
 
2.6 In vivo assay in zebrafish 
 
Compounds. Glutarimide, hydantoin, succinimide, ethosuximide, γ-butyrolactam, δ-
valerolactam, and sodium barbiturate (all from Sigma) were dissolved in water to make 
400 mM stock solution.  
Cloning. The zebrafish cereblon (zcrbn) gene annotated at http://www.ensembl.org was 
amplified by nested PCR from cDNA, using primer pairs 5`- 
AGAGCGGATTGTAAACACACGGC, 5`- TGTGTGAAGGCAACAACTTGTGTTC for the 
first reaction set up and 5`- CGGATCCGATGGCTGCTGAGAGG, 5`- 
CTCTAGAGTCACAGGCACAGCAAGCGTG for the second. The PCR product was 
digested with BamHI and XbaI and cloned in the pCS2+ vector. All clones were verified by 
DNA sequencing. zCRBN possesses double mutation Y389A/W391A, which corresponds to 
the human CRBN
Y384A/W386A
 and MsCI4
Y83A/W85A
. The positions of zCRBN mutation are 
different from described by Handa and co-workers since gene annotation was taken from 
http://www.ensembl.org, but not NCBI database (Gene ID: 445491) that results in 15 amino 
acid extended N-terminus of the protein (Ito et al., 2010). 
Fish treatment. Zebrafish were maintained at 28°C on a 14-hours light / 10-hours dark 
cycle. The breeding was done as previously described (Nüsslein-Volhard C, Dahm R, 2002). 
The examined species was Danio rerio 
leot1
. The stock solutions of compounds were diluted in 
E2 medium to a final concentration of 400 µM. 2 hours post fertilization, embryos were 
dechorinated in E2 medium containing 2 mg/ml pronase (Sigma) for 8 min at room 
temperature, washed five times, and immediately transferred to the medium containing the 
potential teratogen. Fish developed for 75 hours post fertilization in the drug-containing E2 
medium, which was exchanged every 12 hours.  
Microinjections of capped mRNA. Microinjections were carried out by injection of 
zygotes of 1-cell stage embryos under a microscope (Zeiss, Stemi 2000), using 275 Pa (40 
psi) injecting pressure for 100 ms (World Precision Instruments, Pneumatic PicoPump 
PV820). After linearization of zcrbn_pCS2+ with NotI, capped mRNA was synthesized with 
mMessage mMachine kit and cleaned up via lithium chloride precipitation (both Ambion). 
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mRNA was dissolved in nuclease free water at 200 ng/µl and 20% (v/v) phenol red solution 
(Sigma- Aldrich, P0290-100ML). 
Measurement of pectoral fins. 3 days old embryos were anesthetized and fixed in the 
1% agarose for further imaging with Zeiss, SteREO Discovery. The length of the pectoral fins 
was measured using self-developed software, which allows curvature determination in a semi-
automatic fashion. The diagnostic criteria were estimated as follows: "no effect" for fins 
exceeding 85% of the fin length of the control; "mild" for fins corresponding to 75-85% of the 
control length; "medium" for fins shortened to 60 to 75% of length; and "severe" for fins 
shorter than 60% of the control length. 
 
 
2.7 Immunoprecipitation of FLAG-MsCI4 and mass spectrometric analysis 
 
Bacterial cells were resuspended in the lysis buffer (25 mM HEPES pH 7.3, 
130 mM NaCl, 20 mM KCl, 4 mM MgCl2, 0.5 % Nonidet P-40, 0.5 mM DTT, 1 mM PMSF, 
protease inhibitors (EDTA-free, GE Healthcare), DNase I). Samples were sonicated, using a 
Branson Sonifier (G. Heinemann), centrifuged at 48,700 x g for 45 minutes at 4 °C to clear 
the lysates. The supernatants were collected and protein concentration was determined (Pierce 
BCA kit). In parallel, FLAG-MsCI4 or FLAG-MsCI4
YW/AA
 was coupled to anti-FLAG M2 
magnetic beads (Sigma) equilibrated with binding buffer (25 mM HEPES pH 7.3, 130 mM 
NaCl, 20 mM KCl, 4 mM MgCl2, 0.5 % Nonidet P-40). Equal amounts of cell extract were 
mixed with coupled beads in binding buffer, optionally in the presence of 50 µM thalidomide 
or the appropriate concentration of DMSO. 100 µl of the beads suspension was used for each 
sample condition. Samples were incubated for 4 hours at 4 °C with gentle mixing. After 
incubation, the resin beads were washed 3 times with 1 ml wash buffer (25 mM HEPES pH 
7.3, 130 mM NaCl, 20 mM KCl, 4 mM MgCl2, 0.5 % Nonidet P-40) to remove non-
specifically bound proteins. Target molecules were eluted by incubation of the beads with 
200µl of 0.1 M Glycine-HCl, pH 2.0 for 5 minutes with gentle shaking. Protein precipitation 
was performed overnight at -20 °C following addition of 800 µl of cold 100 % acetone. 
Solutions were centrifuged at 17,000 x g at 4 °C, pellets were collected and dried. After 
solubilization, protein concentration was determined by Bradford method (Bradford, 1976). 
Tryptic digestion of 12 µg/sample was performed at the Proteome Center (Universität 
Tübingen) with on the stage methylation labeling (Boersema et al., 2009). After mixing LC-
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MS/MS analysis on a Proxeon Easy-nLC coupled to an LTQ-Orbitrap XL was conducted. 
The data were processed, using MaxQuant software (version 1.5.1.0). and had a setting of 1 % 
for the false discovery rate (Käll L., et al., 2008). 
 
 
2.8 Protein co-immunoprecipitation from bacterial cell extract  
 
E. coli cells overexpressing the candidate binding protein were resuspended in lysis 
buffer (25 mM HEPES pH 7.3, 130 mM NaCl, 20 mM KCl, 0.5 % Nonidet P-40, 
5 % glycerol, 1 mM PMSF, protease inhibitors (EDTA-free (GE Healthcare), DNase I)). 
Samples were sonicated, using a Branson Sonifier (G. Heinemann), and centrifuged at 
48,700 × g for 45 minutes at 4 °C to clear the lysates. The supernatants were pre-cleared by 
incubation with 20 µl protein A/G magnetic beads (Sigma) for 1 hour at room temperature. 
FLAG-MsCI4 or FLAG-MsCI4
YW/AA
 was added to the pre-cleared lysates at a final 
concentration of 0.8 mg/ml and incubated for 2 hours at room temperature. In parallel 40 µl 
protein A/G beads were coupled to 10 µg rabbit anti-FLAG antibodies (Dianova) for each 
sample.  Subsequently, the coupled beads were combined with bacterial lysates containing 
overexpressed FLAG-MsCI4 or FLAG-MsCI4
YW/AA
 and incubated for 2 hours at room 
temperature. The beads were washed 3 times with 1 ml wash buffer (25 mM HEPES pH 7.3, 
130 mM NaCl, 20 mM KCl, 0.5 % Nonidet P-40, 5 % glycerol) to remove non-specifically 
bound proteins. Target molecules were eluted by incubation of the beads with 200 µl of 0.1 M 
Glycine-HCl pH 2.0 for 5 minutes with gentle shaking. Following addition of 800 µl of cold 
100 % acetone, proteins were precipitated overnight at -20 °C. Subsequently, solutions were 
centrifuged at 17,000 x g at 4 °C, pellets were collected, dried, and dissolved in the LDS or 
SDS sample buffer (Invitrogen). Samples were loaded on the Bis-Tris gels (Invitrogen) and 
further analyzed by Western blotting. 
 
 
2.9 Western blotting 
 
Proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane 
(pore size 0.45 µm, Whatman) in 25 mM Tris, 150 mM Glycine, and 10 % methanol for 
1 hour at 30 V, using an XCell II Blot Module (Invitrogen). The membrane was blocked with 
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5 % BSA in PBS with 0.1 % Tween 20 (PBST) for 2 hours at room temperature. Proteins 
were detected by incubation of the membrane for 16 hours at 4 °C with primary antibodies in 
2 % BSA in PBST. Membrane was washed three times with PBST and incubated for 1 hour at 
room temperature with HRP-conjugated secondary antibodies in 2 % BSA in PBST. After 
washing with PBST, bands were developed with Clarity Western ECL substrate (Bio-Rad) 
and imaged with a FUSION Xpress (Peqlab). 
The antibodies and their dilutions are listed in Appendix IV. 
 
 
2. 10 Mammalian cell culture 
 
2.10.1 Cloning procedure for mammalian expression 
 
The coding DNA of target genes was amplified by PCR using the plasmid or human 
cDNA as a matrix for the reaction and gene specific oligonucleotides carrying sites for 
restriction enzymes. The PCR product was extracted from the gel (Qiagen kit), cleaved with 
appropriate restriction enzymes and subsequently ligated into an expression vector treated 
with the same enzymes. Cloning details for human genes used for mammalian expression are 
summarized in the Appendix V. Plasmids were delivered into E. coli competent cells by 
heatshock. A positive clone selection was performed based on the antibiotic resistance and 
confirmed by DNA sequencing. 
 
 
2.10.2 Mammalian cell culture, maintenance, and transfection 
 
Adherent HEK293T or HELA cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10 % fetal bovine serum, 100 µg/ml penicillin, 
100 µg/ml streptomycin, and 2 mM L-Glutamine (all from Invitrogen) at 37 °C in a 
humidified atmosphere with 5 % CO2 (DuBridge et al., 1986).  
For transient transfection, HEK293T cells were seeded in medium without antibiotics in 
100 mm dishes or 75cm
2
 flasks (both Greiner Bio-One) and cultured till 90 % confluency. 
DNA and lipofectamine 2000 (Invitrogen) were mixed separately with OPTIMEM 
(Invitrogen) medium (unless other is specified), following the manufacturer’s protocol. Two 
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solutions were combined, incubated at room temperature for 20 minutes for lipid-DNA 
complex formation and added dropwise to the cells. The medium was exchanged after 
6 hours. For smaller dishes the amount of DNA was adjusted accordingly. Cells were 
harvested after 24 hours of transfection by centrifugation at 1,000 x g and frozen at -20 °C. 
For SILAC-based mass spectrometric analysis HEK293T were grown for 6 passages in 
appropriate medium containing isotope-labeled amino acids. For each condition, cells from a 
25 cm
2
 flask were harvested by spinning them down at 1,000 x g. The pellet was resuspended 
in lysis buffer (50 mM Tris-HCl pH 8.0, 6 M urea, 2 M thiourea, 1 % N-Octylglucoside, 
4 mM MgCl2 and 10 µg/ml DNase I), vortexed, and incubated for 10 minutes at room 
temperature. Supernatants were prepared by centrifugation at 2,800 x g, 10 °C for 30 minutes 
and further given for an isotope incorporation check to the Proteome Center (Universität 
Tübingen). Transfection was performed with samples containing ≥ 96 % of labeled amino 
acids. The procedure was the same as it is described above with one modification: instead of 
OPTIMEM the SILAC medium (Invitrogen) deprived from amino acid isotopes was used for 
preparation of lipid-DNA complex. 20 µM thalidomide or appropriate DMSO concentration 
was used for cell treatment. 
 
 
2.10.3 FLAG-CRBN immunoprecipitation and mass spectrometric analysis 
 
Cells were resuspended in 500μl lysis buffer (20 mM Tris-HCl pH 7.5, 130 mM NaCl, 
20 mM KCl, 10 % glycerol, 5 mM EDTA, 0.5 % Triton X-100, 20 µM thalidomide or 
appropriate DMSO concentration, 1 mM PMSF, phosphatase inhibitor cocktail 2 (Sigma, 
dilution 1:100), protease inhibitors (EDTA-free, GE Healthcare)), incubated on ice for 
5 minutes, homogenized by 5–10 passages through a needle, centrifuged at 17,000 × g for 
5 minutes at 4 °C to clear the lysates and the supernatants were collected. Protein 
concentration was determined to adjust it equally for all the samples (Pierce BCA kit). The 
cell extract was added to anti-FLAG beads (Sigma) preliminary equilibrated in 20 mM Tris-
HCl pH 7.5, 150 mM NaCl and incubated for 4 hours at 4 °C with gentle mixing to capture 
the FLAG-CRBN. 100 µl of the beads suspension was used for each condition. Following 
incubation, the resin beads were washed 3 times with 1 ml wash buffer (20 mM Tris-HCl 
pH 7.5, 130 mM NaCl, 20 mM KCl, 10 % glycerol, 5 mM EDTA, 0.5 % Triton X-100, 
20 µM thalidomide or appropriate DMSO concentration) to remove non-specifically bound 
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proteins. Target molecules were eluted by incubation of the beads with 0.1 M Glycine-HCl 
pH 2.0 for 5 minutes with gentle shaking. After determination of protein concentration (Pierce 
BCA kit), the eluates samples were further analyzed by MS analysis at the Proteome Center 
(Universität Tübingen).  
 
 
2.10.4 Protein co-immunoprecipitation from mammalian cell extract  
 
Overexpression was done separately for each protein of interest. 10
7
 cells per sample 
were resuspended in lysis buffer (25 mM HEPES pH 7.3, 130 mM NaCl, 20 mM KCl, 
10 % glycerol, 1 mM EDTA, 0.5 % Nonidet P-40, 1 mM PMSF, phosphatase inhibitor 
cocktail 2 (Sigma, dilution 1:100), protease inhibitors (EDTA-free, GE Healthcare)). The 
lysates were incubated on ice for 5 minutes, homogenized by 5–10 times passages of the cells 
through a needle, cleared by centrifugation for 30 minutes at 17,000 x g and 4 °C. The protein 
extracts with HA-CRBN and its FLAG- or Myc-tagged potential binding partner were 
combined and added to anti-HA magnetic beads (Sigma) preliminary equilibrated in the 
buffer (25 mM HEPES pH 7.3, 130 mM NaCl, 20 mM KCl, 10 % glycerol, 1 mM EDTA, 
0.5 % Nonidet P-40). 40 µl of the beads suspension was used for each condition. Appropriate 
samples overexpressing HA- or FLAG-tagged LacZ were prepared as controls. Extracts were 
incubated for 4 hours at 4 °C with gentle mixing to capture the HA-CRBN. The resin beads 
were washed 3 times with 1 ml wash buffer (25 mM HEPES pH 7.3, 130 mM NaCl, 20 mM 
KCl, 10 % glycerol, 1 mM EDTA, 0.5 % Nonidet P-40) to remove non-specifically bound 
proteins. Target molecules were eluted by incubating the beads with 200 µl of 0.1 M Glycine-
HCl pH 2.0 for 5 minutes with gentle shaking. Proteins were precipitated overnight at -20 °C 
after addition of 800 µl of cold 100 % acetone. Pellets were collected by centrifugation at 
17,000 x g at 4 °C, dried and dissolved in the LDS or SDS sample buffer (Invitrogen). 
Samples were loaded on Bis-Tris or Tris-Acetate gels (Invitrogen) and further analyzed by 
Western blotting. 
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2.11 Generation of C. elegans transgenes 
 
The gene of secreted C. elegans cereblon protein is annotated as R08B4.3. PCR 
fragments were amplified from wild type C. elegans genomic DNA as depicted in Fig. 2.11.1. 
A R08B4.3::GFP reporter was constructed by fusion PCR to obtain the R08B4.3 amplicon in 
frame with gfp, which was generated from the pPD95.75 (Hobert, 2002). Three different 
promoter regions were used separately for designing the constructs: natural promotor of 
R08B4.3, ges-1, and myo-3. PCR products were visualized by standard agarose gel 
electrophoresis. After purification from the gel (Qiagen kit), DNA was injected into gonads of 
adult worms together with the pRF4 plasmid (rol-6) as a coinjection marker as described 
(Mello et al., 1991). The expression of the coinjection marker restrains worm movement to a 
circle trajectory. All constructs were verified by sequencing.  
 
 
 
Figure 2.11.1. Outline of fusion PCR protocol for R08B4.3::GFP reporter construction. 
 
 
2.12 Nematode maintenance and synchronization 
 
Nematodes (C. elegans N2 Bristol strain) were maintained on NGM (Nematode 
Growing Media) agar plates seeded with Escherichia coli OP50 as food source and stored at 
20 °C. Synchronized populations of C. elegans were obtained by hypochlorite treatment. 
Worms were allowed to grow to young adult stage and then injected into gonads. The 
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transgenes showing the features of marker expression were picked for the F2 generation, 
which were subsequently checked for the GFP signal that is indicative for intended construct 
expression. 
 
 
2.13 Preparation of C. elegans cell extracts 
 
Synchronized populations of C. elegans were resuspended in extraction buffer (50 mM 
HEPES pH 7.3, 130 mM NaCl, 20 mM KCl, 0.5 % Triton X-100, 10 % glycerol, 
4 mM MgCl2, 5 mM 2-Mercaptoethanol, 1 mM DTT, 1 mM PMSF and protease inhibitors 
(EDTA-free, GE Healthcare)), sonicated, and centrifuges for 30 minutes at 17,000 x g and 
4 °C. Supernatants were collected and total protein concentrations were determined, using 
Pierce BCA kit. 30 µg of protein extract per lane of a 15 % SDS-PAGE was loaded and 
further analysed by Western blotting. 
 
 
2.14 Anti-CeCRBNsecΔ1-15 antibody production 
 
Antigen preparation. Protein expression was performed at 37 °C for 4 hours and 
induced with 1 mM IPTG. Cells were pelleted, resuspended in 6 M Guanidinium chloride, 
20 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM 2-mercaptoethanol, 4 mM MgCl2, DNase I 
and protease inhibitors (EDTA-free, GE Healthcare), and lysed, using a French pressure cell. 
The sample was applied on a nickel affinity column equilibrated with 6 M Guanidinium 
chloride, 20 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM 2-mercaptoethanol. The His-tagged 
protein was eluted with a gradient of 0–0.5 M imidazole. Protein containing fractions were 
pooled and dialyzed against 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM 
2-mercaptoethanol. The His-tag was cleaved overnight at 4 °C by TEV protease. The protein 
mixture was loaded on a nickel affinity column to bind the His-tagged TEV protease and the 
cleaved linker. The target protein was found in the flow through, pooled and concentrated in 
20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM 2-mercaptoethanol, 0.1M L-Arginine. SDS-
PAGE analysis was performed at each stage to monitor purity of the sample. 
Rabbit immunization. Animals were screened before immunization by Western blot 
analysis by testing the pre-immune serum against CeCRBNsecΔ1-15 at a dilution of 1:500. As 
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the tested serum did not show any pre-existing reaction against our protein of interest, one of 
the rabbits was subsequently injected with 1 mg/ml protein solution. An 8-week 
immunization schedule for the generation of the antibodies was applied, which included one 
priming injection followed by 2 biweekly injections and one booster injection followed by the 
blood collection. 
Antibody purification. Serum was prepared after incubation of the sample at 37 °C for 
1 hour and centrifugation at 1,000 x g for 15 minutes. The presence of antibodies in the serum 
was checked by Western blotting using purified CeCRBNsecΔ1-15 as an antigen. 65 days after 
initial injections, rabbit’s blood was collected and used for serum preparation and further 
antibodies purification. IgG fraction was extracted overnight by ammonium sulfate (40 % of 
saturated solution) precipitation at 4 °C. Pellet was collected by centrifugation for 30 minutes 
at 3,000 x g and 4 °C, resuspended in and dialyzed against PBS buffer to get rid of 
ammonium sulfate leftovers. The antibody purification was performed, using a NHS-activated 
column (GE Healthcare) with CeCRBNsecΔ1-15 coupled to it following manufacturer’s 
instructions. The working dilution of anti-CeCRBNsecΔ1-15 antibodies was determined by 
Western blotting and was as high as 1/1,000. 
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3 RESULTS AND DISCUSSION 
 
3.1 Thalidomide mimics uridine binding to an aromatic cage in cereblon 
Marcus D. Hartmann, Iuliia Boichenko, Murray Coles, Fabio Zanini, Andrei N. Lupas, 
Birte Hernandez Alvarez 
Journal of Structural Biology. 2014; 188(3): 225–32 
 
3.1.1 Synopsis 
 
Thalidomide and related immunomodulatory drugs (IMiDs) lenalidomide and 
pomalidomide possess anti-cancer activity with a particularly high efficiency in treatment of 
multiple myeloma (MM). In addition to the therapeutic properties of thalidomide, its 
derivatives also inherited the teratogenic properties of the compound. Therefore, their usage is 
strictly controlled. The protein cereblon, which together with DDB1 and Cul4A forms an E3 
ubiquitin ligase complex, was identified as a direct target of thalidomide in the cell. The C-
terminal region of cereblon is responsible for thalidomide binding. It shares a high degree of 
conservation among bacteria and eukaryotes. This region was named CULT domain (cereblon 
domain of unknown activity, binding cellular ligands and thalidomide). Using high-resolution 
structures of a bacterial model system, we demonstrate how cereblon proteins bind their ligand. 
The domain carries a peculiar binding pocket built from three invariant tryptophan residues 
forming an aromatic cage for ligand docking. Additionally, the structure of “humanized” 
MsCI4
Y101F
 mutant was solved to provide an indistinguishable binding pocket of bacterial 
CULT from human cereblon. Furthermore, we show that IMiDs mimic the binding of uridine 
to the CULT domain, revealing the first physiological ligand of cereblon proteins universally 
present in all domains of life. These findings are further supported by an in vivo experiment 
demonstrating fins malformations in zebrafish embryos upon uridine treatment, analogous to 
an experiment performed with thalidomide by Handa and coworkers (Ito et al., 2010). The 
injection of the thalidomide binding-deficient zcrbn
YW/AA
 mRNA, but not zcrbn wild type 
mRNA, rescues the phenotype, demonstrating that this effect is indeed cereblon-dependent. 
Based on these data and the knowledge about the interaction of human cereblon with DDB1, 
we supposed a possible involvement of cereblon in the recognition of uracil in DNA. However, 
experiments investigating this possibility failed to show any binding of the CULT domain to 
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RNA as well as uridine containing DNA so far (see chapter 3.4.2). Alternatively, the 
architecture of the binding pocket suggests binding of cationic ligands such as methylated 
lysine or arginine residues. It is conceivable that cereblon recognizes such a modification of its 
substrates similar to histone readers, which recognize named post-translational modifications in 
chromatin. 
The high sequence similarity between the bacterial and the eukaryotic CULT domain 
supported by their structural conservation points at the fact, that the bacterial protein represents 
an accurate model system for studying the CULT domain. 
 
 
3.1.2 Own contributions 
 
I performed the in vivo studies published in this paper. These included cloning 
procedures of zcrbn wild type and mutant gene, in vitro transcription, breeding of the fish, 
injections of mRNA into embryos, imaging of embryos, and data analysis. Silvia Deiss helped 
me to mount the embryos in the agarose before imaging. Together with Fabio Zanini (AG 
Neher) we discussed the algorithm of data analysis and he wrote an image analysis program. 
Finally, I prepared the according figures and contributed to the preparation of the manuscript. 
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3.2 Structural dynamics of the cereblon ligand binding domain 
Hartmann MD, Boichenko I, Coles M, Lupas AN, Hernandez Alvarez B 
PLoS ONE.2015; 10(5): e0128342. 
 
3.2.1 Synopsis 
 
The protein cereblon, the primary target of immunomodulatory drug thalidomide in the 
cell, has been structurally characterized in several studies (Hartmann et al., 2014; Fischer et. 
al., 2014; Chamberlain et. al., 2014). Its thalidomide-binding region, named CULT domain, 
possesses an aromatic binding pocket formed by three invariant tryptophan residues, which is 
structurally conserved from bacteria to eukaryotes. Structural studies show the glutarimide ring 
of different ligands, including thalidomide, lenalidomide, pomalidomide, and uridine to bind to 
the pocket in the same fashion. With MsCI4 from M. gryphiswaldense, we have established a 
bacterial protein as a proper model system for the structural characterization of the 
thalidomide-binding domain on the basis of high sequence and structure similarity. In the 
present study, we aimed to extend our knowledge about possible conformational changes upon 
cereblon substrate recognition by comparison of the ligand-free and the ligand-bound state of 
the bacterial CULT domain. Analysing soaking experiments, we show that the CULT domain 
adopts a different conformation upon ligand binding. Washing out the ligand from the crystals 
causes unfolding of about one third of the domain. The effect of ligand binding on protein 
stability was examined by biophysical assays revealing an increase in thermal stability of the 
domain upon interaction with thalidomide or uridine. Our data indicate that a large proportion 
of the CULT domain folds in the presence of its ligand. Using our bacterial model system, we 
further show, that the C-terminal truncation of 24 amino acids in cereblon, which causes mild 
mental retardation in humans, does not affect ligand binding to the pocket. Finally, our studies 
unravel the structural flexibility of the CULT domain upon substrate binding, providing a 
further piece in the puzzle towards deciphering cereblon function in the cell. 
 
 
3.2.2 Own contributions 
 
I performed thermal shift assay studies, analysed the data, prepared the according figures, 
and contributed to the preparation of the manuscript.  
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3.3 A FRET-based assay for the identification and characterization of cereblon 
ligands  
Iuliia Boichenko, Silvia Deiss, Kerstin Bär, Marcus D. Hartmann, 
Birte Hernandez Alvarez 
Journal of Medicinal Chemistry; 2016; DOI: 10.1021/acs.jmedchem.5b01735 
 
3.3.1 Synopsis   
 
IMiD binding modulates the affinity of cereblon for its substrates. Degradation of the 
homeobox transcription factor MEIS2, which is implicated in many aspects of human 
development, is impaired by IMiD treatment (Fisher et al., 2014). Furthermore, IMiDs have 
been shown to stimulate the degradation of IKFZ1/3 and CK1ɑ in a cereblon-dependent 
manner, thus triggering the anti-cancer effect of the drugs. Therefore, based on its functional 
modulation upon ligand binding, cereblon represents on one hand a useful tool for targeted 
protein degradation that is highly valuable in cancer treatment. On the other hand, cereblon 
mediates the teratogenic effects of IMiDs. In the present study, we establish a FRET-based in 
vitro assay for testing the binding affinities of cereblon to potential ligands. Members of the 
three main groups of proteins containing a CULT domain, namely the thalidomide-binding 
domain from H. sapiens, MsCI4 from M. gryphiswaldense, and the secreted cereblon homolog 
from C. elegans, were taken for a comparative analysis exploring their ligand binding 
properties. The “humanized” MsCI4Y101F mutant was used since it has an indistinguishable 
binding pocket from human cereblon. We demonstrate that the three proteins, on a relative 
scale, show identical substrate affinities with similar specificities for selected ligands, including 
succinimide, which was identified as a new binding moiety for cereblon proteins. Based on its 
high stability, availability, and easiness in handling, we demonstrate that, using MsCI4 as a 
model protein, our assay presents a robust tool to screen for new cereblon ligands and also to 
test novel pharmacologically interesting compounds for their teratogenic potential mediated via 
cereblon. 
 
 
3.3.2 Own contributions 
 
I designed the construct and cloned the gene of the secreted C. elegans protein. I set up 
the baculovirus insect cell expression system, which was used for production of the two 
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eukaryotic proteins (the human CULT domain and the secreted C. elegans homolog). Further I 
optimized expression and developed a purification scheme for the two eukaryotic proteins from 
Sf9 cells. Finally, I contributed to the preparation of the manuscript. 
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3.4 Additional results and discussion  
 
In this chapter I am describing unpublished results obtained during my PhD work. 
 
3.4.1 The CULT domain: structural insight 
 
The mystery of thalidomide teratogenicity has been explored for many years, but only 
recently the protein cereblon was identified as a cellular target of the drug (Ito et al., 2010). It 
is widely spread among eukaryotes, except fungi, and functions as a substrate receptor of the 
CUL4-DDB1 E3 ubiquitin ligase complex. 
IKFZ1/3 and CK1ɑ are degraded upon treatment of the myeloma cells with 
lenalidomide, which is the structural homolog of thalidomide (Krönke et al., 2014; Lu et al., 
2014; Gandhi et al., 2013; Krönke et al., 2015). Thalidomide binding to cereblon caused 
opposite effects for the homeobox transcription factor MEIS2, which is implicated in various 
aspects of human development (Fisher et al., 2014). The modulatory effects of IMiDs on 
cereblon function point at a key role of the thalidomide-binding domain in cereblon function. 
This significance is further supported by the sequence conservation of this domain from 
bacteria to eukaryotes. 
The key to understanding protein function is its structure. It provides information about 
a three-dimensional conformation of the molecule, revealing specific features, which refer to 
a comprehension of the role of the protein in the cell. Therefore, the first goal was to obtain 
the structure of the CULT domain as a rational basis for its functional insight. 
 
Expression and purification of cereblon homologs from bacterial and insect cells  
Aiming to solve the structure of the CULT domain, we chose representatives from the 
three main subgroups (Fig. 1.4) of cereblon homologous proteins: human full length CRBN, 
the secreted C. elegans lacking its secretion signal sequence (CeCRBNsecΔ1-15), and the 
bacterial MsCI4. The bacterial cereblon homolog was successfully expressed in E. coli and 
purified under native conditions (Hartmann et al., 2014). However, the eukaryotic proteins 
appeared to be insoluble when expressed in E. coli and subsequent refolding experiments of 
the proteins that were purified under denaturing conditions failed. To overcome this problem, 
we produced domains of human cereblon separately in E. coli, but yielded again insoluble 
proteins for all of them (Fig. 3.4.1.1A and Appendix I). 
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Figure 3.4.1.1. Constructs of human cereblon expressed in E. coli (A) and insect cells (B). 
Successfully purified human CULT domain is circled in red. 
 
 
Recent studies reported the annelid Alvinella pompejana, which inhabits hydrothermal 
vent sites, to be an attractive metazoan target for structural biology research. Since proteins 
from thermophiles are stable and more obedient for crystallization experiments, we expressed 
the LON-containing cereblon homolog from Alvinella pompejana, which shows 50 % 
sequence identity to human CRBN, fused to His- or His-SUMO-tags in E. coli strains C41 
(DE3) and Lemo 21 (DE3). Compared to other E. coli (DE3) strains, protein expression in the 
Lemo 21 strain is additionally controlled by the natural inhibitor of T7 RNA polymerase – 
lysozyme, which production is regulated by adding L-rhamnose to the expression medium at 
levels from 0 to 2 mM. However, expression using these E. coli strains did not increase the 
solubility of the proteins. In a next step, we set up the baculovirus-insect cell expression 
system, which is more suitable for producing eukaryotic proteins. CeCRBNsecΔ1-15 
containing a C-terminal His-linker was successfully expressed and purified by Ni affinity 
chromatography from Sf9 cells. After cleavage of the tag by TEV protease, the protein was 
again loaded on the affinity chromatography column. The flow through fraction was collected 
for further concentration of the pure CeCRBNsecΔ1-15 protein (Fig. 3.4.1.2A). Contrary, 
hCRBN was only poorly expressed and highly sensitive towards proteolytic degradation. In 
order to rectify these difficulties, another construct was made: the His-tag was fused to the N-
terminus and two additional Z-domains (so called ZZ-tag, Gülich et al., 2000) were inserted 
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between the His–tag and the protein to yield higher expression and solubility (Fig. 3.4.1.1). 
Additionally, to increase hCRBN stability, it was co-expressed and co-purified with its 
binding partner hDDB1 and/or thalidomide. Since none of these measures could improve the 
protein production, we designed a series of truncated constructs of hCRBN for expression in 
insect cells (Fig. 3.4.1.1). Finally, human CRBNΔ1-315, which exclusively consists of the 
CULT domain, was successfully expressed and purified from insect cells (Fig. 3.4.1.2B) 
(Boichenko et al., 2016). Detailed information of all constructs designed for cereblon 
expression trials are listed in the Appendix I. 
All three proteins: MsCI4, CeCRBNsecΔ1-15, and the human thalidomide-binding 
domain hCRBNΔ1-315 were set up for crystallization with thalidomide. The eukaryotic 
proteins did not yield any crystals, whereas the crystal structures of the bacterial CULT 
domain from M. gryphiswaldense bound to thalidomide and other ligands were solved 
(Hartmann et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1.2. Purification of CeCRBNsecΔ1-15 (A) and hCRBNΔ1-315 (B) by Ni-affinity 
chromatography after cleavage of the His-tag by TEV protease. A. CeCRBNsecΔ1-15 was found 
in the FT (flow through). B. hCRBNΔ1-315 was also found in the FT (flow through). As the 
size of His-ZZ-tag is similar to the size of hCRBNΔ1-315, fractions were also analyzed by 
Western blotting. M – marker. 
 
At the same time, two other studies published the structures of chicken (Fischer et. al., 
2014) and human (Chamberlain et. al., 2014) cereblon in complex with hDDB1. Additionally, 
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the structure of mouse thalidomide-binding domain in complex with thalidomide was 
deposited to the PDB (PDB-ID 4TZC, deposited by Chamberlain et al). 
Taken together, all available structures of CULT domains, from human, chicken, 
mouse, and bacteria, show a high degree of its conservation. The RMSD over 100 Cα 
positions between the human and the bacterial protein is less than 1Å (Hartmann et al., 2014, 
Fig. 5), emphasizing MsCI4 appears to be a proper model system to clarify the function of the 
CULT domain. 
 
 
3.4.2 What are the physiological ligands of the CULT domain? 
 
Does the CULT domain recognize uracil in DNA? 
The CULT domain is highly conserved from bacteria to human, especially amino acid 
residues involved in hydrophobic pocket composition. Although recent structural studies 
show that the substrate specificity towards certain drugs might vary in dependence of single 
amino acid residues at the entrance of the pocket (Krönke et al., 2015). Notably, thalidomide-
binding domain displays the same binding mode for its ligands. Therefore, we suppose that 
the CULT domain recognizes the same or at least similar ligand(s) in pro- and eukaryotes.  
Searching among natural compounds for cereblon ligand, we noticed that pyrimidines 
resemble glutarimide moiety of thalidomide (Fig. 3.4.2.1). Indeed, uracil, but not cytidine or 
thymine, was demonstrated to bind the CULT domain of cereblon (Hartmann et. al., 2014). A 
possible physiological role of uridine binding by cereblon is not known so far. Given the 
interaction between cereblon and DDB1, a multifaceted protein that is also involved in DNA 
repair (Scrima et al., 2008), it could be involved in processes of uracil recognition and 
elimination from damaged DNA. For secreted cereblon proteins, a similar involvement in the 
detection of viral DNA or RNA in the extracellular space is conceivable. 
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Figure 3.4.2.1. Structural formulas of thalidomide and pyrimidines. The groups, which were 
supposed to bind the CULT domain, are circuled in red; the groups, which bind the CULT 
domain, are marked in green. 
 
In order to prove these assumptions, a number of experiments were performed. Possible 
binding of the CULT domain to uracil-containing DNA or RNA was tested in SEC 
experiment, EMSA assays, and pull downs with biotinylated single- or double-stranded DNA 
as bait. Tested proteins include MsCI4, CeCRBN and hCRBN. The pull down experiments 
were performed in binding buffer and for the bacterial and the human proteins also in the 
presence of the appropriate cell extract in order to provide other unknown components that 
are probably essential for an interaction. However, all performed experiments did not give any 
hint for an interaction between the CULT domain and nucleic acids. 
 
Does the CULT domain specifically recognize protein modifications? 
As already mentioned (see chapter 3.1.1), the binding pocket of the CULT domain 
resembles an aromatic cage of other, unrelated protein domains such as PHD, chromo, WD40, 
Tudor, MBT, Ankyrin Repeats, and PWWP. They recognize different methylation states of 
lysine and arginine residues: unmethylated (me0), mono- (me1), di- (me2), and tri- (me3) 
methylated for lysine and unmethylated (me0), mono- (me1), dimethylated symmetrically 
(me2s) and asymmetrically (me2a) for arginine, respectively (Fig. 3.4.2.2 and Fig. 3.4.2.3) 
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Figure 3.4.2.2. Structural formulas of ligands bound by aromatic cages showing similar 
architecture to the binding pocket of the CULT domain. The groups, which were expected to 
bind the CULT domain, are circuled in red. 
 
 
Many of such post-translational modifications are found in histones, representing an 
important part of the so called “histone code”, which carries epigenetic information extending 
the genetic message beyond DNA sequences. Histone readers are proteins that decode these 
messages by recognizing distinct modifications and subsequently initiating downstream 
signaling processes. Notably, methylation states of lysine residues K4, K9, and K27 of 
histone 3 (H3K4, H3K9, H3K27) regulate chromatin activity and are coupled with the 
function of E3 ubiquitin ligase activity. Histone ubiquitination helps in unwinding the 
nucleosome and allows enzymes to access their substrates (Higa et al., 2006; Lewis et al., 
2010; Kuscu et al., 2014; Xu et al., 2010; Zhao et al., 2010).  
Baek and co-workers reported methylation-dependent ubiquitination by the 
Cul4/DDB1/DCAF1 E3 ubiquitin ligase complex (Lee et al., 2012). Based on available 
structural and functional data, it is conceivable that the recognition of post-translationally 
modified histone or non-histone proteins by cereblon represents a possible scenario. 
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Figure 3.4.2.3. A comparison of the aromatic cages of MsCI4 and histone readers. Pocket-
forming residues are marked in green and ligands are marked in blue (summarized from 
Hartmann et al., 2014; Taverna et al., 2007; Yun et al., 2011). 
 
 
Using the FRET-based assay (Boichenko et al., 2016), we tested the binding of the 
bacterial and the human CULT domain to the three forms of methylated lysine and arginine. 
The unmethylated forms served as controls. Since no interaction was detected, we assumed 
that the context of a linear motif, in which methylation is found, might play an auxiliary role 
in the recognition. Therefore, we further examined several H3 peptides with different 
methylation states of K4, K9 or K27 flanked by 4-6 amino acid residues on both sites. The 
methylation state of these residues was previously shown to be dependent on the 
DDB1/Cul4A E3 ubiquitin ligase activity (Higa et al., 2006). Nevertheless, no binding of the 
mentioned histone peptides to the CULT domain could be detected. 
Readers of posttranslational modification in proteins often do not only identify one 
modification, they rather read combinations of multiple modifications, which might also be of 
different type. Considering this, we expanded our search and started a screen of histone 
peptide microarrays containing the histone code library with most of today known post-
translational modifications of histones and their possible combinations spotted on glass slides. 
The experiment was comparatively conducted for MsCI4, the C. elegans variant 
CeCRBNsecΔ1-15, and hCRBNΔ1-315, in dependence of thalidomide presence. Despite 
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knowing that histones do not represent physiological substrates for the secreted C. elegans 
homolog as well as the bacterial MsCI4, we included them in the study. The given 
conservation of the binding pocket of the CULT domain, which was used as bait in the screen, 
raised the expectation of binding of a potential ligand to all three proteins. Unfortunately, 
these analyses remained unsuccessful for several reasons. Data analysis turned out to be 
difficult for the eukaryotic proteins as the background noise signal appeared to be high, which 
was apparently caused by unspecific sticking of the proteins to the glass material. This 
prevented us from drawing final conclusions. In the case of the bacterial protein, we obtained 
a lot of false positive results, which made the data inconclusive and difficult to interpret. 
Nonetheless, aliphatic chains with one or more branched methyl groups, such as Nε-
trimethyllysine, Nε-butyryllysine, Nε-propionyllysine, N-methylarginine, and asymmetric 
dimethylarginine, appeared to be generally preferred.  
MEIS2, the only endogenous substrate known so far, which binding to cereblon is 
ablated by thalidomide, contains an N-terminal highly conserved region (Fisher et al., 2014, 
Lupas et al., 2015). The arginine, histidine, and tyrosine residues in this region appear to be 
likely candidates for recognition by the CULT domain. However, a test of this hypothesis in 
our in vitro binding assay using a peptide encoding the N-terminal 16 amino acid residues of 
MEIS, optionally with different methylation states of the arginine residue in position 4, 
remained unsuccessful. 
 
Does the CULT domain recognize cationic ligands? 
In silico analysis further suggested cationic ligands like carnitine, betaine, choline, and 
their derivatives to bind to the CULT domain (Lupas et al., 2015) (Fig. 3.4.2.1). These 
compounds, quaternary amines and additionally all proteinogenic amino acids were tested in 
the FRET-based assay for their possible binding to the CULT domain without any positive 
results. 
 
The presence of the CULT domain in proteins that are localized inside as well as 
outside of the cell indicates the availability of the candidate ligand in both environments. 
Continuing our search for such ligands, we have started collaboration with the screening unit 
at the Institute of Molecular Pharmacology (AG Kries, FMP, Berlin). Here, the FRET-based 
assay is applied in a high-throughput screen of low-molecular weight ligand libraries.  
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3.4.3 Cereblon-mediated teratogenicity of pharmacological compounds  
 
The molecular mechanism of the thalidomide-cereblon interaction became clear after 
obtaining the crystal structure of their complex. As we previously showed, two hydrogen 
bonds between the drug and the binding pocket of cereblon were shown to be crucial for this 
interaction (Hartmann et al., 2014). Further, we assumed that other pharmacological 
compounds resembling the structure of the glutarimide moiety of thalidomide might also bind 
cereblon in a similar fashion and, therefore, could be potential teratogens. An extensive search 
of possible ligands of cereblon was performed based on their structural similarity to 
glutarimide. We found a set of different pharmaceutical compounds that share common 
structural features with thalidomide, including succinimide, ethosuximide, hydantoin, 2,4-
thiazolidinedione, and barbiturates (Fig 3.4.3.1). 
Importantly, these compounds represent basic building blocks of pharmaceuticals used 
in treatment of various disorders. For example, ethosuximide is the first remedy in absence 
seizures medication, thiazolidinedione derivatives are prescribed to treat type II diabetes, and 
barbiturates have sedative effects on the central nervous system. Interestingly, a possible 
correlation between the structural similarity of some of these compounds to thalidomide and 
their potential teratogenic properties has already been reported by Gary Shull in 1984, long 
before cereblon was identified as a molecular target of thalidomide in the cell. 
 
 
 
Figure 3.4.3.1. Potential cereblon ligands identified based on their structural similarity to 
thalidomide.  
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Upon binding of these compounds to cereblon, E3 ubiquitin ligase function might be 
affected. We employed our FRET-assay to test the interaction of the CULT domain with the 
identified compounds. Indeed, with exception of barbiturate, they were shown to bind MsCI4 
with affinities in the micromolar range (Table 3.4.3.1). In the structure of the MsCI4-
thalidomide complex, only the NH- and one of the neighboring keto groups directly interact 
with the protein. Based on this, we surmised that the minimal binding moiety in the ring 
system also interacts with the binding pocket of cereblon. Accordingly, we determined 
binding constants for γ-butyrolactam and δ-valerolactam composed of 5 and 6 membered 
rings, respectively (Fig. 3.4.3.1), to be in the micromolar range. 
Performing a comparative analysis of the binding affinities of MsCI4 with the human 
CULT domain, we observed higher affinities of the bacterial protein to its ligands. As shown 
by further studies using the mutant MsCI4
Y101F
, this is a result of an additional hydrogen bond 
that is formed between Y101 of the bacterial protein and the compounds. The human protein 
does not make this auxiliary contact as it carries phenylalanine in the corresponding position. 
However, considering that only the CULT domain was analyzed in the assay, the N-terminal 
domains of  human CRBN, which are absent in our construct, are expected to stabilize 
protein-ligand binding in vivo (Hartmann et al., 2015). 
 
Table 3.4.3.1 Binding affinities of the CULT domains from M. gryphiswaldense and H. sapiens 
to different compounds. 
 
Ligand  
MsCI4
WW/FF 
IC50 [µM] 
 
MsCI4WW/FF 
Ki [µM] 
 
hCRBNΔ1-315 
IC50 [µM] 
 
hCRBNΔ1-315 
Ki [µM] 
1-(N-2-MANT-imidoethyl)-uracil - 3.3 ± 0.3 (KD) - 7.9 ± 0.7 (KD) 
Succinimide 7.6 ± 1.0 4.3 34.5 ± 4.8 26.2 
Glutarimide 48.9 ± 8.9 27.8 135.8 ± 19.2 103.1 
Hydantoin 76.3 ±14.8 43.4 464.3 ± 124.7 352.7 
Ethosuximide 239.1 ± 20.4 136.0 2616 ± 455 1987 
γ-Butyrolactam 100.6 ± 19.0 57.2 2700 ≈2000 
δ-Valerolactam 257 ± 35.7 146.2 no binding - 
Barbiturate no binding - no binding - 
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Based on the observed binding of the majority of the tested ligands to cereblon, we 
assumed that they might have teratogenic effects. To verify this hypothesis, we used an in 
vivo assay in zebrafish embryos, which was previously established by Handa and co-workers 
to demonstrate cereblon-dependent thalidomide teratogenicity. Dechorinated embryos were 
grown in the medium containing the appropriate drug for 75 hours post fertilization, and 
pectoral fin length was subsequently measured and used as a diagnostic criterion of impaired 
development. As shown in Fig. 3.4.3.2, succinimide, ethosuximide, hydantoin, and 
glutarimide cause fins malformation in zebrafish. Consistently, the phenotype was rescued by 
injection of zcrbn
 YW/AA
 mRNA encoding a binding-deficient mutant of CRBN, but not by 
injection of wild type zcrbn mRNA, which additionally indicates that the teratogenic effect is 
indeed mediated via cereblon. 
As expected, barbiturate does not cause fins malformation in zebrafish (Fig. 3.4.3.3), 
which is consistent with no observed binding to the CULT domain in our in vitro test 
(Table 3.4.3.1). Despite the interaction of the lactams with MsCI4 in vitro, these compounds 
do not impair fins development (Fig. 3.4.3.3), apparently due to their fast decay in the fish-
living medium or in the embryos themselves. Notably, in the in vitro assay hCRBNΔ1-315 
does not show affinities for lactams comparable to MsCI4.The additional hydrogen bond in 
the bacterial protein might represent a possible explanation for this observation as described 
above. 
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Figure 3.4.3.2. Glutarimide, hydantoin, ethosuximide and succinimide cause developmental 
defects in zebrafish. A.Typical examples of zebrafish embryos belonging to four phenotypic 
groups showing different grades of fin malformation, as evaluated from the length of the 
pectoral fin. B. Incidence of fin deformities under drug treatment. The color of the bars 
corresponds to A. 
 
 
Taken together, our findings indicate possible off-target effects of various, clinically 
relevant pharmaceuticals broadly used in medicine, which become visible as cereblon-
mediated developmental defects. The separation of teratogenic and therapeutic properties of 
ligands mediated via their binding to cereblon is an important requirement to guarantee for the 
safety of these pharmaceuticals. In this context, our in vitro assay represents an appropriate 
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tool for testing the teratogenic potential of such drugs. However, beside these detrimental 
effects, the specific binding of ligands to cereblon offers a useful tool for triggering targeted 
protein degradation mediated by the CRBN-DDB1-E3 ubiquitin ligase complex. 
 
 
Figure 3.4.3.3. Incidence of fins deformity in zebrafish after treatment with 400 µM sodium 
barbiturate, δ-valerolactam or γ-butyrolactam.  
 
 
3.4.4 Interaction of MsCI4 with transcription termination factor Rho 
The previous studies revealing cereblon binding partners were focused on gain of 
function effects upon drug-treatment. As IMiDs are artifical ligands, the obtained data may 
reflect an incomplete picture of cereblon action under physiological conditions (Krönke et al., 
2014; Lu et al., 2014; Gandhi et al., 2013; Krönke et al., 2015, Fisher et al., 2014). 
Since the question about the natural ligand(s) recognized by the CULT domain does not 
have an explicit answer so far, another approach was pursued in order to uncover cellular 
processes that CULT domain participates in. We were interested in binding partners of the 
domain with particular focus on interactions requiring the complicity of the aromatic pocket. 
Therefore, a candidate approach was used to reveal potential binding partners from a pull 
down experiment with bait protein and cell lysate. The experiment was performed with the 
CULT domain of MsCI4 and cell extract of M. gryphiswaldense. Mass spectrometry was 
applied to identify proteins that bound to the bait MsCI4, which was immobilized on 
magnetic beads. FLAG-tagged MsCI4 and MsCI4
YW/AA
, a binding-deficient mutant, were 
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used as baits for comparative analysis. Given its small size, high specificity and minimal 
interference with protein function, the FLAG tag is frequently used for this purpose. FLAG-
MsCI4 was purified to homogeneity (Fig. 3.4.4.1) and bound to the anti-FLAG magnetic 
beads. 
 
 
 
 
 
 
 
 
Figure 3.4.4.1. Purification of FLAG-MsCI4 by Ni-affinity chromatography after cleavage of 
the His-tag by TEV protease. FLAG-MsCI4 was found in the FT (flow through). M – marker. 
 
 
Subsequently, we incubated the beads with M. gryphiswaldense cell extract, which was 
prepared as a natural source of potential protein binders. The mass spectrometric analysis was 
conducted to perform quantitative proteomics on the basis of stable labeling of peptides by 
dimethylation (Boersema et al., 2009). The according analyses were performed at the 
Proteome Center (Universität Tübingen). In Fig. 3.4.4.2, the practical approach is 
schematically depicted. In addition to the baits FLAG-MsCI4 and FLAG-MsCI4
YW/AA
, we 
used FLAG-MsCI4 in the presence of thalidomide to block the binding pocket. Data 
comparison of the samples FLAG-MsCI4 and FLAG-MsCI4
YW/AA
 were expected to reveal 
proteins binding to the aromatic cage of the CULT domain. Mass spectrometric analysis 
detected numerous proteins, which were pulled down by MsCI4 for each given condition 
(Fig. 3.4.4.3). 
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Figure 3.4.4.2 Schematic overview of the immunoprecipitation (IP) experiment to identify 
binding partners of MsCI4 from M. gryphiswaldense cell lysate and following proteomic 
analysis. H - “heavy” labeled samples, M – “medium” labeled samples, L – “light” labeled 
samples. 
 
 
During data analysis, we concentrated our attention on proteins interacting with the 
pocket. These proteins are expected to be present in the samples with FLAG-MsCI4 as bait, 
but to be absent in samples containing thalidomide or using FLAG-MsCI4
YW/AA
 as bait. 
Firstly, we selected candidate binders based on the difference between FLAG-MsCI4
 
wild 
type protein and (I) FLAG-MsCI4
YW/AA
; (II) FLAG-MsCI4
 
wild type protein sample 
additionally containing thalidomide. The difference was set to be at least two fold in intensity 
signal. Thalidomide treatment prevented 9 proteins to interact with FLAG-MsCI4, whereas 
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usage of FLAG-MsCI4
YW/AA 
mutant obstructed the interaction with 30 proteins in comparison 
to the wild type protein. Secondly, we excluded from these lists proteins with low sequence 
coverage as an indicator of low confidence. Thirdly, as the biological function of the pocket 
was violated in both cases, when thalidomide was present as well as when the bait 
MsCI4
YW/AA
 was used, we searched for candidate proteins found to be less abundant in both 
samples. Correspondingly, we short-listed 5 candidates for following studies, which 
interaction with FLAG-MsCI4 was abolished upon thalidomide treatment or FLAG-
MsCI4
YW/AA 
application (Fig. 3.4.4.3 C and D).  
 
 
Figure 3.4.4.3. Mass spectrometric analysis revealing potential binding partners of the CULT 
domain. A, C. Comparison of samples using FLAG-MsCI4 as bait in the presence and in the 
absence of thalidomide. B, D. Comparison of samples using either FLAG-MsCI4 or mutant 
FLAG-MsCI4
YW/AA
 as bait. Selected candidates are coloured. Seq. cov. – sequence coverage, H 
– “heavy”, M – “medium”, L – “light”. 
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Several proteins, for example putative GGDEF: diguanylate cyclase (GGDEF; 
V6EVZ1) and putative NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 
(V6EY28), bound to FLAG-MsCI4 in the presence of thalidomide according to mass 
spectrometric analysis. Surprisingly, they also interacts with FLAG-MsCI4
YW/AA
, which 
binding pocket is disrupted and, therefore, is not expected to bind its ligands. Considering this 
discrepancy, we did not select these proteins for further validation in the present study. 
The candidate proteins are involved in various cellular processes, including 
carbohydrate metabolism and amino acid biosynthesis, fatty acid and purine metabolism, 
regulation of transcription and protection against reactive oxygen species. Comparison of 
domain composition of the candidate proteins did not reveal any similarities. 
Since pull down experiments with cell lysates result in the isolation of large multi-
protein complexes, in which many proteins only indirectly interact with the bait (Köcher et. 
al., 2007), additional in vitro validation of their binding to the CULT domain was required for 
all the selected candidates. Therefore, we performed co-immunoprecipitation experiments to 
confirm possible direct binders. 
The selected candidate genes were amplified from M. gryphiswaldense DNA and cloned 
in pETHis1a vector for expression of N-terminally His-tagged proteins in E. coli C41 (DE3). 
Expression of the genes showed that only lipopolysaccharide transport protein B and 
transcription termination factor Rho were found in the soluble fractions. The expression of the 
other candidates was further optimized, using the E. coli Arctic Express strain, which 
possesses plasmids encoding chaperones. The chaperones are produced upon exposure to low 
temperature in order to promote folding and increase the solubility of the overexpressed 
protein. Nevertheless, the solubility of some of the candidates remained rather poor and 
required detection by Western blotting. Performed co-immunoprecipitation experiments 
showed that only the His-tagged transcription termination factor Rho expressed in E. coli 
specifically interacts with FLAG-MsCI4 (Fig. 3.4.4.4). For the other candidates no binding to 
the bait could be confirmed, suggesting that they were indirectly interacting with the CULT 
domain, possibly as parts of macromolecular complexes. Alternatively, the absence of a 
detectable interaction could result from improper folding or low binding affinities under given 
experimental conditions.  
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Figure 3.4.4.4. Western blot analysis of potential binding partners of the CULT domain co-
immunoprecipitated with FLAG-MsCI4. FLAG-MsCI4 was immunoprecipitated (IP) with anti-
FLAG antibodies from the E. coli cell extract expressing prey proteins (I). Immunocomplexes 
were then immunoblotted with anti-FLAG and anti-His antibodies. B - control for unspecific 
binding of prey protein to the beads. 
 
 
Next, we tested the interaction between the transcription termination factor Rho and 
FLAG-MsCI4 in the presence of thalidomide or by using FLAG-CULT
YW/AA
 mutant as bait. 
Surprisingly, we could not detect any effect as it was expected from the mass spectrometric 
data that showed decreased abundance of Rho in the presence of thalidomide (Fig. 3.4.4.5). 
One explanation for this observation might be that Rho additionally binds to amino acid 
residues located outside of the aromatic cage. Given that both proteins are present in a high 
excess, even low-affinity binding could be detected by Western blotting. Alternatively, it 
might be possible, that another unknown molecule, except thalidomide, which is not present 
in the heterologous E. coli expression system in sufficient amount or at all, is required for 
blocking the MsCI4 interaction with Rho. 
Transcription termination factor Rho is a ring-shaped hexameric RNA/DNA helicase, 
which regulates gene expression in bacteria by unwinding RNA/DNA heteroduplex, using the 
energy from ATP hydrolysis. The Rho-mediated termination is dependent on the recognition 
of a specific pyrimidine-rich sequence in the nascent RNA called rut (rho utilization). Initial 
RNA contact with Rho promotes a closure of the hexameric ring with RNA in its central 
channel. 
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Figure 3.4.4.5. Western blot analysis of transcription termination factor Rho co-
immunoprecipitation with FLAG-MsCI4. The FLAG-MsCI4 was immunoprecipitated (IP) with 
anti-FLAG antibodies from the E. coli cell extract (I). Immunocomplexes were immunoblotted 
with anti-FLAG and anti-His antibodies. WT – wild type FLAG-MsCI, YW/AA - FLAG-
MsCI4
YW/AA
 mutant. 
 
 
This further activates an ATP binding and hydrolysis, allowing translocation of the 
complex along the RNA (for review see Boudvillain et al., 2013). After reaching the RNA-
polymerase Rho stimulates its release from the DNA matrix and dissociation of the mRNA. 
Additionally, Rho’s activity is modulated by riboswitches, leading to a premature termination 
of the transcripts as a negative regulatory mechanism of their expression (Hollands et al., 
2012). Our results suggest a possible involvement of the CULT domain in transcriptional 
regulation in bacteria. However, further studies have to confirm the specificity of this 
interaction and to elucidate the functional role of the interplay between Rho and the CULT 
domain. 
 
 
3.4.5 Proteomic analysis of CULT-mediated hCRBN binding partners 
 
The effect of thalidomide treatment was studied in embryonic stem cells on the 
transcriptomics level (Megananthan et al., 2012) and revealed disturbed expression of 
transcription factors involved in limb, heart, and embryonic development after 14 days of 
differentiation. The expression pattern of transcription factors required for neuronal 
development and axon outgrowth was altered, stressing the importance of cereblon in the 
brain. Additional studies investigating proteomic alterations in response to thalidomide 
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treatment were conducted on myeloma cells, showing gain of function effects after drug 
treatment (Krönke et al., 2014). These experiments shed light on the function of cereblon in 
the specific cell lineages, but provide a limited insight into a general role of cereblon in the 
cell, which is ubiquitously expressed in all tissues. Although cereblon was identified as a 
primary target of thalidomide, there is limited knowledge about the consequences of this 
interaction for the cells and affected biological processes. Therefore, we performed an 
analysis of proteins co-immunoprecipitating with FLAG-tagged cereblon (FLAG-CRBN) 
from HEK293T cell extracts in the presence of thalidomide or appropriate DMSO 
concentrations. The experiment was performed as a SILAC-based comparative proteomic 
analysis in HEK293T cells representing a powerful tool for the detection of protein-protein 
interactions. The accurate quantification of protein abundance in both drug-treated and control 
samples allowed us to distinguish true interactions from experimental contaminants. As 
CRBN is present in the cytoplasm as well as in the nucleus (Lopez-Girona et al., 2012), whole 
cellular extract expressing FLAG-CRBN was used for performing a pull down with anti-
FLAG magnetic beads (Fig. 3.4.5.1).  
The mass spectrometric analysis identified several proteins, the binding of which was 
gained upon drug treatment. The scatter plot demonstrates log2 Heavy/Light ratios for two 
replicates containing proteins bound to cereblon in the absence and presence of thalidomide, 
respectively (Fig. 3.4.5.2). Candidate binding proteins, which are color-marked in 
Fig. 3.4.5.2, were chosen by comparative analysis of the obtained data. Binding of these 
proteins to cereblon was acquired upon thalidomide treatment. Many of them contain Zn 
finger motifs, a conspicuous feature of DNA-binding proteins, particularly transcription 
factors, and are known to be part of multi-protein complexes. Moreover, most of them are 
involved in transcriptional repression and gene silencing. 
70 
 
 
 
Figure 3.4.5.1. Schematic overview of the immunoprecipitation experiment and following 
proteomic analysis to identify cereblon binding partners from HEK293T cells treated or non-
treated with thalidomide. H – “heavy”, L – “light”. 
 
 
 
Figure 3.4.5.2. Results of SILAC-based mass spectrometric analysis revealed potential binding 
partners of cereblon. H – “heavy”, L – “light”. 
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For validation of binding to cereblon, selected candidates were analyzed further in 
single co-immunoprecipitation experiments with CRBN as bait. Cereblon was expressed with 
an N-terminal HA-tag and coupled to anti-HA magnetic beads. Prey constructs (candidates 
and lacZ as a control) were expressed containing an N-terminal Myc- or FLAG-tag. Due to 
difficulties in gene amplification on the human cDNA considering their high GC content, not 
all of the selected candidates could be cloned. The expression of successfully cloned potential 
binding partners, namely WIZ, PKCB1, HIC2, PATZ, LSM12 homolog, and EHTM1, was 
tested. With the exception of PKCB1, all the proteins demonstrated expression sufficient to 
perform the co-immunoprecipitation experiment. The binding experiments showed that none 
of these candidates directly interacts with cereblon (Fig.3.4.5.3). We assume that these 
proteins are parts of large multi-protein complexes that contain a direct cereblon target, which 
still remained unknown to us. 
  
 
Figure 3.4.5.3. Western blot analysis of co-immunoprecipitation experiments analysing 
interaction between potential binding partners and cereblon. HA-CRBN coupled to beads served 
as bait to co-immunoprecipitate Myc- or FLAG-tagged prey proteins from the whole cell extract 
of transiently transfected HEK293T. (I). Immunocomplexes were then immunoblotted (IB) with 
anti-FLAG, anti-Myc or anti-WIZ antibodies. 
 
 
The binding of WIZ protein to cereblon was affected by thalidomide at most as detected 
by mass spectrometric analysis. WIZ associates with the heteromeric EHTM1/EHTM2 lysine 
methyltransferases protein complex, which is responsible for mono- and di-methylation of 
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H3K9, stabilizes and links this complex to CtBP corepressor machinery (Ueda et al., 2006; 
Kuppuswamy et al., 2008) (Fig. 3.4.5.4). Therefore, we assume that all three proteins were 
pulled down as a part of macromolecular complex, in which they are only indirectly bound to 
cereblon. 
  
 
Figure 3.4.5.4. Representation of CtBP corepressor machinery (modified from Kuppuswamy et 
al., 2007 and Bian et al., 2015) 
 
 
Two isoforms of the 13 known isoforms of WIZ were identified in HEK293T cells, 
which migrate as 150 kDa and 125kDa proteins in the gel. Co-immunoprecipitation 
experiments signified that neither of them binds cereblon directly (Fig. 3.4.5.3.). Additionally, 
we monitored Myc-WIZ expression in HEK293T cells upon thalidomide treatment and HA-
CRBN co-expression. Neither the presence of thalidomide nor HA-CRBN affects Myc-WIZ 
expression in the cells even upon usage of proteasome inhibitor MG132 (Fig. 3.4.5.5). 
In the 2015 study, Yu and colleagues identified that ZNF644 together with WIZ targets 
the EHTM1/EHTM2 complex to specific gene loci for H3K9 methylation (Bian et al., 2015). 
Both ZNF644 and WIZ have many zinc finger motifs, which recognize DNA sequences and 
mediate the recruitment of histone modifying enzymes. The post-translation modifications of 
histones lead to changes in transcriptional regulation of the gene. 
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Figure 3.4.5.5. WIZ expression in HEK293T cells is not affected by cereblon co-expression and 
thalidomide treatment. A. Myc-WIZ expression with gradual increase of HA-crbn_pcDNA3.1 
added. B. The same, but HA-lacZ_pcDNA3.1 was used as a control. 50 µM final concentration 
of thalidomide or 0.05 % DMSO was used. Cells were transfected with 4 µg of Myc-
wiz_pcDNA3.1 and 2, 4, or 8 µg of HA-crbn_pcDNA3.1 (or HA-lacZ_pcDNA3.1) in 6-
well plates (Greiner Bio-One). 
 
 
The Cul4A/DDB1 complex associates with several DCAFs, that are components of 
histone methyltransferase complexes (Higa and Zhang, 2007; Lee and Zhou, 2007; Lewis et. 
al, 2010; Kuscu et. al., 2014). In addition to that, ddb1 and cul4A gene expression in 
mammalian cells is essential for trimethylation of H3K4, H3K9, H3K27, thus triggering 
chromatin transcriptional activity (Higa et. al., 2006). Histone ubiquitination is required for 
disassembly of the nucleosome particle and the accessibility of its components for the 
enzymes, which methylate histones or DNA. 
The binding of EHTM1/EHTM2 lysine methyltransferases protein complex, which 
specifically mono- and dimethylates H3K9, a hallmark of inactive chromatin, was also 
abrogated upon exposure to the drug in our experiments. Taken together, all these 
observations point at the fact that cereblon is implicated in chromatin organization. 
Cul4A/DDB1 constitutes numerous E3 ubiquitin ligase complexes modulating different 
cellular processes, and cereblon, as a part of such a molecular assembly, might play a role in 
the regulation of transcription. Given the fact that the CULT domain of cereblon possesses the 
aromatic cage resembling the one from histone readers, it could trigger E3 ubiquitin ligase 
activity upon recognition of post-translational modification(s) of yet unknown proteins. 
In 2010, evidence about the methylation-dependent ubiquitination raised the idea of the 
existence of a so called “methyl degron” (Lee et. al., 2012). Considering that the histone 
methyltransferases in addition to the histones also methylate non-histone proteins, CRBN 
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could alternatively recognize non-histone methylated substrates for their further ubiquitination 
and degradation.  
 
 
3.4.6 Cereblon co-immunoprecipitates demethylase LSD1 
 
 
Detailed studies of the interactome of human methylases and demethylases using yeast 
two-hybrid system identified cereblon as a binding partner of SUV39H1 and LSD1 (KDM1A) 
(Weimann et al., 2013). The histone methyltransferase SUV39H1 specifically trimethylates 
H3K9, using monomethylated H3K9 as a substrate. This process initiates heterochromatin 
formation and triggers epigenetic transcriptional repression. Histone demethylase LSD1 
demethylates mono- and dimethylated H3K4 and H3K9, thereby, depending on the context, 
acting either as a coactivator or a corepressor. The corepressor function is mediated by 
demethylation of H3K4me, a specific tag for epigenetic transcriptional activation, whereas 
H3K9me demethylation leads to an activation of transcription. This attracted our attention 
since the CULT domain of cereblon has a very peculiar aromatic cage, which 
resembles the ones from histone readers that recognize different kinds of arginine or lysine 
methylation states (mono-, di-, trimethylation) (Fig. 3.4.2.3). Given that the cereblon 
interacting protein DDB1 is an important participant in DNA repair as well as hetero- and 
euchromatin transition, cereblon might be involved in histone recognition. Additionally, 
LSD1 was found as cereblon binding partner in our pilot mass spectrometric analysis with a 
weak intensity signal, which might result from a low abundance of the LSD1 in the cell. 
We performed co-immunoprecipitation experiments in HEK293T cells to demonstrate 
that cereblon binds LSD1 and SUV39H1. Indeed, FLAG-LSD1, but not SUV39H1, was 
confirmed to interact with HA-fused cereblon (Fig. 3.4.6.1). This binding is invulnerable to 
thalidomide treatment, suggesting that the LON domain or N-terminal unstructured region of 
cereblon mediate this interaction. 
 
 
 
 
 
 
75 
 
 
 
 
Figure 3.4.6.1. Binding of cereblon to LSD1 and SUV39H1. HA-CBRN co-immunoprecipitates 
FLAG-LSD1 (A) from HEK293T cells, but not FLAG-SUV39H1 (B).Cereblon was 
immunoprecipitated (IP) with anti-HA antibodies from the whole cell extract (I). 
Immunocomplexes were then immunoblotted (IB) with anti-FLAG antibodies. 
 
 
To identify the regions involved in the binding of these two molecules, further co-
immunoprecipitation experiments were designed, using differently truncated constructs of 
CRBN and LSD1 (Fig. 3.4.6.2). Overexpression trials of truncated cereblon constructs in 
HEK293T and HELA cells failed. Consistently, we observed generally lower expression 
levels of full length cereblon in comparison to other proteins, which we expressed in human 
cells. This might be the result of improper folding and following degradation under the 
condition of overexpression, when the capacity of the cell to cope with high amounts of the 
protein is limited. LSD1 comprises an N-terminal unstructured region, the SWIRM domain, a 
common module for protein-protein and protein-DNA interaction, and an Amine Oxidase 
domain, which possesses the FAD- and substrate binding regions in the catalytic center of the 
enzyme. Additionally, the Amine Oxidase domain contains an insertion of about 100 amino 
acid residues building the Tower domain that interacts with the transcriptional repressor 
CoREST and links the demethylase activity to gene silencing. The co-immunoprecipitation 
experiment with cereblon as bait was conducted for differently truncated LSD1 constructs and 
revealed that the SWIRM and Amine Oxidase domains are required for interaction. 
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Figure 3.4.6.2. Mapping the region of LSD1 required for the interaction with cereblon. Cereblon 
was immunoprecipitated (IP) with anti-HA antibodies from whole extract of HEK293T cells 
mixed with equal amount of the whole extract of HEK293T expressing different FLAG-tagged 
LSD1 constructs. Immunocomplexes were then analyzed by western blotting with anti-FLAG 
antibodies. 
 
 
 
Figure 3.4.6.3. LSD1 crystal structure with the SWIRM marked in green, the Amino Oxidase 
domain marked in cyan, and the Tower domain marked in light grey. The Tower domain is not 
necessary for the interaction with cereblon (modified from Chen et al., 2006) 
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The SWIRM domain alone is not sufficient to preserve the interaction, even if it is 
followed by the N-terminal part of the Amino Oxidase domain. The Amino Oxidase domain 
has a large insertion, the Tower domain, which is indispensable for the binding to the 
corepressor and catalytic activity, but not for interaction with cereblon. After building this 
module the C-terminal part of the molecule flips back to complement the functional catalytic 
domain (Fig. 3.4.6.3). Apparently, the C-terminal part of LSD1 either has an interaction 
interface with cereblon or is required for proper folding of other regions. Thus, we conclude 
that the binding interface of LSD1 is built by the SWIRM and Amino Oxidase domains, 
excluding the embedded Tower domain. 
Additionally, we monitored FLAG-LSD1 expression in HEK293T cells upon 
thalidomide treatment and / or HA-CRBN co-expression. Neither thalidomide nor HA-CRBN 
co-production affected the FLAG-LSD1 expression in the cells even upon usage of 
proteasome inhibitor MG132 (Fig. 3.4.6.4). Cereblon expression slightly impairs the 
production of LSD1. Since we do not observe a reduction of the anti-FLAG signal in 
dependence on the increasing amounts of HA-crbn DNA added, this effect appears likely to 
result from the increased amounts of plasmid transfected into the cells rather than the cereblon 
production itself (Fig. 3.4.6.4A). The absence of any effect in the presence of thalidomide let 
us suppose that the LON domain and / or the N-terminal unstructured region of cereblon, but 
not the thalidomide-binding domain, interact with LSD1. 
The role of LSD1-CRBN binding still remains poorly understood and we envisage 
several possible scenarios of the biological function of this protein tandem. Firstly, LSD1 
demethylates not only histones, but also other proteins. Therefore, it could work on cereblon 
as a substrate that is demethylated. However, post-translational modification of cereblon by 
methylation has not been reported yet. Secondly, cereblon might target the demethylase for 
ubiquitination and subsequent degradation. Thirdly, given that cereblon has an aromatic 
pocket similar to readers of lysine and arginine methylation, it might share its substrate 
proteins with LSD1. It is conceivable that both proteins are part of a bigger protein complex 
facilitating ubiquitination-dependent protein degradation triggered by the methylation state of 
its substrates. 
78 
 
 
 
Figure 3.4.6.4. Expression of LSD1 in HEK293T cells is not affected by cereblon co-expression 
or thalidomide treatment. A. FLAG-LSD1 expression with gradual increase of HA-
crbn_pcDNA3.1 co-transfected. B. The same, but HA-lacZ_pcDNA3.1 was co-
transfected as a control. C. FLAG-LSD1 expression in the presence of thalidomide with 
and without proteasome inhibitor MG 132. 50 µM final concentration of thalidomide or 
0.05 % DMSO was used unless otherwise specified. Cells were transfected with 4 µg of FLAG-
lsd1_pcDNA3.1 and 2, 4 or 8 µg of HA-crbn_pcDNA3.1 (or HA-lacZ_pcDNA3.1) in 6-
well plates (Greiner Bio-One). 
 
 
Thalidomide and its derivatives increase the level of p21
WAF-1
 expression in myeloma 
cells. Verhelle and co-workers showed that p21
WAF-1
 upregulation is associated with the 
alteration from methylated to acetylated histone H3K9 on the p21
WAF-1
 promoter (Escoubet-
Lozach et al., 2009). Interestingly, lsd1 knock down reduces lenalidomide- and 
pomalidomide-dependent upregulation of p21
WAF-1
, suggesting that this histone demethylase 
is involved in the regulation of p21
WAF-1
 promoter. Lenalidomide and pomalidomide 
treatment was hypothesized to activate LSD1, which removes the H3K9me2 chromatin 
silencing mark, subsequently allowing the acetylation of this residue and activation of 
transcription. The post-translational modifications of histones require the E3 ubiquitin ligase 
machinery for unwinding the nucleosome and permitting entry of enzymes to their substrates 
(Higa et al., 2006; Zhao et al., 2010; Xu et al., 2010; Kuscu et al., 2014). Therefore, we 
surmise a possible function of cereblon in the recognition of protein substrates, the 
methylation state of which is modulated by LSD1. LSD1 is involved in many different 
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processes having pro- or anti-proliferative effects. As a potential oncogene it demethylates 
and inactivates p53 (Huang et al., 2007). In contrast, it also inhibits TGF-β1 expression, 
leading to tumor suppression in breast cancer (Wang et al., 2009). Furthermore, being a part 
of the LSD1/CoREST/HDAC complex, LSD1 regulates expression of key regulators 
(including limb growth controllers), during early embryonic development (Foster et al., 2010; 
Wang J. et al., 2007; Wang Y. et al., 2009). Together with corepressor (CoREST) and histone 
deacetylase enzyme (HDAC), LSD1 forms a large multi-protein complex, which also includes 
the carboxy-terminal binding protein (CtBP). CtBP works as an assembly factor for this 
complex, to which the sequence-specific DNA-binding repressors, LSD1, histone 
deacetylases (HDAC1/2), histone lysine methyltransferases (EHTM1 and EHTM2), and 
corepressors bind (Kuppuswamy et al., 2008) (Fig. 3.4.5.4). Initial deacetylation of histones 
by HDAC1/2 provides access for CoREST and LSD1. Subsequently, LSD1 demethylates 
H3K4me2, which further allows EHTM1/EHTM2 to methylate H3K9, a stable repression 
mark. Such a complex is recruited by a number of transcription factors to operate gene 
silencing of various genes (Foster et al., 2010; Yokoyama et al., 2014). As a binding partner 
of LSD1, cereblon might, depending on the context of the multi-protein complex, bridge 
either repressor or activator and the E3 ubiquitin ligase machinery. The possibility of cereblon 
function in transcriptional regulation is also supported by our data obtained in the SILAC-
based proteome analysis of cereblon binding partners, which identified EHTM1, EHTM2 and 
WIZ to co-immunoprecipitate with cereblon. Different tissues have different expression 
pattern of their transcription factors at any particular time point, which require methylase and 
demethylase activities for their proper functioning. In this context, the linkage of gene 
regulation and ubiquitination might also contribute to the explanation of tissue-specific 
teratogenic effects of thalidomide, which binds to cereblon and inhibits ubiquitin ligase 
activity. 
 
 
3.4.7 Investigation on the sub-cellular localization of the secreted C. elegans 
cereblon protein 
 
Resolving the sub-cellular localization of a protein is an essential step towards 
understanding its function. Animal proteins comprising CULT domain preceded by N-
terminal secretion signal sequence have not been studied yet, despite growing interest in their 
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role outside of the cell. Initial bioinformatic analysis showed that these proteins are predicted 
to function extracellularly (Lupas et al., 2015). Indeed, the homolog from the sand fly 
Phlebotomus arabicus has been found in salivary gland, using MS (Hostomska et. al., 2009). 
In this chapter, I briefly describe our efforts towards revealing the sub-cellular localization of 
C. elegans secreted cereblon protein, which we expected to help us to shed light on the 
biological role of CULT domain outside as well as inside of the cell. 
In C. elegans, two main approaches are generally used to determine the sub-cellular 
localization of a protein: expression of GFP or other fusion constructs or 
immunocytochemistry, both of which have their prerogatives and limitations (Duerr., 2006; 
Wormbook, The C. elegans Research Community, www.wormbook.org). Gene expression 
pattern in C. elegans is frequently determined, using a fusion of the promoter of the studied 
gene to a reporter gene such as lacZ or gfp. This provides information about spatial and 
temporal expression of the gene in the whole organism. Beyond that, further developments of 
this method allow even the determination of the sub-cellular localization of a protein, if the 
reporter gene is fused directly to the full coding sequence of the gene of interest. Therefore, 
we employed the reporter gene fusion method to find out a sub-cellular localization of 
CeCRBNsec. Initially, a construct containing Cecrbnsec gene, annotated as R08B4.3 in 
Wormbase (https://www.wormbase.org), with its own 5’- and 3’-UTR regions and the gfp 
gene inserted in the reading frame was generated by fusion PCR. The fusion product was 
validated by sequencing and further injected into gonads of the adult worms. The transgenes 
were successfully generated as we observed the phenotype caused by marker gene expression 
restraining worm movement to a circle trajectory (Fig. 3.4.7.1). Next, transgenic worms were 
crossed to obtain the second generation of transgenic animals to increase the stability of 
foreign DNA expression. However, fluorescent microscopy did not yield any GFP signal in 
the second as well as the in first progeny. We hypothesize that R08B4.3 gene expression 
might require special conditions for its initiation, which are not known to us at present.  
Considering that any information about the spatial and temporal expression of Cecrbnsec 
within the organism won`t be achieved using this method, we continued with constitutive 
promoters for fusion constructs. Two different constitutively expressed genes were chosen: 
ges-1 (intestinal) and myo-3 (muscle). The DNA constructs were designed similarly to the 
previous one with the exception of 5’-UTR region, which was substituted by ges-1 or myo-3 
promoter regions to make Cecrbnsec constitutively expressed in the intestine or muscles, 
respectively (Fig. 3.4.7.1). Transgenes were prepared as described above. Again, microscopy 
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analysis did not reveal any GFP signal in positive transgenes, which indicated that Cecrbnsec 
is not expressed at the required level or even at all. Previously, abnormal regulation of 
expression from multi-copy transgenic arrays was reported as one of the disadvantages of the 
technique (Mello and Fire, 1995), and we surmise that it explains the absence of the signal in 
our experiments. 
The use of antibodies to visualize the distribution and sub-cellular localization of gene 
products powerfully complements molecular analysis of a protein function. Thus, we further 
decided to employ immunohistochemistry as an alternative technique for determination of the 
sub-cellular localization of the protein. To produce specific antibodies against our target 
protein, we used the CeCRBNsec expressed and purified from E. coli (Fig. 3.4.7.2) as an 
antigen for rabbit immunization. The antibodies were purified from the rabbit serum, using 
antigen covalently coupled to an NHS-activated column. The working concentration of the 
antibodies was determined to be 1:1,000. 
 
 
 
 
 
Figure 3.4.7.1. Reporter gene constructs injected into worms with marker plasmid generate 
positive transgenes. UTR – untranslated region. 
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Figure 3.4.7.2.Purification of CeCRBNsec by Ni-affinity chromatography after cleavage of the 
His-tag by TEV protease. Fractions D4-E5 were pooled and used for immunization. FT (flow 
through), M – marker. 
 
 
As any information concerning either topological or stage-dependent expression of 
CeCRBNsec is missing, we first aimed to determine, at which developmental stage it is 
expressed in worms (Fig. 3.4.7.3A and B). Worms of different stages were separately 
collected after synchronization. Total protein concentration was measured in each worm 
extract (Pierce BSA kit). 30µg of each sample was loaded on the SDS-gel and further 
analyzed by Western blot using generated antibodies (Fig. 3.4.7.3 B). Fig. 3.4.7.3 D 
represents a sensitivity test, which demonstrated that as little as 10 ng of CeCRBNsec can be 
detected under given experimental conditions. Since the CeCRBNsec expression was not 
observed in the protein extracts under normal physiological conditions, we surmise that it is 
dependent on some unknown environmental queues, which are, considering the missing 
knowledge about the protein function, difficult to predict. Alternatively, CeCRBNsec might be 
produced in a very low amount in the organism and, therefore, its detection is limited for 
many methods. 
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Figure 3.4.7.3. CeCRBNsec expression in C. elegans. A. Worm life cycle. B. Western blot 
analysis of different worm stages using the anti CeCRBNsec antibodies. C. Loading control. D. 
Western blot demonstrating the sensitivity of the produced anti CeCRBNsec antibodies against 
recombinant CeCRBNsec. 
 
 
3.4.8 Contributions 
 
This PhD thesis was conducted in the department of Prof. Andrei Lupas, who initiated 
the project, performed bioinformatic analysis, supervised the study, and continuously 
discussed it with our team members. I performed all the experiments under intermediate 
supervision of Birte Hernandez Alvarez, who designed the experimental work together with 
Marcus Hartmann unless otherwise specified. In this chapter, my contributions to the 
experiments are listed, which have not been published yet. My contributions to the 
publications, presented in this thesis, are described before (3.1.2, 3.2.2, 3.3.2). 
 
3.4.1 CULT domain: structural insight 
As mentioned in 3.1.2, I performed cloning, expression, and purification trials for all 
presented constructs, except the bacterial ones. The three construct of N-terminally truncated 
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human cereblon were designed by Birte Hernandez Alvarez and cloned by Silvia Deiss into 
pFAST-Bac vector. I performed expression studies in insect cells and purified the proteins. 
 
3.4.2 What are the physiological ligands of CULT? 
The DNA / RNA binding studies using SEC were initiated by Birte Hernandez Alvarez 
and continued by myself after joining the department. I further performed all EMSA and pull 
down experiments with biotinylated DNA, biotinylated peptides and microarrays. Klaus 
Kopec helped me with the microarray analysis. Silvia Deiss provided technical assistance in 
the conduction of pull downs with biotinylated peptides. The FRET-based ligand binding 
assay was established by Birte Hernandez Alvarez and some of the measurements were 
performed by Kerstin Bär.  
 
3.4.3 Cereblon-mediated teratogenicity of pharmacological compounds 
Marcus Hartmann initiated the study of cereblon binding to pharmaceuticals sharing 
structural similarity with thalidomide. The FRET-based ligand binding assay was established 
by Birte Hernandez Alvarez and some of the measurements were performed by Kerstin Bär. I 
established the in vivo assay in zebrafish, performed all experiments and analyzed the data. 
Silvia Deiss helped me to mount the embryos in the agarose before imaging the fish. 
 
3.4.4 The bacterial CULT domain interacts with transcription termination factor Rho 
Birte Hernandez Alvarez initiated and designed the study. I contributed to the 
experimental design of the experiments for validation of identified binding proteins. I 
performed all experiments described in this chapter. Mass spectrometric analysis was 
conducted at the Proteome Center (Universität Tübingen). 
 
3.4.5 Proteomic analysis of CULT-mediated hCRBN binding partners 
Birte Hernandez initiated and designed the study, performed pull down for SILAC-
based proteomic analysis, and analyzed the data. I cloned and expressed binding candidates 
and performed co-immunoprecipitation experiments. Mass spectrometric analysis was 
conducted at the Proteome Center (Universität Tübingen). 
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3.4.6 Cereblon co-immunoprecipitates demethylase LSD1 
I initiated the study; together with Birte Hernandez Alvarez I designed the experiments. 
All the experimental work was conducted by me. 
 
3.4.7 On the sub-cellular localization of C. elegans secreted cereblon  
All experiments with worms were performed by me under the supervision of 
Igor Iatsenko from the Department of Integrative Evolutionary Biology. The experimental 
setup was designed by Adrian Streit, Igor Iatsenko and me. Martin Schückel supported me in 
antibody production by injecting animals and collecting the blood samples. 
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4 CONCLUSIONS 
 
In summary, I present here the study of cereblon proteins with particular focus on their 
thalidomide-binding domain, also referred to as CULT. By determining the crystal structure 
of the bacterial homolog of the CULT domain we demonstrated how cereblon recognizes its 
ligand. The CULT domain harbors a binding pocket formed by three conserved tryptophan 
residues that build an aromatic cage for ligand docking. Using bacterial MsCI4 as a model 
system, we show that a part of the CULT domain folds upon ligand binding, accompanied by 
an increase of the thermal stability of the protein. Searching for natural ligands of the CULT 
domain, we identify uridine mimicking thalidomide binding, which is demonstrated by 
structural studies as well as in vivo. Up to now, uridine represents the only known 
physiological ligand of cereblon proteins that is universally present in bacteria and 
eukaryotes. Additionally, we note that the binding pocket of the CULT domain resembles the 
aromatic cage of lysine or arginine methylation readers. Although no interaction between the 
protein and these amino acids and their methylated derivatives could be shown in vitro, we 
consider that in the context of a specific flanking sequence, such residues are conceivable as 
ligands of cereblon. 
Further, we developed a FRET-based in vitro assay for testing binding and affinities of 
cereblon to its ligands. Comparative analysis of the thalidomide-binding domains from H. 
sapiens, M. gryphiswaldense, and C. elegans displayed similar affinities to the same ligands 
on a relative scale, suggesting that all these proteins bind the same natural ligand. Moreover, 
this study demonstrated the expedience of the bacterial protein as a robust model system for 
testing the substrate specificity of the CULT domain to its ligands, such as newly developed 
pharmacologically relevant compounds. Using a FRET-based assay, we showed that various 
pharmaceuticals broadly used in medicine interact with the CULT domain in the micromolar 
range, displaying their off-target effect. In vivo test further validated their cereblon-dependent 
teratogenicity in zebrafish embryos. In time, the assay provides a useful tool for the 
characterization of the teratogenic potential of new compounds mediated via cereblon. 
Searching for interacting proteins, we showed that the bacterial CULT domain binds to 
transcription termination factor Rho, suggesting its role in transcriptional regulation. 
Similarly, proteins involved in transcriptional repression and gene silencing were shown to 
co-immunoprecipitate with human cereblon via its CULT domain from HEK293T cells. This 
is further supported by the fact that hCRBN interacts with demethylase LSD1, which is 
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essential for transcriptional regulation. Development of multicellular organism is controlled 
by temporal and spatial expression of specific genes, which is regulated by transcription 
repression and activation complexes. Taken all together, our results provide a promising 
starting point for following investigations to unravel cereblon function that possibly includes 
transcriptional regulation, particularly during limb formation. 
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Appendix I 
 
 Origin Vector Cloning 
sites  
Tag Expression 
system 
Expression 
level 
Remarks 
MsCI4 Magnetospirillum 
gryphiswaldense 
pETHis1a NcoI, 
BamHI 
N-terminal-His-
FLAG 
E. coli +++ partly 
soluble 
MsCI4
YW/AA
 Magnetospirillum 
gryphiswaldense 
pETHis1a NcoI 
BamHI 
N-terminal-His-
FLAG 
E. coli +++ partly 
soluble 
CRBN Homo sapiens pETHis1a NcoI 
BamHI 
N-terminal-His E. coli ++ insoluble 
CRBN Δ1-79  
Homo sapiens pET His1a NcoI 
BamHI 
N-terminal-His E. coli + insoluble 
CRBN Δ1-186  
Homo sapiens pETHis1a NcoI 
BamHI 
N-terminal-His E. coli ++ insoluble 
CRBN Δ1-318 
Homo sapiens pETHis1a NcoI 
BamHI 
N-terminal-His E. coli +++ insoluble 
CRBN 80-318  
Homo sapiens pETHis1a NcoI 
BamHI 
N-terminal-His E. coli ++ insoluble 
CRBN 32-247 
Homo sapiens pETHis1a NcoI 
HindIII 
N-terminal-His E. coli +++ 
 
insoluble 
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CeCRBNsecΔ1-15 
Caenorhabditis elegans pETHis1a NcoI 
BamHI 
N-terminal-His E. coli +++ 
 
insoluble 
CRBN 
Alvinella pompejana pETHis1a_NdeI NdeI 
BamHI 
N-terminal-His E. coli +++ 
 
insoluble 
CRBN 
Alvinella pompejana pET28b AgeI N-terminal-His-
SUMO 
E. coli +++ 
 
insoluble 
CRBN Homo sapiens pFAST-Bac/CT 
TOPO 
Blunt-end 
cloning 
C-terminal-His Sf9 +++ 
 
degradation 
CeCRBNsecΔ1-15 
Caenorhabditis elegans pFAST-Bac/CT 
TOPO 
Blunt-end 
cloning 
C-terminal-His Sf9 +++ 
 
- 
CRBN Homo sapiens pFastBac_NcoI NcoI 
XhoI 
N-terminal-His-
ZZ 
Sf9 +++ 
 
degradation 
CRBNΔ1-108 Homo sapiens pFastBac_NcoI NcoI 
XhoI 
N-terminal-His-
ZZ 
Sf9 ++ 
 
degradation 
CRBN Δ1-193 Homo sapiens pFastBac_NcoI NcoI 
XhoI 
N-terminal-His-
ZZ 
Sf9 ++ 
 
degradation 
CRBN Δ1-315 Homo sapiens pFastBac_NcoI NcoI 
XhoI 
N-terminal-His-
ZZ 
Sf9 +++ - 
CRBN 76-186 Homo sapiens pFastBac_NcoI NcoI N-terminal-His- Sf9 + - 
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HindIII ZZ  
CRBN 76-249 Homo sapiens pFastBac_NcoI NcoI 
HindIII 
N-terminal-His-
ZZ 
Sf9 + 
 
degradation 
CRBN 76-316 Homo sapiens pFastBac_NcoI NcoI 
HindIII 
N-terminal-His-
ZZ 
Sf9 + 
 
degradation 
DDB1 Homo sapiens pFAST-Bac/CT 
TOPO 
Blunt-end 
cloning 
C-terminal-His Sf9 +++ - 
DDB1 Homo sapiens pFAST-NdeI AgeI 
XbaI 
N-terminal-His Sf9 +++ - 
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Appendix II 
 
 PCR 
product 
Restriction 
Enzymes  
Tag used in 
petHis1a 
Expression strain Expression 
level 
Solubility 
Transcription termination factor Rho 
 
+ NdeI 
BamHI 
N-terminal-His E. coli C41 +++ ++ 
Aspartokinase + NdeI 
BamHI 
N-terminal-His E. coli Arctic 
Express 
+++ + 
Lipopolysaccharide transport protein B: 
ATP-binding component of ABC 
superfamily  
 
+ NdeI 
BamHI 
N-terminal-His E. coli C41 +++ ++ 
Putative glyoxalase I family protein putative 
Methylmalonyl-CoA epimerase  
 
+ NdeI 
BamHI 
N-terminal-His E. coli Arctic 
Express 
+++ ++ 
3-isopropylmalate dehydratase large subunit  
 
+ NdeI 
BamHI 
N-terminal-His E. coli Arctic 
Express 
+++ + 
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Appendix III 
 
Name  Oligonucleotides 
 
bio C+ 5`-AAGTCCTGAATGAATCAAGCAGGCGTTGAAG-3` 
 
bio U+ 5`-AAGTCCTGAATGAATUAAGCAGGCGTTGAAG-3` 
 
bio G- 5`-CTTCAACGCCTGCTTGATTCATTCAGGACTT-3` 
 
bio C+/bio G- 5`-AAGTCCTGAATGAATCAAGCAGGCGTTGAAG-3` 
3`-TTCAGGACTTACTTAGTTCGTCCGCAACTTC-5` 
 
bio U+/bio G- 5`-AAGTCCTGAATGAATUAAGCAGGCGTTGAAG-3` 
3`-TTCAGGACTTACTTAGTTCGTCCGCAACTTC-5` 
 
bio CC+ 5`-GATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATG-3` 
bio UU+ 5`-GATCCTTTGATCTTTTUTACGGGGTCTGACGCTCAGTGGAAUGAAAACTCACGTTAAGGGATTTTGGTCATG-3` 
bio GG- 5`-CATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATC-3` 
bio UU+/bio GG- 5`-GATCCTTTGATCTTTTUTACGGGGTCTGACGCTCAGTGGAAUGAAAACTCACGTTAAGGGATTTTGGTCATG-3` 
3`-CTAGGAAACTAGAAAAGATGCCCCAGACTGCGAGTCACCTTGCTTTTGAGTGCAATTCCCTAAAACCAGTAC-5` 
 
bio CC+/bio GG- 5`-GATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATG-3` 
3`-CTAGGAAACTAGAAAAGATGCCCCAGACTGCGAGTCACCTTGCTTTTGAGTGCAATTCCCTAAAACCAGTAC-5` 
 
 
«+» and «–» show complementary strands. All DNA sequences, except «–» strands in the 
double stranded DNA, carried biotin (bio) at their 5`. 
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Appendix IV 
 
Antibodies Dilution 
Mouse anti-His (Dianova; DIA-900) 1/1,000 
Rabbit anti-FLAG (Dianova; ABR-01098) 1/1,000 
Mouse anti-HA (Covance; MMS-101R200) 1/1,000 
Rabbit anti-HA (Sigma; H6908) 1/1,000 
Rabbit anti-Myc (Abcam; ab9106) 1/1,000 
Goat anti Wiz (Acris GmbH; AP16897PU-N) 1/500 
Rabbit anti-actin (Sigma; A2066) 1/1,000 
Rabbit anti-CeCRBNsec (in-house made) 1/1,000 
Anti-mouse HRP (Sigma; A4416-1ML) 1/3,500 
Anti-rabbit  (Sigma; A0545-1ML) 1/3,500 
Anti-goat (Sigma; A5420-1ML) 1/7,500 
Anti-mouse (Sigma; SAB3701116) 1/1,000 
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Appendix V 
 
 Matrix PCR product Restriction Enzymes  Tag used in pcDNA3.1 
CRBN plasmid + HindIII 
XhoI 
N-terminal-His 
CRBN plasmid + HindIII 
XhoI 
N-terminal-FLAG 
CRBN plasmid + HindIII 
XhoI 
N-terminal-Myc 
CRBN plasmid + HindIII 
XhoI 
N-terminal-HA 
DDB1 plasmid + KpnI 
AgeI 
N-terminal-His 
DDB1 plasmid + KpnI 
AgeI 
N-terminal-FLAG 
DDB1 plasmid + KpnI 
AgeI 
N-terminal-Myc 
DDB1 plasmid + KpnI 
AgeI 
N-terminal-HA 
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WIZ human cDNA + NheI 
AgeI 
N-terminal-Myc 
HIC2 human cDNA + NheI 
AgeI 
N-terminal-Myc 
EHTM1 gene synthesis - NheI 
AgeI 
N-terminal-Myc_pCMV6* 
EHTM2 human cDNA - NheI 
AgeI 
N-terminal-Myc 
PATZ1 human cDNA + NheI 
AgeI 
N-terminal-Myc 
zinc finger protein 644 human cDNA + NheI 
AgeI 
N-terminal-Myc 
zinc finger protein 687 human cDNA + BamI 
AgeI 
N-terminal-Myc 
PKCBP human cDNA + NheI 
NotI 
N-terminal-Myc 
LSM12 human cDNA + NheI 
AgeI 
N-terminal-Myc 
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myc-associated zinc finger 
protein 
human cDNA - Nhe I 
Age I 
N-terminal-Myc 
LSD1 human cDNA + Nhe I 
Xho I 
N-terminal-FLAG 
SUV39H1 human cDNA + Nhe I 
Bam I 
N-terminal-FLAG 
LSD1 FLAG-LSD1 pcDNA3.1 + Kpn I 
Xho I 
C-terminal-HA* 
Δ1-108CRBN HA-CRBN pcDNA3.1 + Nhe I 
Xho I 
N-terminal-HA 
Δ1-194CRBN HA-CRBN pcDNA3.1 + Nhe I 
Xho I 
N-terminal-HA 
Δ1-314CRBN HA-CRBN pcDNA3.1 + Nhe I 
Xho I 
N-terminal-HA 
175-877
Δ419-520
 LSD1 FLAG-LSD1 pcDNA3.1 + Nhe I 
Xho I 
N-terminal-FLAG 
175-260 LSD1 FLAG-LSD1 pcDNA3.1 + Nhe I 
Xho I 
N-terminal-FLAG 
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175-288 LSD1 FLAG-LSD1 pcDNA3.1 + Nhe I 
Xho I 
N-terminal-FLAG 
1-291 LSD1 FLAG-LSD1 pcDNA3.1 + Nhe I 
Xho I 
N-terminal-FLAG 
294-877 LSD1 FLAG-LSD1 pcDNA3.1 + Nhe I 
Xho I 
N-terminal-FLAG 
175-418 LSD1 FLAG-LSD1 pcDNA3.1 + Nhe I 
Xho I 
N-terminal-FLAG 
*ordered
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Keywords:
Immunomodulatory drug
IMiD
Revlimid
PomalystThalidomide and its derivatives lenalidomide and pomalidomide are important anticancer agents but can
cause severe birth defects via an interaction with the protein cereblon. The ligand-binding domain of
cereblon is found, with a high degree of conservation, in both bacteria and eukaryotes. Using a bacterial
model system, we reveal the structural determinants of cereblon substrate recognition, based on a series
of high-resolution crystal structures. For the ﬁrst time, we identify a cellular ligand that is universally
present: we show that thalidomide and its derivatives mimic and compete for the binding of uridine,
and validate these ﬁndings in vivo. The nature of the binding pocket, an aromatic cage of three tryptophan
residues, further suggests a role in the recognition of cationic ligands. Our results allow for general
evaluation of pharmaceuticals for potential cereblon-dependent teratogenicity.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Thalidomide was originally introduced for its sedative and
anti-emetic properties in the 1950s, but banned from the market
in the early 1960s due to teratogenic effects that had led to severe
developmental defects in about 10,000 newborns. In the decades
after its withdrawal, it was also discovered to possess anti-
inﬂammatory, immunomodulatory and anti-angiogenic properties,
thus promising valuable treatment for a broad range of clinical
conditions (Bartlett et al., 2004; Franks et al., 2004). Especially,
its success as an anti-cancer agent paved the road for a renaissance
and promoted the development of a new class of immunomodula-
tory drugs (IMiDs) based on thalidomide as a lead compound.
However, many important and promising derivatives like lenalido-
mide (CC-5013, Revlimid) and pomalidomide (CC-4047, Pomalyst)
potentially inherited thalidomide’s teratogenic properties, severely
limiting their use.
Thalidomide consists of a phthaloyl ring and a glutarimide ring
with a chiral carbon; it racemizes in vivo and only the (S)-enantio-
mer is thought to be teratogenic (Bartlett et al., 2004; Franks et al.,
2004). Lenalidomide and pomalidomide have the same architec-
ture with modiﬁed phthaloyl moieties (Fig. 1). In 2010, Handa
and co-workers identiﬁed the protein cereblon as a primary targetof thalidomide (Ito et al., 2010). They showed that cereblon associ-
ates with damaged DNA binding protein 1 (DDB1), a core compo-
nent of the DDB1/cullin4 (CUL4) E3 ubiquitin ligase complex
which is known as a key player in the nucleotide excision repair
pathway. These E3 ligase complexes employ a large number of
different DDB1-CUL4-associated factors (DCAFs) with different
substrate speciﬁcity as substrate receptors (Iovine et al., 2011).
Cereblon constitutes a novel DCAF for this complex, altering its
ubiquitin ligase activity upon thalidomide binding, which may in
turn cause its teratogenic effects. The region critical for DDB1
binding was found to reside in the middle part of the cereblon
protein, whereas the binding site for thalidomide was mapped to
the C-terminal 104 amino acids: the two point mutants of human
cereblon hCrbnY384A and hCrbnW386A and especially the double
mutant hCrbnYW/AA had signiﬁcantly lowered thalidomide-binding
activity. Also lenalidomide and pomalidomide were shown to bind
to cereblon, competing for the same binding site (Lopez-Girona
et al., 2012). Moreover, it was found that the degradation of the
transcription factors Ikaros and Aiolos by the Cereblon/DDB1/
CUL4 E3 ligase is stimulated by these IMiDs in multiple myeloma
cells (Gandhi et al., 2014; Kronke et al., 2014). These downstream
factors can however only represent a subset of the natural targets,
as they do not occur outside the animal kingdom, whereas
cereblon occurs throughout eukaryotes, except fungi.
By sequence analysis (Lupas et al., 2014), human cereblon is a
multi-domain protein: an N-terminal intrinsically unstructured
region is followed by a LON domain and a C-terminal domain that
contains the thalidomide-binding site deﬁned by Ito et al. (2010).
226 M.D. Hartmann et al. / Journal of Structural Biology 188 (2014) 225–232The C-terminal domain, which we named CULT (cereblon domain
of unknown activity, binding cellular ligands and thalidomide), is
also found as the sole domain in two other protein families, one
comprising secreted proteins of eukaryotes and the other cytosolic
proteins of bacteria. CULT domains contain three strictly conserved
tryptophan residues, one of which (W386 in hCrbn) was identiﬁed
as critical for thalidomide binding (Ito et al., 2010).
Searches for distant homologs show that the CULT domain is
related to proteins sharing a common fold formed by two four-
stranded, antiparallel b-sheets that are oriented at approximately
a right angle, and pinned together at their tip by a zinc ion
(Lupas et al., 2014). We have named this fold the b-tent for the
prominent arrangement of its b-sheets. Proteins of this fold show
considerable functional and structural divergence, including an
absence of most sequence motifs characteristic for CULT domains;
however, the location of the substrate binding site appears to be
conserved among all members of the fold (Lupas et al., 2014).
Here we determined crystal structures of a bacterial CULT
domain from Magnetospirillum gryphiswaldense MSR-1, bound to
thalidomide and other ligands. With a sequence identity of 35%,
it is as similar to the human thalidomide binding domain as
domains from other eukaryotic clades. Substantiated by an NMR-
based assay and in vivo data, the structures provide the molecular
basis for thalidomide teratogenicity and, for the ﬁrst time, reveal
potential natural ligands that are universally present in all
organisms with cereblon proteins.2. Experimental procedures
2.1. Cloning
The gene encoding MsCI4 was synthesized codon-optimized for
expression in Escherichia coli. It was cloned in pETHis_1a, a modi-
ﬁed pETM vector (sequence available at http://www.embl.de/
pepcore/pepcore_services/strains_vectors/vectors/bacterial_expres-
sion_vectors/index.html) for overexpression of the protein in E. coli
with a N-terminal hexa-histidine tag followed by a cleavage site of
TEV (Tobacco Etch Virus) protease.
Mutants MsCI4YW/AA and MsCI4Y101F were constructed using
QuikChange Site-Directed Mutagenesis Kit (Stratagene) with wild
type MsCI4 in pETHis_1a as a template and mutagenic primers. The
correctness of all clones was veriﬁed by DNA sequencing.2.2. Protein expression and puriﬁcation
All proteins were expressed in E. coli C41 (DE3) cells. After
induction of protein expression in the logarithmic phase at
A600 = 0.6, the cultures were shaken for 4 h at 37 C. Cells were
pelleted, resuspended in 20 mM Tris, pH 7.5, 100 mM NaCl,
5 mM 2-Mercaptoethanol, 4 mM MgCl2 , DNase I and Protease
Inhibitor Cocktail (Roche Applied Science), and lysed using a
French pressure cell. After centrifugation of the extract, the super-
natant was applied on a NiNTA agarose column equilibrated in
20 mM Tris, pH 7.9, 300 mM NaCl, 5 mM 2-Mercaptoethanol. His-
tidine tagged proteins were eluted with a gradient of 0–0.5 M
imidazole. MsCI4 wildtype or mutant protein containing fractions
were pooled and dialyzed against 20 mM Tris, pH 7.5, 150 mM
NaCl, 5 mM 2-Mercaptoethanol. The histidine tag was cleaved
overnight at 4 C by TEV protease. The protein mixture was loaded
on a NiNTA column to which the histidine tagged TEV protease and
the cleaved linker bound. Cleaved MsCI4 proteins were found to
be in the ﬂow through. They were pooled and concen-
trated to 14 mg/ml in 20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM
2-Mercaptoethanol.2.3. NMR spectroscopy
Comparison of spectra of MsCI4 alone and in presence of thalid-
omide revealed signiﬁcant chemical shift changes for many reso-
nances, including several prominent, upﬁeld-shifted methyl
groups. One such methyl group shifts from 0.31 to 0.89 ppm
on binding of thalidomide, providing a trivial assay for ligands
employing a thalidomide-like binding mode. Typically, 1D proton
spectra were acquired on 50 lM protein samples both alone and
in the presence of 10–500 lM ligand. Uracil, uridine and deoxyur-
idine induce these characteristic chemical shift changes at the low-
est concentrations tested. Other pyrimidine nucleobases and
nucleosides tested (cytosine, cytidine, deoxycytidine, thymidine
and deoxythymidine) did not, with concentrations of at least
500 lM. For these compounds ligand-detected experiments (STD
(Meyer and Peters, 2003) and water-LOGSY (Dalvit et al., 2000))
were also used to probe for binding where characteristic chemical
shift changes were not detected. Here ligand protein concentration
ratios of 10:1 were employed with ligand concentrations of
500 lM. A negative result in these experiments used to place a
conservative lower limit on binding afﬁnity at twice this concen-
tration, i.e. 1 mM. These assays were repeated for the MsCI4Y101F
mutant (thalidomide, uracil, uridine and deoxyuridine) and for the
MsCI4YW/AA double mutant (thalidomide and uridine).2.4. Crystallography
Crystallization trials were performed at 294 K in 96-well
sitting drop plates with 50 ll of reservoir solution and drops
containing 400 nl of protein solution in addition to 400 nl of
reservoir solution. The protein solution in the individual
co-crystallization trials contained the additives listed in Table 1,
in addition to 17 mg/ml of protein in 20 mM Tris, pH 7.5,
150 mM NaCl, 5 mM 2-Mercaptoethanol. Most of the different
co-crystallization trials yielded crystals in multiple similar
conditions. The conditions for the crystals used for structure
determination are listed in Table 1. All crystals were loop
mounted and ﬂash-cooled in liquid nitrogen. Where necessary,
crystals were transferred into a separate drop of cryo-solution
as indicated in Table 1 prior to ﬂash-cooling. All data were
collected at beamline X10SA (PXII) at the SLS (Paul Scherrer
Institute, Villigen, Switzerland) at 100 K using a PILATUS 6 M
detector (DECTRIS) at a wavelength of 1 Å. Diffraction images
were processed and scaled using the XDS program suite
(Kabsch, 1993). The ﬁrst structure, MsCI4thalidomide, was
solved exploiting the anomalous signal of the structural zinc
ions. Three zinc sites, belonging to the three monomers in the
asymmetric unit, were identiﬁed with SHELXD (Sheldrick,
2008). Density modiﬁcation with SHELXE yielded an electron
density map of excellent quality, which was subsequently traced
with ARP/WARP (Perrakis et al., 1999). The structures of
MsCI4pomalidomide, MsCI4lenalidomide, MsCI4deoxyuridine
and MsCI4Y101Fthalidomide were subsequently solved based on
the MsCI4thalidomide coordinates. All structures were com-
pleted by cyclic manual modeling with Coot (Emsley and
Cowtan, 2004) and reﬁnement with REFMAC5 (Murshudov
et al., 1999). Analysis with Procheck (Laskowski et al., 1993)
showed excellent geometries for all structures. Data collection
and reﬁnement statistics are summarized in Table 2. All molec-
ular depictions were prepared using MolScript (Kraulis, 1991)
and Raster3D (Merritt and Bacon, 1997). All coordinates and
structure factors were deposited in the Protein Data Bank
(PDB) under the accession codes 4V2Y (MsCI4thalidomide),
4V2Z (MsCI4pomalidomide), 4V30 (MsCI4lenalidomide), 4V31
(MsCI4deoxyuridine) and 4V32 (MsCI4Y101Fthalidomide).
Fig.1. How cereblon recognizes its ligands. (a) The structure of thalidomide, its derivatives, and related pyrimidine nucleosides. Encircled in green are the functional groups
that are recognized by cereblon; encircled and crossed out in red are groups that are incompatible with the binding pocket. Pomalidomide and lenalidomide have modiﬁed
phthaloyl rings but the same glutarimide ring as thalidomide and are therefore bound in the same way. The uracil moiety of uridine is bound in the same way as the
glutarimide ring of thalidomide, whereas the thymine moiety of thymidine is too bulky and the cytosine moiety of cytidine cannot form the necessary hydrogen bonds. (b)
Cartoon representation of one monomer of MsCI4 in complex with thalidomide in two orientations. Shown in detail are the three tryptophan residues forming the boundaries
of the binding pocket, Y101 (white), and four conserved cysteines that coordinate a structural zinc ion. In the left orientation, an approximate twofold symmetry axis is
apparent, which relates the beta sheet in dark gray color to the beta sheet in light gray color; this axis passes through the zinc binding site. (c) Sequence alignment of MsCI4
with the thalidomide-binding domain of human Cereblon, together with the secondary structure of the crystal structure. The residues in the binding site are highlighted in
bold red, the cysteines of the zinc binding site in red. Identical residues are marked with ‘‘|’’, similar residues with ‘‘:’’. The sequence identity is 35% over 104 aligned positions.
(d) Detailed view of the binding pocket of MsCI4 in complex with different ligands, including a superposition of the pocket in complex with thalidomide and deoxyuridine,
and a detailed view of the MsCI4Y101F mutant pocket in complex with thalidomide. Highlighted are the hydrogen bonds formed between the ligands and the protein.
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A zebraﬁsh pectoral ﬁn deformity assay was performed as
described by Ito et al. (2010) with the following modiﬁcations:
(1) The zebraﬁsh cereblon (zcrbn) gene, as annotated at http://
www.ensembl.org, was ampliﬁed by PCR from cDNA; (2) The exam-
ined species was Danio rerio leot1; (3) zcrbn mRNA was dissolved innuclease-free water at 200 ng/ll; (4) The length of the pectoral ﬁns
was measured using self-developed software, which allows curva-
ture determination in a semi-automatic fashion. The deformity
was classiﬁed as ‘‘no effect’’ for ﬁns exceeding 85% of the control
length, ‘‘mild’’ for ﬁns corresponding to 75–85% of the control
length, ‘‘medium’’ for ﬁns shortened to 60–75%, and ‘‘severe’’ for
ﬁns shorter than 60% of the control length.
Table 1
Crystallization conditions and cryo protection.
Structure Protein solution additives Reservoir solution (RS) Cryo solution
MsCI4thalidomide 3 mM thalidomide
3% (v/v) DMSO
0.1 M magnesium chloride
0.1 M sodium citrate pH 5
15%(w/v) PEG 4000
RS + 15% (v/v) PEG 300
MsCI4pomalidomide 3 mM pomalidomide
3% (v/v) DMSO
0.1 M sodium acetate pH 4.6
15 %(w/v) PEG 20,000
RS + 15% (v/v) PEG 300
MsCI4lenalidomide 3 mM lenalidomide
3% (v/v) DMSO
15 %(w/v) PEG 6000
5 %(w/v) glycerol
RS + 10% (v/v) PEG 300
MsCI4deoxyuridine 3 mM deoxyuridine 0.1 M citric acid pH 3.5
25 %(w/v) PEG 3350
–
MsCI4Y101Fthalidomide 3 mM thalidomide
3% (v/v) DMSO
0.2 M sodium chloride
0.1 M phosphate-citrate pH 4.2
20 %(w/v) PEG 8000
RS + 10% (v/v) PEG 300
Table 2
Data collection and reﬁnement statistics.
MsCI4thalidomide MsCI4pomalidomide MsCI4lenalidomide MsCI4deoxyuridine MsCI4Y101Fthalidomide
Data collection
Space group P212121 P212121 P212121 P212121 P212121
Cell dimensions a, b, c (Å) 56.5, 60.1, 88.5 56.5, 60.1 88.5 56.7, 59.7, 88.1 56.8, 60.0, 88.4 56.8, 60.0, 88.4
Resolution (Å) 37.3–1.40 (1.48–1.40)a 37.3–1.45 (1.54–1.45)a 37.3–1.85 (1.96–1.85)a 37.4–1.80 (1.91–1.80)a 37.4–1.90 (2.01–1.90)a
Rmerge 7.4 (73.2) 3.8 (44.9) 7.3 (41.6) 8.5 (50.5) 8.6 (77.3)
I/rI 12.46 (1.73) 16.32 (2.45) 8.41 (1.96) 8.71 (2.33) 15.06 (2.59)
Completeness (%) 99.6 (97.7) 99.5 (99.1) 98.7 (98.0) 98.8 (97.4) 99.9 (99.5)
Redundancy 6.69 (6.39) 3.40 (3.37) 2.86 (2.81) 2.87 (2.74) 6.99 (6.91)
Reﬁnement
Resolution (Å) 37.3–1.40 37.3–1.45 37.3–1.85 37.4–1.80 37.4–1.90
No. reﬂections 57,028 51,290 24,829 27,173 23,212
Rwork/Rfree 0.16/0.19 0.17/0.20 0.19/0.24 0.16/0.22 0.18/0.24
PDB code 4V2Y 4V2Z 4V30 4V31 4V32
a Highest resolution shell is shown in parenthesis.
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3.1. Cereblon isoform 4 from M. gryphiswaldense
For crystallization and in vitro experiments, we designed con-
structs of full-length cereblon and isolated thalidomide binding
domains from different eukaryotes as well as one bacterial repre-
sentative, cereblon isoform 4 from M. gryphiswaldense MSR-1
(MsCI4; 124 residues). While the work with the eukaryotic con-
structs was cumbersome and did not yield crystals, the bacterial
protein was highly rewarding: With soluble expression in E. coli
at high yields and facile puriﬁcation with standard chromatogra-
phy methods, it poses a very robust model system. Further, we
expressed and puriﬁed two mutants of MsCI4. The double mutant
MsCI4YW/AA with the mutations Y83A and W85A is the equivalent
to the binding deﬁcient double mutant hCrbnYW/AA with mutations
Y384A and W386A. The other mutant is MsCI4Y101F, with a substi-
tution in the binding pocket as described later on. To conﬁrm that
MsCI4 indeed binds to thalidomide, we employed a simple NMR-
based assay that relies on chemical shift changes that occur upon
ligand binding. Thereby we found that wild-type MsCI4 and
MsCI4Y101F both have binding constants for thalidomide in the
low micromolar range, whereas the binding constant of the double
mutant MsCI4YW/AA was shifted to the millimolar range. Crystalli-
zation trials were performed for MsCI4 and MsCI4YW/AA, both in
apo form and in presence of thalidomide. Only the trial with MsCI4
and thalidomide was successful; crystals appeared within 2 days in
a wide range of conditions.
3.2. Crystal structures in complex with thalidomide, lenalidomide and
pomalidomide
The best dataset collected from these crystals could be scaled to
a resolution of 1.4 Å in space group P212121. The structure could besolved by exploiting the anomalous signal of the structural zinc
ions of the b-tent fold; three such ions were located in the asym-
metric unit, belonging to 3 MsCI4 molecules. All three monomers
are bound to thalidomide and have the same overall conformation,
resembling the expected b-tent fold with two orthogonal b-sheets
(Fig. 1).
The thalidomide binding site is formed by the three conserved
tryptophan residues W79, W85 and W99, corresponding to
W380, W386 and W400 of hCrbn, which constitute 3 sides of a
rectangular aromatic cage. W79 and W85 form opposite walls of
the cage, sandwiching the glutarimide ring at van der Waals
distance, and are orthogonal to W99. Opposite of W99, the glutari-
mide ring forms two hydrogen bonds to backbone atoms, one
between the amino group and F77O and the other between the dis-
tal keto group and W79N. A third hydrogen bond is formed
between the distal keto group and the hydroxyl group of a tyrosine,
Y101, corresponding to F402 of hCrbn, which forms the bottom of
the cage. (Fig. 1). From the racemic mixture of thalidomide used in
the crystallization trial, the (S)-enantiomer is speciﬁcally selected
by the geometry of the pocket. In further co-crystallization exper-
iments we obtained the structures of the MsCI4lenalidomide
and the MsCI4pomalidomide complex in the same crystal form
as MsCI4thalidomide. As lenalidomide and pomalidomide are
derivatives of thalidomide that are only modiﬁed in the phthaloyl
moiety, and the interactions with the binding pocket are exclu-
sively mediated via the glutarimide ring, the binding modes of
the three compounds are identical (Fig. 1).
Of all interactions that the ligands form with the binding
pocket, the hydrogen bond with Y101 is speciﬁc for MsCI4, as
Y101 corresponds to a phenylalanine (F402) in hCrbn. This led us
to conﬁrm the validity of our results in the point mutant
MsCI4Y101F, replacing the tyrosine to phenylalanine and thereby
creating a binding pocket that should be chemically indistinguish-
able from hCrbn. NMR-based measurements of this mutant with
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wild-type MsCI4. This is further underpinned by a crystal structure
obtained for the MsCI4Y101Fthalidomide complex, which is identi-
cal to the wild-type complex, except for lacking a hydrogen bond
to the substituted tyrosine (Fig. 1).3.3. Uridine as a cellular ligand
Given the binding mode of thalidomide, what can we infer
about a potential natural ligand? As cereblon is supposed to act
as a DCAF of DDB1, a DNA related ligand seemed plausible. In this
context, the binding mode and the structural similarity of the glu-
tarimide ring to pyrimidine bases suggested to us that the natural
substrate of the thalidomide-binding domain might be a pyrimi-
dine nucleoside – uridine, cytidine or thymidine (Fig. 1a). Of these,
only uridine and thymidine are theoretically able to form the same
hydrogen bonds within the binding pocket as glutarimide does.
Furthermore, the cage formed by the three tryptophan residues
might sterically discriminate between thymidine and uridine, as
the additional methyl group of thymidine would clash with the
W99 side chain. We therefore assumed that the binding site would
selectively bind uridine. To test this hypothesis, we assayed MsCI4
and MsCI4Y101F with different nucleobases, nucleosides and deoxy-
nucleosides using NMR. Both proteins indeed bind uracil, uridine
and deoxyuridine with binding constants in the low micromolar
range, comparable to the results obtained for thalidomide. In con-
trast, a lower limit for the binding constants for a panel of other
pyrimidine nucleobases, nucleosides and deoxynucleosides could
be established in the millimolar range (Fig. 2). In support of
these ﬁndings, we subsequently obtained the structure of the
MsCI4deoxyuridine complex by co-crystallization, again with
the same crystal form as for MsCI4thalidomide. As anticipated,
the uracil ring of the nucleoside is bound in the same way as the
glutarimide ring of the IMiD compounds (Fig. 1).
To verify these ﬁndings in vivo, we examined the effects of
thalidomide and pyrimidine nucleosides on zebraﬁsh development
based on a pectoral ﬁn deformity assay reported by Ito et al.Fig.2. Thalidomide and nucleosides in the NMR-based ligand binding assay. The
traces show 1D proton spectra on 50 lMMsCI4 at 600 MHz. A detail is shown of the
region containing methyl groups that are up-ﬁeld shifted by close contacts with
aromatic groups, and are thus presumably within the protein core. Spectra are
shown in the absence of ligand (black) or with various ligands at the indicated
concentrations, with changes in signal positions and intensities indicative of
binding. For thalidomide (orange) and uridine (blue), a signal appears upon binding
(black arrow) that is characteristic of their speciﬁc binding mode. This signal does
not appear for cytidine (green) and thymidine (purple). Similar spectra with varying
concentrations of ligands were used to estimate binding constants. (For interpre-
tation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)(2010). Therein we found that embryos treated with uridine exhi-
bit an identical incidence of malformations as embryos treated
with thalidomide, whereas treatment with cytidine or thymidine
did not show any effect. As for thalidomide, the effect of uridine
treatment could be rescued by the injection of zcrbnYW/AA mRNA,
encoding the binding-deﬁcient double mutant of zebraﬁsh cereb-
lon (Fig. 3).3.4. The aromatic cage
While the inferences on uridine were driven by structural sim-
ilarity on the ligand side, consideration of the nature of the binding
pocket suggests yet another class of natural ligands: Aromatic
cages of similar architecture are a characteristic, if not deﬁning fea-
ture of many binding sites for compounds with methylated ammo-
nium or guanidinium groups. Therein, ligand binding is dominated
by cation-p interactions between the cationic ligand and the many
p systems of the aromatic cage (Dougherty, 1996). Examples are
found in binding sites for betaine- and choline-derived ligands in
metabolism and neurotransmission, and in binding sites for the
readout of posttranslational modiﬁcations of lysine and arginine
residues. The latter are especially prominent in histone tails, where
different methylation states of speciﬁc lysine and arginine residues
have a direct effect on chromatin structure and gene expression,
and are passed on to daughter cells as epigenetic markers
(Gayatri and Bedford, 2014; Yun et al., 2011). In Fig. 4 we compare
the aromatic cage of cereblon to representative exemplars of cages
with speciﬁcity for deﬁned methylation states of lysine and argi-
nine residues, especially of PHD-, Tudor- and Tudor-like domains
(Li et al., 2006; Su et al., 2014). While the majority of these cages
are built from a mixture of phenylalanine, tyrosine and tryptophan
residues, in individual cases they are dominated by tryptophan
residues as in cereblon. Such an example is the cage mounted on
an ankyrin repeat structure in Fig. 4. Therein, the tryptophan resi-
dues form hydrogen bonds with their indole residues that stabilize
the cage structure, which could not be formed by phenylalanine or
tyrosine. Likewise, the strictly conserved tryptophan residues in
the cereblon cage appear to serve a similar stabilizing function.
The binding of suitable ligands to the cage remains to be shown;
our ﬁrst attempts, assaying the binding of betaine- and choline
derived ligands as well as individual lysine and arginine residues
in different methylation states by NMR, were inconclusive.4. Discussion
In this study we have established a simple and robust bacterial
model system for the characterization of the CULT domain, the tha-
lidomide binding domain of cereblon. Due to its easy handling, the
bacterial protein is highly amenable to exhaustive biochemical
characterization, enabling us to screen for ligands on a large
scale. Here we report the ﬁrst results of our characterization and
screening efforts, which are driven by the insights derived from
the presented high-resolution crystal structures.
With uridine, we unravel a natural cellular ligand that is univer-
sally present. As the previously identiﬁed downstream factors
Ikaros and Aiolos are restricted to animals, they can only account
for a subset of the total range of physiological substrates of cereb-
lon. In contrast, uridine bears physiological implications for all
organisms with cereblon proteins. We have shown that of all pos-
sible nucleosides, cereblon speciﬁcally binds uridine, that uridine
causes the same teratogenic phenotype as thalidomide, and that
it competes for the same binding site. Cereblon has been impli-
cated in different activities, as in the modulation of ion channels
(Liu et al., 2014), the regulation of AMP-activated protein kinase
(Lee et al., 2011), and in the general development of the nervous
Fig.3. Zebraﬁsh pectoral ﬁn deformity resulting from thalidomide and nucleoside treatment. The images illustrate the diagnostic criteria of the pectoral ﬁns of embryos at
75 h post fertilization. Uridine treatment causes similar developmental defects as evoked by thalidomide, whereas cytidine and thymidine treated embryos remain
unaffected. As for thalidomide, the effect of uridine treatment can be rescued by injecting zcrbnYW/AA mRNA, but not by injecting zcrbn wt mRNA.
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binding is unclear. However, taken together with the fact that
cereblon is a cofactor of DDB1, a central regulator of the cellular
response to DNA damage, our results suggest that cereblon recog-
nizes uracil in DNA. Uracil occurs in DNA because of misincorpora-
tion of dUMP or deamination of cytosine, and is usually excised
by uracil-DNA glycosylases (Visnes et al., 2009). Therefore, one
possible scenario for the role of cereblon is in DNA maintenance
and quality control. However, as the DDB1-CUL4 E3 ligase system
is only present in eukaryotes, bacterial cereblon can only express
this function in another context. Indeed, MsCI4 alone showed no
afﬁnity for uracil-containing DNA.
Looking from another perspective, following the comparison of
the aromatic cages, it is conceivable that the natural ligands of
cereblon are methylated lysine or arginine residues in histone tails
or transcription factors. It is established that the DDB1/CUL4 E3
ubiquitin ligase associates with several DCAFs that are core
components of histone methylation complexes (Higa et al., 2006).
Moreover, and more recently, the DCAF ‘‘DCAF1’’ was shown to rec-
ognize monomethylated lysines within a speciﬁc sequence motif,
targeting histone and non-histone proteins for methyl-dependentubiquitination by the DCAF1/DDB1/CUL4 ligase. (Lee et al., 2012).
With an analogous involvement in the recognition of such modiﬁ-
cations, cereblon in its E3 ubiquitin ligase complex could act in a
DNA context, in which the binding of uridine would rather
pose an ancillary effect. However, our binding studies in this direc-
tion were so far inconclusive. It should be noted that also
Chamberlain et al. (2014) (see below) were not able to demon-
strate the binding of small cationic ligands to a thalidomide
binding domain.
The validity and accuracy of the bacterial model system, which
is based on the high sequence similarity and essentially perfect
conservation of the aromatic cage, is further supported by two
recent studies: At the time of submission, Fischer et al. (2014),
and later, during review of this work, Chamberlain et al. (2014)
published crystal structures of cereblon proteins in complex with
IMiD drugs from chicken, human and mouse with the respective
resolutions of 3 Å, 3 Å and 1.9 Å. Fig. 5 shows representative
structures of the thalidomide binding domains from these three
organisms superimposed onto the MsCI4thalidomide complex,
all with RMSD values <1 Å and a virtually identical geometry of
the aromatic cage. Together with our in vivo experiments, verifying
Fig.4. The aromatic cage of the thalidomide binding pocket compared to the aromatic cages for the readout of speciﬁc methylation states of lysines and arginines with the
bound substrates symmetrical dimethylated arginine, asymmetrical dimethylated arginine, trimethylated lysine and dimethylated lysine. PDB codes are given in parenthesis.
For the cages of cereblon and the ankyrin repeat on the bottom right, hydrogen bonds of the tryptophan side chains are indicated.
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eukaryotic cereblon, this further highlights the major advantage
of MsCI4 in allowing for high-resolution binding studies in a
simple and minimal model system.
Using the structural insight gained by the presented crystal
structures, we were able to derive certain structural rules for
cereblon-binding ligands. This is exempliﬁed by the selectivity
for uridine over thymidine and cytosine, showing that the ligand
needs to form speciﬁc hydrogen bonds while conforming to sterical
requirements set by the aromatic cage. As glutarimide and
uracil alone also bind to this pocket, it is conceivable thatFig.5. A comparison of MsCI4thalidomide to IMiD-bound thalidomide binding
domains from human, chicken and mouse, which were published shortly before
submission (chicken) or during peer review (human, mouse) of this work. All
structures superimpose with an RMSD < 1 Å.pharmaceuticals with accessible glutarimide- or uracil-like moie-
ties could have teratogenic effects by binding to cereblon with
the same binding mode. Moreover, it must be considered that
pharmaceuticals might have metabolic products that fulﬁll the
requirements for cereblon binding. In fact, in the performed
in vivo assay, we cannot exclude that at least part of the effect is
due to metabolic products that retained the glutarimide or uracil
moiety. To gain more detailed insight into the speciﬁc structural
parameters for cereblon-mediated teratogenicity, a systematic
study of ligand speciﬁcity in needed. With a more precise knowl-
edge about the structural requirements, pharmaceuticals could
be rationally designed or modiﬁed to speciﬁcally bind - or not to
bind - to cereblon. With this study we provide a robust protein
construct amenable for high-throughput screening and a proof-
of-principle to assess and reﬁne these structural determinants.
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Abstract
Cereblon, a primary target of thalidomide and its derivatives, has been characterized struc-
turally from both bacteria and animals. Especially well studied is the thalidomide binding do-
main, CULT, which shows an invariable structure across different organisms and in
complex with different ligands. Here, based on a series of crystal structures of a bacterial
representative, we reveal the conformational flexibility and structural dynamics of this do-
main. In particular, we follow the unfolding of large fractions of the domain upon release of
thalidomide in the crystalline state. Our results imply that a third of the domain, including the
thalidomide binding pocket, only folds upon ligand binding. We further characterize the
structural effect of the C-terminal truncation resulting from the mental-retardation linked
R419X nonsense mutation in vitro and offer a mechanistic hypothesis for its irresponsive-
ness to thalidomide. At 1.2Å resolution, our data provide a view of thalidomide binding at
atomic resolution.
Introduction
In 1957, thalidomide was introduced as a potent sedative and anti-nausea drug, and was widely
used by pregnant women to alleviate morning sickness. At the end of 1961 it was banned from
the market as its catastrophic teratogenic side effects had led to horrific birth defects in more
than 10.000 newborns. However, over the decades after its withdrawal, thalidomide was redis-
covered as a promising anti-inflammatory, antiangiogenic and immunomodulatory agent with
high potential in the treatment of a diverse spectrum of diseases including leprosy, AIDS and
cancer. Especially its potential in cancer therapy sparked the search for derivatives with im-
proved properties, which led to the establishment of a new class of immunomodulatory drugs
(IMiDs). The two most relevant derivatives are lenalidomide and pomalidomide, which are
both approved for the treatment of multiple myeloma.
In 2010, the protein cereblon was identified as a target of thalidomide by Ito et al. [1]. Cere-
blon was originally found in a genetic screen for mutations linked to mild mental retardation
[2], and has been implicated in the modulation of ion channels [3], the regulation of AMP-acti-
vated protein kinase [4], and in general neural development [5]. Ito et al. showed that cereblon
associates with damaged DNA binding protein 1 (DDB1) to act as a substrate receptor for the
PLOSONE | DOI:10.1371/journal.pone.0128342 May 29, 2015 1 / 16
OPEN ACCESS
Citation: Hartmann MD, Boichenko I, Coles M,
Lupas AN, Hernandez Alvarez B (2015) Structural
Dynamics of the Cereblon Ligand Binding Domain.
PLoS ONE 10(5): e0128342. doi:10.1371/journal.
pone.0128342
Academic Editor: Andreas Hofmann, Griffith
University, AUSTRALIA
Received: March 1, 2015
Accepted: April 25, 2015
Published: May 29, 2015
Copyright: © 2015 Hartmann et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The structures were
deposited in the Protein Data Bank (PDB) under
accession codes 5AMH (trigonal), 5AMI
(orthorhombic, Wash I), 5AMJ (orthorhombic, Wash
II), 5AMK (hexagonal).
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
DDB1/cullin4 E3 ubiquitin ligase complex. The ubiquitin ligase activity of this complex is al-
tered by thalidomide binding to cereblon [1], and also lenalidomide and pomalidomide were
shown to bind to cereblon, competing for the same binding site [6]. In mammals, cereblon has
a LON domain and a C-terminal thalidomide binding domain. However, homologs of the lat-
ter, also termed the CULT domain, are further found in animals and bacteria as single-domain
proteins, that have all essential residues of the thalidomide binding site conserved [7].
The identification of cereblon as a target for thalidomide has sparked a number of structural
studies. Last year, crystal structures of full-length human [8] and chicken [9] cereblon in com-
plex with DDB1 were reported, as well as the structures of the thalidomide binding domain of
mouse [8] and that of a bacterial representative,Magnetospirillum gryphiswaldense cereblon
isoform 4 (MsCI4) [10]. These studies have shown an exceptional conservation of the domain
across phyla, with a root-mean-square deviation of less than 1 Å over 100 Cα positions be-
tween the bacterial and human proteins. Architecturally, the thalidomide binding domain is a
member of the β-tent fold [7], which consists of two antiparallel beta sheets that are oriented at
an approximately right angle and pinned together at the top via a structural zinc ion. The tha-
lidomide binding site is formed within the larger, C-terminal β-sheet. In most of the structures
it is occupied either by thalidomide, lenalidomide or pomalidomide. These three IMiDs have a
glutarimide moiety in common (see also inset in Fig 1). This moiety is bound within an aro-
matic cage that is mainly formed by three invariant tryptophan residues.
Now, although the thalidomide binding mode is known and invariant among animals and
bacteria, evidence for natural ligands of cereblon are rather sparse. With the transcription fac-
tors Ikaros and Aiolos, the first target proteins of the cereblon/DDB1/cullin4 E3 ligase have
been identified [11, 12]. The degradation of the two proteins is stimulated by thalidomide, lena-
lidomide or pomalidomide in myeloma cells. However, it remains unclear what exactly cere-
blon recognizes in absence of these agents. Given the invariant nature of the thalidomide
binding site between animals and bacteria, a natural ligand universal to all domains of life
seems plausible. Two kinds of such ligands have been proposed so far. One of them was strong-
ly suggested by the nature of the binding pocket. Aromatic cages of similar architecture are typ-
ical binding sites of cationic groups like in the quaternary ammonium compounds betaine or
choline [13] and are especially widespread in proteins reading posttranslationally modified ly-
sine and arginine residues [14, 15]. However, in vitro binding studies of such groups to cere-
blon were inconclusive [8, 10]. The other potential natural ligand is uridine. Based on the
binding mode of the thalidomide glutarimide ring we proposed and verified that cereblon
binds uridine in the same way as thalidomide and with comparable affinity; in a co-crystal
structure with MsCI4, deoxyuridine mimics the binding mode of thalidomide, and in vivo, in a
zebrafish model system, uridine caused the same teratogenic effects as thalidomide [10]. How-
ever, although it is evidently a universal feature of cereblon, we could not consolidate a biologi-
cal context for uridine recognition.
In this study, we take another step towards understanding cereblon substrate recognition by
analyzing the behavior of the thalidomide binding domain in the unliganded state, based on
MsCI4 as a model protein. Via X-ray crystallography, we show the domain in different confor-
mations, and follow the unfolding of a third of the domain upon release of thalidomide in the
crystalline state. Underpinned by biophysical data, our results imply that the domain as a
whole only becomes structured upon ligand binding. They additionally point to the possibility
that the binding site could also assume a different architecture, suitable for the binding of li-
gands of yet unknown nature. Further, we study the effects of premature chain termination, as
caused by the mental-retardation linked R419X nonsense mutation, and find that it does not
affect ligand binding. All results, mapped onto the structure of the multi-domain human cere-
blon, yield an intelligible picture of the structural dynamics of cereblon substrate recognition.
Structural Dynamics of Cereblon Substrate Recognition
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Materials and Methods
Cloning, Expression and Purification
Wild-type MsCI4 and mutant MsCI4YW/AA were prepared as described [10]. The mutant
MsCI4WW/FF with the substitutions W36F andW59F, and mutant MsCI4WWK/FFX with the ad-
ditional substitution K115X were cloned with mutagenic primers using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene) on the basis of wild-type MsCI4 in pETHis-1a. All pro-
teins were expressed and purified as wild-type MsCI4.
CD spectroscopy
Circular dichroism (CD) measurements were performed using a JASCO J810 spectropolari-
meter equipped with a temperature controller. Protein concentrations were 20 μM in 20 mM
Fig 1. Atomic resolution structure of MsCI4•thalidomide. (A) The overall structure of MsCI4•thalidomide
from the trigonal crystal form. (B) Superposition of the latter (in green) with the three MsCI4•thalidomide
monomers from the orthorhombic crystal form (4V2Y, in yellow) and the two MsCI4•thalidomide monomers
from the hexagonal crystal form (this work, in red). While the conformation of the protein and the glutarimide
moiety is virtually identical, the orientation of the phthaloyl moieties differ by up to 13° between the structures.
(C) Stereo close-up of the thalidomide molecule and the three tryptophan residues of the aromatic cage of the
atomic resolution structure, together with an omit electron density map at 1.2 Å resolution. The omit map was
calculated for thalidomide and the three indoles and is contoured at 6.5 sigma. Whereas individual atoms of
the indoles and of the glutarimide ring are sharply localized in the density, the phthaloyl moiety is poorly
resolved due to thermal disorder. (D) Only thalidomide with omit map. (E) Only the tryptophans with omit map.
doi:10.1371/journal.pone.0128342.g001
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Tris, pH 7.6, 50 mM KF. Spectra and melting curves were recorded using a 0.1 cm path length
cuvette, a bandwidth of 1 nm, and a response of 1 s. For far-UV CD spectra, a scanning speed
of 100 nm/min and a data pitch of 1 nm were used. Thermal denaturation was monitored at
222 nm with a temperature ramp of 1°C per minute and a data pitch of 0.5°C. JASCO software
was used for subtraction of buffer baselines, smoothing and determination of melting points.
Fluorescence spectroscopy
Fluorescence was measured using a 2 ml cuvette in a JASCO FP-6500 spectrofluorometer at
protein concentrations of 20 μM in 20 mM Tris, pH 7.5, 50 mM KF and optionally ligand con-
centrations of 200 μM. Samples were excited at 295 nm and emission spectra were recorded
using the following settings: data pitch 0.5, excitation bandwidth 1 nm, emission bandwidth
3 nm, response 0.5 s and scan speed 200 nm/min. For data analysis, the JASCO software was
used.
Thermal shift assay (Differential scanning fluorimetry)
Ligation dependent thermal stability changes were assayed via differential scanning fluorimetry
for wild-type MsCI4 and the binding deficient mutant MsCI4YW/AA. Samples containing
100μM protein and 400μM ligand in buffer (20 mM Tris, pH 7.5, 150 mMNaCl, 0.5 mM
2-Mercaptoethanol) supplemented with 50x SYPRO Orange dye (Sigma-Aldrich) were set up
in 96-well real-time PCR plates (Thermo Scientific). The sample temperature was continuously
ramped up from 25°C to 95°C at a rate of 1.25°C/min in a CFX96TM Real-Time System (Bio-
Rad) monitoring the fluorescence of the dye with a temperature resolution of 0.5°C. The exper-
iments were performed in three repeats for MsCI4 and MsCI4YW/AA, and five repeats for
MsCI4WWK/FFX. The experiments for thalidomide and thymidine—including the controls
without ligand—were performed in presence of 0.4% DMSO. The statistical significance of the
shifts caused by the ligands was assessed with a two sample equal variance t-test.
Crystallization, Data collection and Structure determination
Crystallization trials were performed at 294 K in 96-well sitting drop plates with 50 μl of reser-
voir solution and drops containing 400 nl of protein solution in addition to 400 nl of reservoir
solution. The protein solution contained 3 mM thalidomide and 3% (v/v) DMSO in addition
to 17 mg/ml of MsCI4 in a buffer containing 20 mM Tris, pH 7.5, 150 mMNaCl, 5 mM 2-Mer-
captoethanol. In addition to the described orthorhombic crystal form [10], the screen yielded
two further crystal forms, one trigonal and one hexagonal, with the crystallization conditions
detailed in Table 1. Crystals of the trigonal form were loop mounted directly from the plate
and flash-cooled in liquid nitrogen. For the hexagonal crystal form, crystals were transferred
Table 1. Crystallization conditions and cryo protection / washing procedure.
Crystal form Reservoir solution (RS) Cryo/washing
solution
Trigonal 100 mM sodium acetate pH 4.6, 2.2 M calcium chloride -
Orthorhombic
(Wash I)
100 mM sodium acetate pH 4.6, 20%(w/v) PEG 6000 RS + 10% (v/v)
PEG 300
Orthorhombic
(Wash II)
100 mM tri-Sodium citrate pH 5.6, 1.0 M Ammonium
phosphate
RS + 20% (v/v)
PEG 300
Hexagonal 64 mM Sodium citrate pH 7.0, 100 mM HEPES pH 7.0, 10%
(w/v) PEG 5000 MME
RS + 20% (v/v)
PEG 300
doi:10.1371/journal.pone.0128342.t001
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into a separate drop of cryo-solution prior to flash-cooling, and crystals of the orthorhombic
form were washed for 40 h in a cryo-solution as indicated in Table 1. All data were collected at
100 K and a wavelength of 1 Å on a PILATUS 6M detector at beamline PXII of the Swiss Light
Source (PSI, Villigen, Switzerland). Diffraction images were indexed, integrated and scaled
using XDS [16]. The structures of the washed orthorhombic crystals, which contain 3 mono-
mers of MsCI4 in the asymmetric unit (ASU), were solved on the basis of the MsCI4•thalido-
mide coordinates 4V2Y; the other two structures were solved by molecular replacement with
MOLREP [17], locating one monomer of MsCI4 in ASU of the trigonal crystal form and 4
monomers in the ASU of the hexagonal crystal form. The structures were finalized by cyclic
manual modeling with Coot [18] and refinement with REFMAC5 [19]. Data collection and re-
finement statistics are summarized in Table 2. All molecular depictions were prepared using
MolScript [20], BobScript [21], and Raster3D [22]. The structures were deposited in the Pro-
tein Data Bank (PDB) under accession codes 5AMH (trigonal), 5AMI (orthorhombic, Wash I),
5AMJ (orthorhombic, Wash II), 5AMK (hexagonal).
NMR Spectroscopy
NMR experiments were performed as described [10]. Significant, characteristic chemical shift
changes were associated with binding of ligands employing a thalidomide-like binding mode.
Typically, 1D proton spectra were acquired on 50 μM protein samples both alone and in the
presence of 10–500 μM ligand. Like thalidomide, uridine induced these characteristic chemical
shift changes at the lowest concentrations tested. Cytosine and thymidine did not, with concen-
trations of at least 500 μM. Here, this assays was repeated for the MsCI4WWK/FFX mutant with
thalidomide, uridine, thymidine and cytosine, yielding affinities in the same range as for wild-
type MsCI4.
Table 2. Data collection and refinement statistics.
Crystal form Trigonal Orthorhombic Hexagonal
(treatment) - Wash I Wash II -
Data collection
Space group P3221 P212121 P212121 P6122
Cell dimensions
a, b, c (Å) 51.7,51.7, 84.7 57.3, 59.6 86.7 56.7, 59.7, 88.1 137.9, 137.9, 154.4
Resolution (Å) 30.8–1.20 (1.27–1.20)* 37.3–1.75 (1.86–1.75)* 37.2–1.75 (1.86–1.75)* 39.0–2.90 (3.07–2.90)*
Rmerge 5.7 (74.4) 4.8 (68.2) 6.6 (47.6) 9.9 (53.2)
I/σI 11.85 (1.78) 16.98 (1.90) 9.79 (2.16) 10.53 (2.22)
Completeness (%) 99.7 (99.3) 99.7 (98.7) 97.7 (96.5) 99.1 (98.3)
Redundancy 3.91 (3.69) 4.23 (4.23) 2.86 (2.79) 2.97 (2.95)
Reﬁnement
Resolution (Å) 30.8–1.20 37.3–1.75 37.2–1.75 39.0–2.90
No. reﬂections 39531 29087 28637 18776
Rwork / Rfree 0.13 / 0.16 0.17 / 0.21 0.15 / 0.19 0.17 / 0.22
# chains / AU 1 3 3 4
PDB code 5AMH 5AMI 5AMJ 5AMK
*Highest resolution shell is shown in parenthesis.
doi:10.1371/journal.pone.0128342.t002
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Results and Discussion
A view of thalidomide binding at atomic resolution
We previously reported the structure of MsCI4 bound to thalidomide from an orthorhombic
crystal form [10]. We now obtained a new, trigonal crystal form of MsCI4•thalidomide that
yielded a dataset with a resolution of 1.2 Å. The crystals contain one monomer in the asymmet-
ric unit (ASU) in space group P3221 (Fig 1A), which has the same conformation as in all other
known co-crystal structures of MsCI4. This structure superimposes closely with the 3 other
monomers of MsCI4•thalidomide from the orthorhombic crystal form and the 2 further new
MsCI4•thalidomide monomers described below. However, between all structures, there is a
significant difference in the conformation of the thalidomide molecule (Fig 1B): while the glu-
tarimide moieties superimpose tightly, the phthaloyl moieties protruding from the binding
pocket differ in their orientation by up to 13°. This angular freedom is especially apparent in
the atomic resolution electron density. In an omit map calculated with missing thalidomide
and tryptophan side chains in Fig 1C–1E, the individual atoms of the tryptophan side chains
and of the glutarimide moiety are sharply resolved, while the density of the phthaloyl moiety
shows much less detail and the most distal part shows no density at the depicted sigma level.
This is a consequence of conformational disorder of the phthaloyl ring system, which is also
apparent from its anisotropically refined thermal ellipsoids (not shown), which are widened in
the plane of the ring system. An obvious rationale for this conformational freedom lies in the
lack of specific interactions of the phthaloyl moiety with the protein. A similar degree of free-
dom can be derived from a superposition of the individual monomers of MsCI4 in complex
with pomalidomide, lenalidomide or deoxyuridine. This underlines that there is no selective
recognition for any part of the ligand apart from the glutarimide (or uracil) moiety.
Unfolding upon ligand release in the crystalline state
To gain deeper insight into substrate binding, it was highly desirable to know the apo state of
the thalidomide binding domain. As we have so far not been able to crystallize MsCI4 in the
absence of ligands [10], we tried the following prolonged soaking experiment: We soaked crys-
tals of the original orthorhombic crystal form of MsCI4•thalidomide for many hours in the
cryo-protectant solution in order to “wash out” thalidomide from the binding sites. Diffraction
experiments were performed with crystals from two different crystallization conditions after
40 h of washing. In the two resulting structures, thalidomide was retained in two of the three
monomers in the ASU, but released in the third monomer. Strikingly, the loss of the ligand was
accompanied by the unfolding of a large portion of the protein around the binding site. In one
of the structures, “Wash II”, three regions totaling to 37% of the previously structured part of
the main chain were no longer traceable in the electron density. The largest is the most N-ter-
minal unfolded region, which starts between β2 and β3 and comprises the hairpin formed by
β3 and β4, leaving only a C-terminal remainder of β4. The second region starts in the middle of
β5, comprises the first tryptophan of the aromatic cage, and ends at the cage’s second trypto-
phan at the start of β6, rendering its indole side chain disordered. The third and smallest region
is the loop connecting β7 and β8. In the other structure, “Wash I”, the second and third region
were unfolded to the same extent, whereas the β-hairpin in the first region was still mostly
structured, albeit shifted in position. The unfolding process is detailed in Fig 2.
Of the three unfolded regions, the first one does not form specific interactions with thalido-
mide but stabilizes the geometry of the aromatic cage and thus of the second region. In particu-
lar, it fixes the first tryptophan (W79) of the cage in its conformation by forming a hydrogen
bond with the indole-side chain [10]. It further contains a highly conserved NPxG motif at the
Structural Dynamics of Cereblon Substrate Recognition
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tip of the β3-β4 hairpin [7]. The second region constitutes the largest part of the thalidomide
binding site, contributing two of the three tryptophans of the aromatic cage (W79 and W85)
and forming hydrogen bonds to the glutarimide moiety [10]. Moreover, it contains the tyrosine
Fig 2. Partial unfolding of MsCI4 upon loss of thalidomide. Crystals of the orthorhombic crystal from two crystallization conditions were washed for 40 h in
a solution without thalidomide. For the initial structure (grey) and both experiments, “Wash I” (brown) and “Wash II” (black), the monomer that had the ligand
washed out (chain C) is depicted in two perspectives. Loss of ligand was accompanied by the unfolding of three regions. The structures after washing are
overlaid with the initial structure in transparent. On the bottom, the sequence alignment of MsCI4 with human cereblon details the unfolded regions and
indicates secondary structure elements. The unfolded regions are shaded. In “Wash I”, the unfolding of the first region is incomplete, so the hairpin formed by
the 3rd and 4th β-strand is still folded, albeit shifted in position. The C-terminal segment deleted in the R419Xmutant of human cereblon and the
corresponding segment in MsCI4 are underlined. Key-residues are highlighted red.
doi:10.1371/journal.pone.0128342.g002
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residue (Y83) that was found to have an impact on cereblon function in the thalidomide-bind-
ing deficient mutant hCrbnY384A [1]. This conserved tyrosine forms hydrogen bonds with the
third region and is part of a common hydrophobic core of the second and third region. It is
therefore conceivable that the two regions fold and unfold in a concerted manner and that the
third region, which does not directly contribute to thalidomide binding, serves to stabilize the
binding site in the bound conformation. Hypothetically, an MsCI4Y83A substitution corre-
sponding to hCrbnY384A would disrupt the common hydrophobic core and therewith the mu-
tual stabilizing interactions.
We note that in this experiment the unfolding happened within a given crystal packing,
which per se restrains the conformational freedom. It would therefore be conceivable, that the
extent of unfolding was limited by these restraints. However, the regions found flexible here
are in perfect agreement with those identified in the following in further crystal forms of
MsCI4 and mouse cereblon.
A crystal structure with intertwined MsCI4 monomers in different
conformations
In addition to the orthorhombic and the high-resolution trigonal crystal form, we obtained a
hexagonal crystal form in a co-crystallization screen with thalidomide; we solved the structure
of this third crystal form by molecular replacement, locating four monomers in the ASU. Sur-
prisingly, only two of them are in the known thalidomide-bound conformation—the other two
form an intertwined dimer and have no thalidomide bound. The two monomers of this dimer,
depicted blue and pink in Fig 3, are in grossly different conformations: The blue monomer
adopts an overall conformation comparable to the thalidomide-bound state but has the β3-β4
hairpin shifted in position. Therefore, the stabilizing hydrogen bond between the hairpin and
the first tryptophan (W79) of the cage is broken, and the latter is found flipped out of the aro-
matic cage. In contrast, the conformation of the pink monomer is very different. The binding
pocket is not formed and essentially all regions previously identified to be flexible are dramati-
cally different from the thalidomide-bound conformation: In the first flexible region, the loop
connecting β2 and β3 is disordered to a similar extent as in the “Wash I” structure, while the
β3-β4 hairpin is shifted in position and even has another strand register. The whole second
flexible region is found in an entirely different conformation—the amplitude of its largest dis-
placement, at W79, is 30Å. Consequently, as also Y83 is not in place to anchor the second to
the third region, the third flexible region is actually found in two alternative conformations,
both different from the thalidomide-bound state.
Intriguingly, the W79 side chain of the pink monomer reaches over to the binding site of
the blue monomer to complete the aromatic cage (Fig 3B). At the later stages of refinement,
electron density of unknown origin became apparent within this cage, which was convincingly
modeled as a DMSO molecule from the thalidomide stock solution. Sterically, the flipping-out
of the W79 side chain from the aromatic cage of the blue monomer was a prerequisite to pro-
vide enough volume for the accommodation of DMSO. Although this particular dimeric con-
formation and the DMSO ligand are seemingly highly artificial, this brings to our attention
that the natural ligand might be structurally quite different from thalidomide, for which the
binding pocket might also adopt a conformation that is unexpectedly different from the thalid-
omide-bound one.
When we superimpose all available conformations of MsCI4, the thalidomide-bound one,
the ones after the washing experiment, and the ones of the two monomers in the intertwined
dimer, we obtain the ensemble depicted in Fig 4. Therein we find a minimal invariant consen-
sus structure that exactly coincides with the structured part of the “Wash II” structure: While
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the three flexible regions derived from the washing experiment are found in a multitude of con-
formations, the remainder of the protein is essentially invariant in all structures.
Folding upon ligand binding in solution
After consolidating structural evidence for immanent flexibility of the thalidomide binding do-
main, we set out to study the effects of ligand binding in solution. Previously, we had estab-
lished an NMR-based ligand binding assay that relies on specific chemical shift changes [10].
Comparison of spectra of wild-type MsCI4 alone and in presence of thalidomide revealed sig-
nificant changes for many resonances, including several prominent, upfield-shifted methyl
groups. One such methyl group shifts from -0.31 to -0.89 ppm on binding of thalidomide.
Chemical shift changes of this extent can be explained by close contact with aromatic moieties.
However, examination of the MsCI4 binding site revealed no candidate methyl groups in con-
tact with the aromatic rings of thalidomide itself. This indicates that ligand binding is associat-
ed considerable conformational rearrangements in residues not directly in contact with the
ligand. This prompted us to further investigate the effects of ligand binding by further spectro-
scopic approaches.
Fig 3. MsCI4 in different conformations in the hexagonal crystal form. Top: The 4 monomers in the ASU are found in three different conformations. The
yellow and green monomer are in the known thalidomide-bound conformation. The blue monomer is in a conformation similar to the thalidomide-bound one,
but its binding site is occupied by a DMSOmolecule, which is accompanied with a displacement of one tryptophan of the aromatic cage (red). The pink
monomer is in an overall distorted conformation and does not have the aromatic cage formed: the β3-β4 hairpin has another strand register, one of the
tryptophans is flipped, and another tryptophan is displaced by 30Å (all in red). A second conformation of the 3rd flexible region is displayed in another shade
of red. Bottom: The blue and the pink monomers form an intertwined dimer, in which the displaced tryptophan of the pink monomer completes the aromatic
cage of the blue one, trapping a DMSOmolecule in a binding site with a modified architecture. Here, the second conformation of the 3rd flexible region of the
pink monomer is in orange.
doi:10.1371/journal.pone.0128342.g003
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Firstly, we analyzed the thermal melting behavior of the protein in absence and presence of
ligands. As judged by CD spectroscopy, apo MsCI4 is at least partially folded: the far-UV spec-
trum is indicative of secondary structure (Fig 5A), and a melting curve shows a thermal transi-
tion at about 70°C (Fig 5B). The effect of ligand binding was examined in a thermal shift assay
with the known binders thalidomide and uridine, as well as the non-binders thymidine and cy-
tidine. If the folding of the flexible regions was dependent on—and stabilized by—ligand bind-
ing, this effect should be manifest in increased thermal stability. Indeed, while thymidine and
cytidine had no influence on MsCI4, thalidomide and uridine had a stabilizing effect, increas-
ing the melting point by about 1°C. As a control, binding deficient MsCI4YW/AA remained vir-
tually unaffected by all ligands (Fig 5C).
Secondly, we monitored ligand binding via tryptophan fluorescence. For increased sensitivity
we devised the mutant MsCI4WW/FF, in which we exchanged the tryptophan residues outside the
binding site, W36 andW59, to phenylalanine. The only remaining tryptophan residues are the
three of the aromatic cage, of which two became disordered in the washing experiment. An in-
spection of MsCI4WW/FF via CD spectroscopy yielded a far UV spectrum and melting behavior
comparable to the wild-type protein (Fig 5A and 5B). Finally, fluorescence emission spectra were
recorded in presence of uridine, thymidine and cytidine as well as in absence of ligands. The
emission maximum of apo MsCI4WW/FF was found at 355 nm, which is indicative for mostly sol-
vent exposed indole side chains, and was not shifted in presence of thymidine and cytidine. In
presence of uridine, the maximum was however shifted to shorter wavelength, which can be ex-
plained by a shielding from the solvent and hence folding of the binding site (Fig 5D).
The mental retardation-linked nonsense mutation does not affect
thalidomide binding
As MsCI4 has proven a robust and reliable model system for which we have a set of useful spec-
troscopic techniques at hand, we employed it in a yet different scope: We reproduced the
Fig 4. An ensemble of the available MsCI4 conformations. (A) Superposition of the thalidomide-bound
conformation (yellow), the blue and pink monomers from Fig 3, the “Wash I” structure (thin dark grey), and the
“Wash II” structure (thick dark grey). One alternate conformation of the pink monomer in the 3rd flexible region
is depicted in purple. (B) same as (A), but from the other perspective and in stereo. (C) The consensus (Wash
II) structure together with the individual ensembles of the 1st, 2nd and 3rd flexible regions.
doi:10.1371/journal.pone.0128342.g004
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mental retardation-linked hCRBNR419X nonsense mutation in MsCI4 with the corresponding
K115X substitution for in vitro characterization. With tryptophan fluorescence studies in
Fig 5. Biophysical characterization of MsCI4 andmutants. (A) Far-UV CD spectra of wild-type (WT) MsCI4 and mutants MsCI4WW/FF and MsCI4WWK/FFX,
and (B) corresponding melting curves, monitored at 222 nm. (C) Thermal stability of MsCI4 and binding deficient MsCI4YW/AA in presence of thalidomide,
uridine, thymidine and cytidine, as determined in the thermal shift assay. Only thalidomide and uridine lead to a shift in melting temperature with (two-tail) p-
values of 1.5e-3 and 4.9e-2 as determined in a two sample equal variance t-test. (D) Tryptophan fluorescence spectra of MsCI4WW/FF in presence of uridine,
thymidine and cytidine. The emission maximum is shifted to shorter wavelength only in presence of the binder uridine, which can be indicative for the folding
of the binding site. Note also the pronounced quenching effect indicative for binding. (E) same as (C) for the MsCI4WWK/FFX mutant. As for the WT,
thalidomide and uridine lead to a thermal shift, with p-values of 4.0e-4 and 1.2e-3. (F) same as (D) for the MsCI4WWK/FFX mutant. The presence of uridine has
the same effect as on the WT.
doi:10.1371/journal.pone.0128342.g005
Structural Dynamics of Cereblon Substrate Recognition
PLOS ONE | DOI:10.1371/journal.pone.0128342 May 29, 2015 11 / 16
mind, we directly introduced the substitution in the MsCI4WW/FF background, yielding the
mutant MsCI4WWK/FFX.
The R419X mutation in hCRBN renders the protein irresponsive to thalidomide—The over-
all ubiquitination behavior of the E3 ligase however seems unaffected [23]. With R419 being lo-
cated directly at the end of the penultimate β-strand, the premature stop effectively leads to the
deletion of the last strand of the N-terminal β-sheet. It was therefore unclear whether the do-
main was still properly folded, which is the first question we wanted to answer with
MsCI4WWK/FFX. After the mutant’s behavior during expression and purification was similar to
the wild-type, we examined it via CD spectroscopy. The resulting far-UV spectrum was compa-
rable to MsCI4 and MsCI4WW/FF and—strikingly—the melting point was almost identical
(Fig 5A and 5B). Consequently, the premature stop had seemingly no impact on the stability of
the domain, so we examined its ligand binding abilities.
In analogy to MsCI4 and MsCI4WW/FF, we studied MsCI4WWK/FFX in a thermal shift assay
and via tryptophan fluorescence spectroscopy in the presence of thalidomide, uridine, thymi-
dine and cytosine. Essentially, all results were as for full-length MsCI4: Thalidomide and uri-
dine yielded an increase in thermal stability of about 1°C, and uridine caused a shift of the
tryptophan fluorescence emission maximum to shorter wavelength, while thymidine and cyto-
sine had no effect (Fig 5E and 5F). Therefore, ligand binding is unaffected by the premature
stop, which we ultimately verified in our NMR ligand binding assay: The affinities for both tha-
lidomide and uridine lie in the low micromolar range as determined for the wild-type protein.
Consequently, the phenotype of thalidomide irresponsive hCRBNR419X is apparently not due
to a defect in ligand binding.
Structural comparison to mouse cereblon
Further support for our findings on the structural dynamics is provided by the available crystal
structures of the thalidomide binding domain of mouse cereblon [8]. Here, crystal structures
originating from two different crystal forms show the thalidomide binding domain in several
different conformations, as depicted in Fig 6.
The first crystal form contains four thalidomide-bound monomers in the ASU which form
two pairs of interlaced molecules. In these pairs, the interface is formed by the thalidomide
binding sites and thalidomide molecules, such that the latter form contacts with the aromatic-
cages of both monomers. As a consequence, the β3-β4 hairpin cannot fold and remains mostly
disordered. In this region, the otherwise identical four monomers of the ASU differ from each
other: the region is disordered to different extents and the traceable parts are found in different
conformations. The whole range of this flexible region matches the first one of MsCI4. Despite
the missing stabilizing interaction between the β3-β4 hairpin and the first tryptophan of the
cage, the binding site is in the usual thalidomide-bound conformation. This is facilitated by
contacts to the thalidomide molecule of the other chain in the interlaced pairs. The neighboring
thalidomide molecule forms a hydrogen bond with the tryptophan, which substitutes for the
missing bond with the hairpin, and stabilizes the indole side chain in the bound conformation.
The second crystal form contains two monomers without ligands in the ASU. They adopt a
conformation similar to the thalidomide-bound one. However, these two monomers also do
not form the β3-β4 hairpin: the whole segment corresponding to the first flexible region is
found in varying conformations. Via hydrophobic side chains from that region, the molecules
stabilize the binding sites of neighboring monomers: While monomer A has the side chain of
M349 stuck into the opening of the aromatic cage of monomer B, monomer B has the side
chain of P348 stuck into the opening of the aromatic cage of another monomer A. In this fash-
ion they form an endless array of intertwined molecules throughout the crystal. However, as
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the stabilizing hydrogen bond between the first tryptophan of the cage and the β3-β4 hairpin is
lost and not substituted, the geometry of the aromatic cage is impaired. In analogy to the inter-
twined dimer of MsCI4 in the hexagonal crystal form, the corresponding tryptophan deviates
from the thalidomide-bound conformation.
Although the conformations found in both mouse crystal forms are highly artificial, they
emphasize that the flexible nature of the binding site as identified and characterized in MsCI4
is indeed not a special feature of the bacterial representative but of general significance, also for
animal cereblon. As in the intertwined MsCI4 dimer, the conformation of the unliganded
mouse structure is only brought about by the crystal packing.
The thalidomide binding domain embedded in the E3 ligase complex
To understand their functional relevance, we mapped the flexible regions onto the structure of
human full-length cereblon (Fig 7). This structure [8] is bound to lenalidomide and is in a vir-
tually identical conformation to the structures of chicken cereblon in complex with thalido-
mide, lenalidomide or pomalidomide [9]. Therein, the thalidomide binding domain is packed
tightly to the N-terminal LON domain. A large portion of the interface between the domains is
formed by the first flexible region. Further, the LON domain has a short N-terminal extension,
which folds along the thalidomide binding site. As this extension, which was initially predicted
to be unstructured, is exclusively in contact with the flexible regions, it seems plausible that its
folding is concerted with the folding of the binding site; upon substrate binding, it would fold
Fig 6. The thalidomide binding domain of mouse cereblon exhibits flexibility comparable to MsCI4. The mouse domain in complex with (blue, sand)
and without thalidomide (yellow, shades of brown) is compared to MsCI4•thalidomide (transparent white). (A) Two thalidomide-bound domains from 4TZC
arranged as an intertwined dimer. (B) Superposition of one monomer to MsCI4•thalidomide, illustrating the unfolded nature of the first flexible region. (C)
Same as (B) but from another perspective, in stereo. (D) Apo mouse domains in 3WX2 are found in two conformations, “yellow” and “brown”, forming an
endless array of interactions in the crystal lattice. (E) Superposition of both apo conformations onto MsCI4•thalidomide, showing the first flexible region in
different conformations. (F) Same as (E) but from another perspective, in stereo. Note that the conformation of the tryptophans on the left is reminiscent of the
flipped tryptophan in the intertwined MsCI4 dimer.
doi:10.1371/journal.pone.0128342.g006
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together with the binding site to stabilize the bound conformation, and possibly anchor the do-
mains in their relative orientations. As determined by the PISA web server (http://www.ebi.ac.
uk/pdbe/pisa/), the interface area between the domains in the fully folded, ligand-bound crystal
structure amounts to 1596 Å2.
Reversely, in the apo state—in which the binding site would not be formed and the exten-
sion would be potentially unfolded—the interface between the domains would be significantly
smaller, possibly allowing for conformational flexibility in the relative orientation of the do-
mains: When the flexible regions are fully excluded from the calculation, the interface area be-
tween the domains is reduced by a factor of 2.6, to 609 Å2. A central part of this reduced
interface is the region that is deleted in the retardation-linked hCRBNR419X nonsense mutant
(Fig 7), which mediates mostly hydrophobic contacts between the domains. When this region
is omitted as well, the interface area is further reduced from 609 Å2 to 363 Å2. Hence, it is likely
that the interface, and thereby the alignment of domains, is disrupted in the mutant. As we
have shown that the R419X mutation does not affect ligand binding, it seems plausible that its
irresponsiveness to thalidomide is due to the impaired inter-domain interface: With the thalid-
omide binding domain unable to dock correctly in the bound conformation, cereblon is not a
functional receptor of the E3 ligase complex.
Conclusions
This work has given insight into thalidomide binding at atomic resolution and revealed an un-
expected degree of immanent structural flexibility of the thalidomide binding domain. We
identify three interconnected flexible regions that fold only upon substrate binding, accounting
for a third of the whole domain. A previously identified important tyrosine residue is found
within the hydrophobic interface in the folded state of these regions, which explains the
Fig 7. The flexible regions andmental retardation mutation in the context of human full length
cereblon. At the top, interaction partner DDB1 is represented by a sphere. The thalidomide binding domain is
in green (rigid core), yellow (flexible regions) and red (deleted C-terminal part in the MsCI4WWK/FFX mutant).
The exact boundaries of the segments are defined in Fig 2. The N-terminal extension of cereblon is in brown,
the remainder of the protein grey.
doi:10.1371/journal.pone.0128342.g007
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binding deficiency of the hCrbnY384A mutant. As deduced from the available crystal structures,
the binding site can fold into a geometry deviating from the thalidomide bound one. This
could imply yet further, different classes of natural ligands, possibly tertiary ammonium groups
which are geometrically reminiscent of the DMSO molecule bound in one of the structures and
which could be bound via cation-π interactions within the aromatic cage. Moreover, our results
imply that within the E3 ligase complex, substrate binding to the thalidomide binding domain
is only properly recognized when the domain is correctly docked to the remainder of the cere-
blon protein—which is potentially corrupted in the mental retardation linked hCrbnR419X mu-
tant. In summary, our results advance the structural basis of substrate recognition beyond a
static picture and provide a mechanistic framework for the understanding of the functional
role of cereblon.
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ABSTRACT: Cereblon serves as an ubiquitin ligase substrate
receptor that can be tuned toward diﬀerent target proteins by
various cereblon-binding agents. This oﬀers one of the most
promising avenues for targeted protein degradation in cancer
therapy, but cereblon binding can also mediate teratogenic
eﬀects. We present an eﬀective assay that is suited for high-
throughput screening of compound libraries for oﬀ-target
cereblon interactions but also can guide lead optimization and
rational design of novel cereblon eﬀector molecules.
■ INTRODUCTION
The protein cereblon is a substrate receptor of the CRL4A E3
ubiquitin ligase complex and the primary target of thalidomide,1
a drug that gained notoriety as a teratogen, inducing severe
malformations in newborns and thus causing the greatest
pharmaceutical catastrophe of the last century. Nevertheless,
thalidomide and its derivatives pomalidomide and lenalidomide
belong to a group of therapeutically important immunomodu-
latory drugs (IMiDs), used in the treatment of multiple
myeloma and other B cell malignancies because of their
antiangiogenic and antineoplastic properties. As established
recently, they mediate both their therapeutic and teratogenic
eﬀects via their interaction with cereblon. The ﬁrst identiﬁed
substrates of the cereblon−CRL4A E3 ligase complex were the
B cell speciﬁc transcription factors IKZF1 and IKZF3. Both
proteins are ubiquitinated in the presence of IMiDs, thus
aﬀecting downstream targets like interleukin-2 (IL-2) or
interferon regulatory factor 4 (IRF4).2−4 The homeobox
transcription factor MEIS2 was later identiﬁed as a ﬁrst
endogenous target for which IMiD binding had the opposite
eﬀect and prevented its degradation.5 More recently, casein
kinase 1A1 (CK1α) has been identiﬁed as another target of
cereblon,6,7 which was surprisingly only recognized and
ubiquitinated in the presence of lenalidomide, while thalido-
mide and pomalidomide had no eﬀect.6 This implies that the
aﬃnity of cereblon can be modulated and directed toward
diﬀerent protein substrates by the binding of diﬀerent eﬀector
molecules.8,9 Consequently, pharmaceutical interest in cereblon
is dipartite. For the majority of pharmaceuticals, to avoid
teratogenic side eﬀects, cereblon poses an oﬀ-target to be
circumvented in early drug development. Conversely, the
speciﬁc development of eﬀector molecules mediating targeted
ubiquitination of disease related proteins via cereblon is an
important emerging ﬁeld in pharmacology.
Cereblon is composed of an N-terminal LON-like domain,
which attaches to the E3 ubiquitin ligase complex, and a C-
terminal domain, which binds thalidomide. Homologues of the
thalidomide-binding domain, also referred to as CULT, are
found as single-domain proteins in bacteria and, preceded by an
N-terminal secretion signal, in lower animals up to ﬁsh.10
Recent studies of the domain from human, chicken, mouse, and
Magnetospirillum revealed an unusually high degree of
conservation between the species.5,11,12 The glutarimide ring
of the IMiDs slots into an aromatic pocket of this domain, built
from three invariant tryptophan residues, and forms hydrogen
bonds with the protein backbone of the pocket. Uracil, the
nucleobase moiety of uridine and the only natural ligand
identiﬁed to date, employs the same binding mode. It however
remains unclear, what cereblon recognizes in the cell in absence
of IMiDs. With the exception of MEIS2, the known substrates
IKZF1, IKZF3, and CK1α are ubiquitinated in an IMiD-
dependent manner, suggesting that the IMiDs might emulate a
posttranslational modiﬁcation targeting these proteins for
degradation. Because of the aromatic nature of the
thalidomide-binding pocket, a modiﬁed cationic protein residue
seems a possible candidate.12 However, no such ligand or
protein modiﬁcation has been identiﬁed yet.
In this work, we present a robust assay for the identiﬁcation
and characterization of cereblon eﬀector molecules, natural or
pharmaceutical. Taking advantage of the invariant tryptophan
residues of the binding pocket, we designed a custom reporter
ligand with a ﬂuorophore that has an overlapping absorption
band with the emission band of tryptophan. Monitoring FRET
signaling, we follow the replacement of the reporter ligand by
potential test compounds and thereby determine IC50 values
and speciﬁc aﬃnity constants. We demonstrate the potential of
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the assay in a comparative characterization of thalidomide-
binding domains from human, Magnetospirillum gryphiswal-
dense, and Caenorhabditis elegans.
■ RESULTS AND DISCUSSION
We have previously established Magnetospirillum gryphiswal-
dense cereblon isoform 4 (MsCI4) as a robust and tractable
model protein for the thalidomide-binding domain.12 For
tryptophan ﬂuorescence experiments, we devised the construct
MsCI4WW/FF, which has two surface tryptophan residues
outside the binding pocket replaced by phenylalanine to
minimize intrinsic ﬂuorescence. In initial measurements,
exciting at 295 nm and monitoring at 350 nm, we observed a
decrease in tryptophan ﬂuorescence with increasing ligand
concentrations,13 which could be used as a trivial binding assay.
However, these measurements were hampered by diﬀerences in
the quenching properties of the ligands, unspeciﬁc binding, and
unspeciﬁc quenching. To minimize such eﬀects and to increase
overall sensitivity, we designed the reporter ligand 1-(N-2-
MANT-imidoethyl)-uracil (MANT-uracil) that binds speciﬁ-
cally to the thalidomide-binding pocket (Figure 1). The N-
methylanthraniloyl (MANT) group constitutes an optimal
acceptor ﬂuorophore for a FRET-based competition assay: its
excitation maximum at 330−350 nm overlaps with the emission
maximum of tryptophan ﬂuorescence and has its own emission
maximum at 430−450 nm. Uracil serves as the binding moiety;
a model in Figure 1 shows how binding of MANT-uracil
positions the MANT ﬂuorophore in close proximity to the
tryptophan residues for eﬃcient FRET. The expected FRET
was veriﬁed measuring single ﬂuorescence emission spectra of
MsCI4WW/FF alone and in the presence of MANT-uracil
(Figure 2A). Whereas MANT-uracil alone is only slightly
excited at 295 nm, a strong emission signal at 440 nm arises in
the presence of equal amounts of protein; this signal increases
upon titration of the ligand to the protein in a concentration-
dependent manner (Figure 2B). On the basis of this
observation, we determined the aﬃnity of MsCI4WW/FF to
MANT-uracil, monitoring the signal at 440 nm, and scaled the
experimental setup to a 96-well format. To ensure a ﬁxed
concentration of the cosolvent, a master dilution series of the
MANT-uracil stock was prepared in DMSO.
Titration of MANT-uracil to the protein yielded a curve
indicative of binding. MANT-uracil as a control shows a linear
increase of the emission signal resulting from the autoﬂuor-
escence of the ﬂuorophore (Figure 2C). A blank-corrected
titration series resulted in the binding curve in Figure 2D.
Given the known stoichiometry of 1:1 and applying a
hyperbolic ﬁt according to the one binding site model, we
obtained an aﬃnity constant of KD = 3.3 ± 0.3 μM for MANT-
uracil.
Figure 1. The ligand-binding mode of cereblon and its exploitation for FRET. (A) Structure of MsCI4 with thalidomide bound to the pocket formed
by three invariant tryptophan residues. (B) The ﬁrst two panels show details of thalidomide and deoxyuridine bound to MsCI4. In the right panel,
the ﬂuorogenic compound 1-(N-2-MANT-imidoethyl)-uracil (MANT-uracil) is modeled into the pocket. The average distance between the
tryptophan residues (gray background) and the MANT-ﬂuorophore (blue background) is approximately 0.7 nm in this model. (C) Principle of the
FRET assay. Upon excitation at 295 nm, the tryptophan residues emit at 350 nm. When MANT-uracil is bound, MANT is excited by this
ﬂuorescence due to its close proximity, resulting in a FRET signal at 440 nm.
Figure 2. Speciﬁc binding of MANT-uracil to MsCI4. (A)
Fluorescence spectra of 10 μM MsCI4, MsCI4WW/FF, and MsCI4WW/FF
in the presence of 10 μM MANT-uracil and MANT-uracil diluted in
buﬀer as a control. The emission maxima of MsCI4WW/FF and wild-
type MsCI4 diﬀer in intensity due to the lacking surface tryptophan
residues. (B) Fluorescence spectra of MsCI4WW/FF (10 μM) in absence
(black) and upon titration of 0.2−44 μM MANT-uracil. (C) FRET
signal for MANT-uracil titrated to 3 μM MsCI4WW/FF (○), MANT-
uracil in assay buﬀer (●), and 3 μM MsCI4WW/FF in assay buﬀer plus
DMSO (corresponding to MANT-uracil diluted from DMSO stock)
(▼). Data points represent the mean of three measurements including
standard deviation. (D) Data analysis of steady-state FRET binding
assay. Fractions of MsCI4WW/FF::MANT-uracil and of free ligand were
calculated from FRET data and ﬁtted according to the one-binding site
model, yielding KD = 3.3 ± 0.3 μM. All experiments were excited at
295 nm.
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In a next step, we performed a ﬁrst competitive binding assay
with thalidomide as a test compound. Again, a master dilution
series of the ligand was prepared in DMSO. As anticipated,
titration of thalidomide to the MsCI4WW/FF::MANT-uracil
complex in assay buﬀer decreased the FRET signal in a
concentration-dependent manner. Plotting of the data using a
log (dose) response curve yielded an IC50 value of 7.8 ± 0.3
μM for thalidomide (Figure 3A). Applying the Cheng−Prusoﬀ
equation14 yielded an absolute inhibition constant of Ki(Thal) =
4.4 μM.
As the stock solution and master dilution series of MANT-
uracil and thalidomide are prepared in 100% DMSO, we
examined for a possible inner ﬁlter eﬀect.15 We found that
DMSO concentrations of up to 5% do not have any eﬀect on
the ﬂuorescence measurements. Further testing for deleterious
eﬀects of the solvent on the measurements, we performed a
competition assay using merely DMSO as the test compound,
within a range of 0−20%. The according log (dose) response
curve implies that DMSO competes with MANT-uracil in the
low-aﬃnity range, yielding an IC50(DMSO) = 0.1% and an
according inhibition constant of Ki(DMSO) = 0.06%, which
corresponds to 10 and 5.7 mM DMSO, respectively. The
binding curve in Figure 3B shows that DMSO concentrations
higher than about 0.03% start to aﬀect the measurement
signiﬁcantly. This result is not surprising, as it supports
observations in a crystal structure of MsCI4 containing a
DMSO molecule bound in the pocket.13 In the experiments
measuring binding of MANT-uracil and thalidomide, the ﬁnal
DMSO concentrations were below the threshold of 0.03%
(0.01% and 0.02%, respectively). However, the low-aﬃnity
binding of DMSO generally limits its use as a solvent for water-
insoluble compounds if the experimental setup requires
concentrations higher than 0.03%. We therefore tested several
alternate aprotic polar solvents for their suitability in the assay
(Figure 3B). Many of them show low-aﬃnity binding or
otherwise impair the protein in a range similar to DMSO.
However, acetonitrile, methanol, and ethanol represent
reasonable alternatives to DMSO; they appear applicable up
to a concentration of about 1%.
The stability of MsCI4WW/FF and MANT-uracil in the assay
was evaluated by monitoring ﬂuorescence at 440 nm over a
period of 48 h, which did not show any signiﬁcant loss in signal
intensity. As a statistical indicator of assay quality, we further
estimated the Z′-factor and obtained value of Z′ = 0.6,
indicating very good quality (Figure 3C).16 Finally, we
performed a comparative analysis of thalidomide-binding
domains. We chose representatives from all three subgroups
of cereblon proteins:10 human hCRBNΔ1-315 from an E3
ligase substrate receptor, the secreted C. elegans variant
CeCRBNsecΔ1-15, and the bacterial MsCI4WW/FF. As MsCI4
diﬀers from the two eukaryotic proteins by an F → Y
substitution in the binding pocket, we also assayed the
canonical variant MsCI4WW/FF, Y101F.12 All proteins were assayed
with the same set of ligands: MANT-uracil itself as a uracil
derivative, thalidomide and its binding moiety glutarimide, and
additionally succinimide as a potential new ligand. We
suspected succinimide to bind because of its structural
similarity to glutarimide as the two compounds merely diﬀer
in ring size, 5 for succinimide and 6 for glutarimide. All
compounds were bound by all proteins, with glutarimide
generally showing the lowest aﬃnity (Table 1). MsCI4WW/FF
has the highest binding aﬃnities for the diﬀerent ligands, with
Ki values in the very low micromolar range. The aﬃnities of
CeCRBNsecΔ1-15 and hCRBNΔ1-315 to the diﬀerent
compounds were signiﬁcantly lower, which we accredit to the
F → Y substitution in MsCI4: in comparison to hCRBN and
Figure 3. Competitive binding assay and solvent eﬀects. (A) Titration of thalidomide (0−80 μM) yields an IC50 of 7.8 ± 0.3 μM, corresponding to
Ki(Thal) = 4.4 μM. (B) Inﬂuence of diﬀerent polar aprotic solvents (0−20% (v/v)) on the assay. (C) Evaluation of assay quality for calculation of Z′-
factor. Scatter plot of FRET values obtained from a 96-well plate containing 40 samples of each, positive control (MsCI4WW/FF::MANT-uracil) and
negative control (MsCI4WW/FF::MANT-uracil, 30 μM thalidomide). Succinimide (30 μM) competing for MANT-uracil binding reduces FRET,
whereas cytosine (30 μM) does not. Means of positive and negative controls are shown by solid lines; dashed lines indicate 3-fold standard
deviations. All experiments contained 2.5 μM MsCI4WW/FF::MANT-uracil and were excited at 295 nm. A and B show means of three measurements.
DMF, N,N-dimethylformamide; DMSO, dimethyl sulfoxide; DMPU, N,N′-dimethylpropylene urea; NMP, 1-methyl-2-pyrrolidinone.
Table 1. Binding Constants of Cereblon Ligand-Binding Domains from Human, C. elegans, and Magnetospirilluma
MANT-uracil ±-thalidomide succinimide glutarimide DMSO
protein KD [μM] IC50 [μM] Ki [μM] IC50 [μM] Ki [μM] IC50 [μM] Ki [μM] IC50 [μM] Ki [μM]
MsCI4WW/FF 3.3 ± 0.3 7.8 ± 0.3 4.4 7.6 ± 1.0 4.3 48.9 ± 8.9 27.8 10000 (0.1%) 5690 (0.06%)
hCRBNΔ1-315 7.9 ± 0.7 29.9 ± 7.8 22.7 34.5 ± 4.8 26.2 135.8 ± 19 103.1 181000 (1.3%) 137490 (1%)
CeCRBNsecΔ1-15 16.0 ± 0.4 18.6 ± 1.9 16.1 6.7 ± 1.0 5.8 50.6 ± 6.2 43.8 361000 (2.6%) 312200 (2.2%)
MsCI4WW/FF, Y101F 22.9 ± 1.1 10.7 ± 0.8 9.6 53.0 ± 6.6 47.8 275.3 ± 24 248.2 737000 (5.3%) 664460 (4.8%)
aData are means of three replicates with standard errors. KD values for MANT-uracil were calculated from FRET data according to the one binding
site model. IC50 curves were obtained from titrations of 0−80 μM thalidomide, 0−5 mM succinimide, 0−20 mM glutarimide, and 0−20% DMSO. Ki
values were calculated from IC50 values using Cheng−Prusoﬀ equation.
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CeCRBN, MsCI4 forms an additional hydrogen bond with the
ligands via the Y101 hydroxy group in the binding pocket.
Structurally, substitution of this tyrosine to phenylalanine as in
the eukaryotic proteins does not aﬀect the geometry of ligand
binding but it decreases aﬃnity, as we now veriﬁed in the
comparison of MsCI4WW/FF, Y101F and MsCI4WW/FF. Consis-
tently, the binding aﬃnities for MsCI4WW/FF, Y101F are lower, in
a range comparable to hCRBNΔ1-315 and CeCRBNsecΔ1-15.
In two cases, aﬃnity constants of hCRBNΔ1-315 for IMiDs
have been reported. For thalidomide, an IC50 value of ≈ 30 μM
was determined in dose−response pulldown experiments, while
ﬂuorescence polarization binding assays yielded a KD of ≈ 250
nM.5,17 Although these experiments are methodologically hard
to compare, the IC50 values determined in the pulldown are
roughly comparable with our results. The KD values determined
by ﬂuorescence polarization are noticeably low but also not
directly comparable as the experiments were performed with
the full hCRBN protein in complex with DDB1, which might
further stabilize the ligand-bound conformation.
■ CONCLUSION
Here, we demonstrated the high potential and general
applicability of our newly developed FRET-based assay. In a
comparative substrate binding study, representatives of all
cereblon proteins showed the same diﬀerential aﬃnities to the
same substrates on a relative scale. Therefore, aﬃnities
determined for one cereblon homologue can be translated to
expectation values for other species. As the bacterial
representative MsCI4 was the most stable, accessible, and
easiest-to-handle protein in our study, it is so far the most
advisable candidate for the general characterization of cereblon
ligand binding. With its amenability for high-throughput
screening, the assay may serve an important role in screening
libraries of pharmaceuticals for potential cereblon-mediated
teratogenic eﬀects. The identiﬁcation of succinimide as a new
cereblon-binding moiety represents a ﬁrst success of this
application. Furthermore, with its high accuracy, the assay is
suited for assisting the rational design of cereblon eﬀectors for
the targeted degradation of disease-related proteins as in cancer
therapy.
■ EXPERIMENTAL SECTION
Molecular Biology. A DNA fragments encoding the C. elegans
cereblon homologue (gi|17569329) lacking the N-terminal secretion
signal and the thalidomide-binding domain of hCRBN (hCRBNΔ1-
315) were codon optimized for expression in insect cells and
synthesized (Genscript). CeCRBNsecΔ1-15 was cloned with a C-
terminal histidine tag and hCRBNΔ1-315 with an N-terminal His-ZZ-
tag into pFastBac/CT-TOPO vector (Life Technology). Recombinant
baculoviruses were generated and ampliﬁed using the Bac-to-Bac
Baculovirus expression system (Life Technology).
Protein Puriﬁcation. MsCI4WW/FF and MsCI4WW/FF, Y101F were
expressed and puriﬁed as described previously.12 CeCRBNsecΔ1-15
and hCRBNΔ1-315 were expressed in Sf9 insect cells. Then 72 h post
infection, cells were harvested by centrifugation. The cell pellet was
resuspended in buﬀer A (50 mM NaH2PO4, pH 8.0, 500 mM NaCl, 5
mM β-mercaptoethanol, 4 mM MgCl2) containing 1 mM PMSF,
protease inhibitor mix, and DNase I. After sonication, cell debris was
pelleted by centrifugation and the supernatant applied onto a NiNTA
column equilibrated with buﬀer A. Bound proteins were eluted with a
linear gradient of 0−0.5 M imidazole in buﬀer A. Protein-containing
fractions were pooled and dialyzed against 20 mM Tris, pH 8.0, 150
mM NaCl, 5 mM β-mercaptoethanol containing additionally 0.1 M L-
arginine for CeCRBNsecΔ1-15. Tags were cleaved using TEV
protease. Applying a second NiNTA column, pure proteins were
ﬁnally separated from TEV protease and cleavage products. Protein
containing fractions were pooled and samples were concentrated in
dialysis buﬀer.
Inner Filter Eﬀect. Assay buﬀer (20 mM Tris, pH 7.5, 150 mM
NaCl, and 0.5 mM β-mercaptoethanol) containing varying DMSO
concentrations (0−20%) and 2.5 μM MsCI4WW/FF::MANT-uracil was
recorded on a Synergy microplate reader in black 96-well plates.
Parameter settings were as described for the multiwell plate assay,
excepting excitation: (350/9 nm).
Fluorescence Spectroscopy. Fluorescence spectra were meas-
ured using a 2 mL cuvette in a JASCO FP-6500 spectroﬂuorometer at
a protein concentration of 20 μM in assay buﬀer. Samples were excited
at 295 nm, and emission spectra were recorded at a data pitch of 0.5,
excitation bandwidth of 1 nm, emission bandwidth of 3 nm, response
of 0.5 s, and scan speed of 200 nm/min. JASCO software was used to
analyze data.
Multiwell Plate Assay. Fluorescence end point measurements
were performed in black 96-well plates on Synergy microplate readers
(BioTek) with the following settings: excitation, 295/9 nm; emission
collection, 440/9 nm; optics, top; read speed, normal; delay, 100 ms,
measurements/data point, 10; read height, 8 mm. All measurements
were done in triplicate; SigmaPlot 12.3 (Systat Software) was used for
data evaluation, curve ﬁtting, plotting, and determination of speciﬁc
constants.
MANT-uracil was obtained by custom synthesis (Jena Bioscience).
All measurements were performed in assay buﬀer. Stock solutions for
MANT-uracil (1 M) and for thalidomide (400 mM) were prepared in
DMSO, all other ligands in assay buﬀer. Highly concentrated master
dilution series of MANT-uracil and thalidomide stocks were prepared
in DMSO and subsequently diluted in assay buﬀer to keep the ﬁnal
DMSO concentration ≤0.02%. Binding of MANT-uracil was measured
by incubating protein (2.5 μM) with increasing concentrations of this
ligand in assay buﬀer. Exciting at 295 nm, ﬂuorescence was monitored
at 440 nm. The autoﬂuorescence of MANT-uracil at the according
concentrations served as a blank. The obtained FRET data resembling
the pool of MANT-uracil bound to protein were used to calculate the
Bmax value, which corresponds to the saturation of the binding pocket
by bound ligand. Given the known binding stoichiometry, for each
data point the relative amount of bound and free MANT-uracil was
calculated. The plots were rescaled and ﬁtted according to the one
binding site model to calculate the speciﬁc aﬃnity constant KD.
For determination of IC50 values, ligand was titrated to a ﬁnal
volume of 120 μL assay buﬀer containing 2.5 μM each, MANT-uracil
and protein. Binding competition was monitored by collecting
emission data sets at 440 nm. Samples containing compound in
buﬀer served as references. IC50 values were determined by applying a
log (dose) response curve on averaged data obtained from three to ﬁve
independent measurements. Ki values were calculated according to
Cheng−Prusoﬀ equation.14
Z′-Factor. The Z′-factor was estimated according to Zhang et al.16
In a black 96-well plate, 40 samples of each, the positive control (2.5
μM MsCI4WW/FF::MANT-uracil, 0.02% DMSO in assay buﬀer) and
the negative control (2.5 μM MsCI4WW/FF, 2.5 μM MANT-uracil, and
30 μM thalidomide in assay buﬀer) were analyzed performing
ﬂuorescence end point measurements according to the assay protocol.
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